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ABSTRACT 
 The skin, the largest organ of the human body, serves as a physical barrier and as such, has many important biological functions. If compromised, timely repair is vital to ensure that the skin can fulfil these roles. During the healing process, the wounded area is cleared from pathogens and debris, a provisional matrix is formed to assist wound closure, the vascular network is restored and ultimately, the tissue is remodelled resulting in scar formation. Cutaneous wound healing is characterised by four overlapping and interdependent phases – haemostasis, inflammation, proliferation, maturation – and involves multiple different cell types. Any disturbances in this highly complex process can delay the healing process and lead to chronic wounds. They are defined as wounds that show no significant healing within four weeks. Chronic wounds affect around 450,000 Australians every year and treatment of these is estimated to cost the health care system $3 billion annually. Persistent and elevated inflammation contributes to the formation of non‐healing wounds and the number of macrophages within a wound can determine the level and duration of inflammation. Macrophages are recruited from the bloodstream and infiltrate the tissue during wound healing. They create a path by degrading the extracellular matrix (ECM), the acellular component that comprises the dermal tissue and plays many important roles in wounded and unwounded skin. The ECM acts not only as a scaffold for the cells, but also regulates cell adhesion, chemotaxis and migration, as well as storing growth factors and cytokines. Matrix metalloproteinases (MMPs) cleave the ECM and thus help remodel the tissue during the healing process. During normal wound healing, MMP activity is tightly controlled. However, in non‐healing wounds increased levels of certain MMPs, such as MMP9 and MMP14, cause extensive tissue damage and contribute to sustained inflammation. MMP14 facilitates macrophage tissue infiltration, which then amplifies the inflammatory response within the wound. Current treatment strategies to reduce MMP levels in the wound fluid or to inhibit their activity have not been effective. For these enzymes to access their substrates, they first have to be secreted as is the case of MMP9 or incorporated into the plasma membrane as is the case with MM14. Preventing the delivery of MMP9 and MMP14 to the cell surface might reduce tissue damage and macrophage infiltration leading to an overall reduction of inflammation. In order to inhibit MMP cell surface delivery, it is necessary to elucidate their intracellular transport route and identify proteins that regulate these pathways in macrophages. 
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At least two major pathways exist in macrophages by which proteins can be delivered to the cell surface. One is a classical pathway where proteins are synthesised in the endoplasmic reticulum (ER), shuttled through the Golgi apparatus and transported to the surface either directly or indirectly through the recycling endosome. One other major secretory pathway is the lysosomal pathway, in which proteins are delivered to the cell surface from the cytosol or the Golgi complex through a lysosome or lysosome‐related organelle. Transport of proteins between these organelles and the cell surface occurs within membrane‐bound vesicles. Delivery of vesicles to target organelles or the plasma membrane requires membrane fusion, which is facilitated by soluble N‐ethylmaleimide‐sensitive‐factor attachment protein receptor (SNARE) proteins at all points in the trafficking pathway. These proteins form a complex of one R‐SNARE on one membrane and two or three Q‐SNAREs on the opposing membrane, which not only brings the membranes into close proximity, but also provides the energy and specificity required for membrane fusion. Each SNARE protein has a precise subcellular distribution and regulates a distinct step in a pathway. The intracellular trafficking pathways and the SNARE machinery responsible for cell surface delivery of MMP9 and MMP14 proteins are mostly unclear in macrophages. It was therefore the aim of this thesis to identify the critical SNARE proteins and pathways required for MMP9 secretion and for MMP14 cell surface delivery in macrophages. Targeting these proteins could reduce MMP activity, macrophage infiltration and inflammation in chronic wounds. The work reported herein shows that the expression and cell surface delivery of MMP9 and MMP14 is upregulated upon activation of macrophages with the bacterial cell wall component lipopolysaccharide (LPS). This is in contrast to neutrophils, which store their MMP9 in tertiary granules prior to secretion and to some cancer cell lines that have been shown to constitutive express MMP14 use a recycling mechanism to regulate the level at the cell surface. Hence, trafficking pathways for individual MMPs can be cell type specific. It was found that in macrophages, the newly made enzymes are trafficked via the Golgi complex prior to MMP9 secretion or incorporation of MMP14 into the plasma membrane. Immunofluorescence microscopy showed that in addition to their localisation in the Golgi complex they both were found in late endosomes/lysosomes.  Using targeted siRNA knockdown of SNARE proteins that regulate distinct pathways in macrophages, the responsible trafficking pathways were further investigated. Disrupting the key MMP intracellular trafficking pathways by reducing the levels of a key SNARE involved in their exocytosis should lead to compromised cell surface delivery of the protein of interest. Surprisingly, for MMP9 multiple SNAREs 
 iv 
involved in the classical or lysosomal pathways were targeted with siRNA but no reduction in MMP9 secretion was found. However, targeting some of these SNAREs, including VAMP3, VAMP4, VAMP7, VAMP8, Stx2 and SNAP23, led to an increase in extracellular MMP9 levels suggesting that an endocytic clearance mechanism might be influencing extracellular MMP9 levels and masking the exocytic pathways. The trafficking of MMP14 was also tested. MMP14 trafficking from the Golgi complex to late endosomes/lysosomes prior to the cell surface was found to be regulated by Golgi R‐SNARE VAMP4, the late endosomal/lysosomal R‐SNAREs VAMP7/8 and the surface Q‐SNARE complex Stx4/SNAP23. In macrophages MMP14 was found to be delivered to podosomes, actin‐rich cell membrane structures implicated in cell migration and matrix degradation. Targeting any one of these SNARE proteins lead to a reduction in gelatin matrix degradation in the area of the podosomes. Accordingly, disrupting this SNARE machinery also significantly reduced the ability of macrophages to effectively invade into both 3D Matrigel™ and collagen I gels. Thus, SNARE proteins that reduce surface MMP14 delivery have been identified providing new potential targets to reduce MMP14 surface activity, attenuate macrophage tissue infiltration, dampen inflammation and improve wound healing outcomes. Overall, this thesis advances the knowledge of trafficking pathways for cell surface delivery of MMP9 and MMP14 in macrophages and identifies key proteins involved in these pathways. For MMP9, further investigation into its endocytic mechanisms of clearance might allow better manipulation of MMP9 levels in the environment to reduce excessive tissue damage in chronic wounds. SNARE machinery responsible for MMP14 cell surface delivery, matrix degradation and macrophage invasion was identified and could represent novel therapeutic targets for the treatment of chronic wounds. 
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 Chapter 1: Literature review  1 
Chapter 1: Literature review 
 
1.1 Introduction Chronic wounds are wounds that show no significant healing after four weeks of receiving evidence‐based care [Frykberg and Banks, 2015]. These include venous, diabetic and pressure ulcers and are debilitating and often very painful. Approximately 450,000 Australians develop a chronic wound annually and wound care is estimated to cost the Australian health system an estimated $3 billion a year [Wound CRC, 2014]. Inflammation is part of the normal wound healing process and occurs even in the absence of infection. However, prolonged and excessive inflammation is a major contributing factor to the recalcitrant nature of chronic non‐healing wounds [Bannon et al., 2013]. The number of macrophages infiltrating a wound can determine the level of inflammation [Martin and Leibovich, 2005]. The influx of macrophages into the skin is partly dependent on the exocytosis of matrix metalloproteinases (MMPs). These proteases promote macrophage mobility by degrading the surrounding extracellular matrix (ECM). They also remove damaged ECM, and play a role in angiogenesis and tissue remodelling during wound healing [Stechmiller et al., 2010]. In order to inhibit MMP cell surface delivery it is necessary to elucidate their intracellular transport route and identify proteins that regulate these pathways in macrophages. The polarised delivery of proteins within membrane‐bound vesicles to the cell surface for exocytosis requires membrane fusion mediated by soluble N‐ethylmaleimide‐sensitive‐factor attachment protein receptor (SNARE) proteins at all points in the trafficking pathway [Jahn and Scheller, 2006] (see section 1.4). Identifying the critical SNARE proteins and pathways for MMP secretion is therefore important to identify potential targets to reduce MMP activity as a therapeutic treatment of chronic wounds. 
1.2 The role of macrophages in cutaneous repair 
1.2.1 Cutaneous tissue repair The skin is the biggest organ of the human body and serves as physical barrier to maintain internal homeostasis. This barrier is crucial for water retention, as well as regulation of the body’s temperature, and provides protection from chemical or mechanical assault, UV radiation, allergens and harmful pathogens. Playing such an important role, it is critical that the integrity of the skin is conserved. If compromised, timely repair is vital to ensure that the skin can fulfil its functions. The intricate process 
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of wound healing is characterised by four overlapping and interdependent phases that involves multiple different cell types, such as fibroblasts, keratinocytes, neutrophils and macrophages, from which some are resident, while others have to be recruited to the wound site [Darby et al., 2014; Koh and DiPietro, 2011; Martin and Leibovich, 2005]. The four phases are haemostasis, inflammation, proliferation and maturation and occur irrespective of the type of injury [Martin and Leibovich, 2005]. Immediately upon wounding, haemostasis and coagulation are initiated to halt blood loss [Martin and Leibovich, 2005]. As a result of the injury, collagen fibres are exposed and clotting factors released, which induces platelets to aggregate and secrete chemical stimuli. Together with cross‐linked fibrin and fibronectin the platelets form a plug that acts to stop blood loss, as well as forms a provisional wound matrix. Next, chemokines, cytokines and growth factors, secreted by platelets and resident inflammatory cells, initiate the inflammatory phase through the recruitment of phagocytic cells from the blood stream to the wounded tissue (Figure 1.1). Neutrophils are the first to arrive at the site of injury only a few hours post‐wounding, while macrophages appear slightly later [Gray et al., 2011]. Together, they are responsible for the removal of tissue debris, as well as the phagocytosis and killing of pathogens to protect the wound from infection. Normally, the inflammatory phase lasts for about 5–7 days [Martin and Leibovich, 2005]. During this time, macrophages also release growth factors and other chemical stimuli that are important for the proceeding phases of the wound healing process. These stimuli will initiate the proliferation phase, which starts around day 3 post‐wounding and lasts for about a week. During this phase, fibroblasts arrive at the wound site to produce collagen III and fibronectin, which is organised into loose bundles, acting as a scaffold for the wound healing process [Darby et al., 2014]. This aids re‐epithelialisation of the wound as keratinocytes proliferate and migrate across the new matrix material [Lau et al., 2009]. Wound contraction through the activity of myofibroblasts helps to reduce the wound diameter and speeds up the healing process [Darby et al., 2014]. To restore blood supply in the new tissue, blood capillaries are formed through sprouting from pre‐existing vessels in a process called angiogenesis. Factors secreted by macrophages stimulate endothelial cells to migrate into the wounded area to build the vasculature [Johnson and Wilgus, 2014]. Macrophages, fibroblasts, the provisional matrix and new blood vessels constitute the granulation tissue and remodelling of it is initiated through the proteolytic activity of MMPs [Stechmiller et al., 2010]. During the remodelling phase of the wound healing process collagen III is replaced with collagen I, laid down in parallel bundles along tension lines to complete wound contraction and increase the strength of the new tissue [Stechmiller 
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et al., 2010]. As this structure is different from the basket‐weave collagen present in uninjured skin, the healing process ultimately leads to the formation of a scar. Elimination of the hypoxic environment and the apoptosis of cells within the granulation tissue results in avascular and acellular tissue at the end of the maturation process [Greenhalgh, 1998]. 
 
Figure 1.1. An overview of cutaneous tissue repair (from Rohl et al., 2015). 
Together with cross-linked fibrin and fibronectin the platelets form a plug that acts to stop blood 
loss, as well as forms a provisional wound matrix. The inflammatory phase is initiated through 
the recruitment of phagoctytic cells from the blood stream to the wounded tissue. Neutrophils 
are the first to arrive at the site of injury, while macrophages follow a bit later. Together, they 
are responsible for the removal of tissue debris, as well as the phagocytosis and killing of 
pathogens to protect the wound from infection. Macrophages also release growth factors and 
other chemical stimuli that are important for the proliferation phase. Fibroblasts arrive at the 
wound site to produce collagen III and fibronectin, acting as a scaffold for the wound healing 
process. This aids re-epithelialisation of the wound as keratinocytes proliferate and migrate 
across the new matrix material. Factors secreted by macrophages stimulate endothelial cells 
to migrate into the wounded area to rebuild the vasculature. Macrophages, fibroblasts, the 
provisional matrix and new blood vessels constitute the granulation tissue and remodelling of 
it is initiated through the proteolytic activity of MMPs.  
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1.2.2 The inflammatory phase Inflammation is a normal part of the cutaneous wound healing process even in uninfected wounds and is mediated by resident mast cells, as well as neutrophils, macrophages and T cells that are recruited from the blood stream upon injury [Eming et 
al., 2007; Koh and DiPietro, 2011]. Upon injury, resident mast cells degranulate to release factors, such as vasoactive histamines. This results in vascular dilation and increased vessel permeability and, together with the secretion of chemotactic factors, allows extravasation of leukocytes. Neutrophils and macrophages are the main leukocytes to enter the tissue after wounding, as revealed by in vivo imaging techniques in mice skin wounds [Rodero et al., 2014]. Yet, they show a different dynamic behaviour in their migration and recruitment (Figure 1.2). In mice, neutrophil recruitment can be observed from 6‐12 h with numbers peaking around one day after wounding, whereas macrophages arrive slightly later but continue to actively infiltrate the tissue until about 48 h post‐injury [Ellett et al., 2011; Gray et al., 2011; Kim et al, 2008; Rodero et al., 2013]. Recruited neutrophils secrete proteases and antimicrobial products, such as ROS, to breakdown damaged tissue and kill pathogens. Clearance of debris and microbes occurs through phagocytosis. Recruitment of neutrophils stops around day 2 and cell numbers decline due to apoptosis and then the phagocytosis of spent neutrophils by macrophages [Kim et al., 2008]. Wound associated macrophages are predominantly recruited from circulating monocytes and resident tissue macrophages play only a minor role in the outcome of skin repair [Macdonald et al., 2010; Rodero et al., 2013; Rodero et al., 2014]. Infiltration of the wound tissue by macrophages occurs in two waves [Rodero et al., 2014]. The first small pool of monocytes enters the wound shortly after injury when the blood vessels are dilated and porous as a result of mast cell degranulation [Rodero et al., 2014]. However, this increased vascular permeability is only transient. Upon repair of the leakage monocytes extravasation must occur actively following their adhesion to the endothelium [Rodero et al., 2013]. Within the wound, monocytes differentiate into wound‐associated macrophages through signals from the local environment, such as matrix contact, cytokines and pathogens [Brown et al., 2014; Mosser and Edwards, 2008]. Once activated, they play many important roles in the wound healing process. Apart from the phagocytosis of spent neutrophils, macrophages assist in the pathogen clearance and wound debridement. The breakdown of devitalised tissue is facilitated through the activity of proteases, such as MMPs, and is important for proper incorporation of new matrix material. Macrophages do not only secrete large quantities of MMPs but they also release many pro‐inflammatory cytokines, such as TNFα, IL‐1 and IL‐6, to mediate the inflammatory response [Daley et al., 2010; Rodero et al., 2013. 
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Additionally, they secrete multiple growth factors, including transforming growth factor (TGF), vascular endothelial growth factor (VEGF) and platelet‐derived growth factor (PDGF), which actively stimulate fibroblast proliferation/differentiation and collagen production, as well as angiogenesis [Mosser et al., 2008]. Macrophage numbers are stable until four to five days after wounding and they then decrease to pre‐wounding levels by day 14 [Rodero et al., 2013; Kim et al, 2008; Ellett et al., 2011]. 
 
Figure 1.2. Dynamics of leukocyte extravasation and macrophage phenotypes during 
wound healing (from Rohl et al., 2015). 
Neutrophil recruitment can be observed within a few hours with numbers peaking around one 
day after wounding, whereas macrophages arrive slightly later but continue to actively infiltrate 
the tissue for longer. Recruitment of neutrophils stops around day two and cell numbers 
decline due to apoptosis and then the phagocytosis of spent neutrophils by macrophages. The 
first small pool of monocytes enters the wound shortly after injury when the blood vessels are 
dilated and porous as a result of mast cell degranulation. Upon repair of the leakage 
monocytes extravasation must occur actively following their adhesion to the endothelium. 
Within the wound, monocytes differentiate into wound-associated macrophages. Once 
activated, they play many important roles in the wound healing process. During the early 
phases of wound healing, pro-inflammatory M1 macrophages predominate. They express high 
levels of the cell surface markers Ly6c and CCR2 and secrete large quantities of the pro-
inflammatory cytokines TNFα, IL-6 and IL-1 as well as MMP9. Macrophages of the M2 type 
are found later in the repair process in response to changes in the environment. They express 
only low levels of Ly6c but express arignase-1, mannose receptor (CD206) and IL-4 receptor. 
They secrete anti-inflammatory cytokines, such as IL-10 and TGFβ, as well as ECM 
components. 
1.2.3 Macrophage phenotypes during cutaneous repair Macrophages play many different and important roles during wound healing, such as pathogen defence, wound debridement as well as stimulation of fibroblast proliferation and angiogenesis [Mosser et al., 2008]. As such they mitigate wound 
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infection and facilitate functional tissue restoration. To accommodate their diverse functions during the wound healing process macrophages can adapt various phenotypes [Mosser and Edwards, 2008]. Accordingly, different types of macrophages can be found in acute murine wounds that change over time. These macrophage phenotypes are aligned along a continuous spectrum between two extremes that are called ‘M1’ and ‘M2’ where M1 macrophages are considered pro‐inflammatory while macrophages of the M2 type are anti‐inflammatory and promote tissue repair. According to this concept, M1 macrophages can be ‘classically activated’ by IFNγ, pathogen‐associated molecular patterns (PAMPs), such as the bacterial cell wall component lipopolysaccharide (LPS), and/or damage‐associated molecular patterns (DAMPs), such as degraded matrix components [Bianchi, 2007; Mosser et al., 2008]. M1 macrophages secrete proteolytic enzymes, such as MMPs, that would allow them to infiltrate and remodel the wound [Daley et al., 2010]. These macrophages have strong microbicidal and phagocytic capacity and produce pro‐inflammatory cytokines (TNFα, IL‐1, IL‐6), superoxide anions, as well as oxygen and nitrogen radicals [Daley et al., 2010; Rodero et al., 2013; Willenborg et al., 2012; Mirza et al., 2013]. They are responsible for pathogen control and removal of necrotic cells and tissue debris, but also recruit other cells to the wound. The removal of microbes, as well as apoptotic cells and debris, reduces the inflammatory potential of the wound environment. Polarisation towards the anti‐inflammatory ‘M2’ type is facilitated by phagocytosis of spent neutrophils and ‘alternative activation’ through IL‐4 and IL‐23 [Brown et al., 2014]. M2 macrophages also produce effector molecules, such as VEGF, PDGFβ, and TGFβ [Mosser et al., 2008]. This recruits endothelial cells and fibroblasts, promotes the deposition of ECM material as well as myofibroblast differentiation and has pro‐angiogenic properties. During the early phases of wound healing (day 1 post‐wounding), pro‐inflammatory M1 macrophages predominate [Daly et al., 2005; Mirza et al., 2013; Rodero 
et al., 2013; Willenborg et al., 2012]. They express high levels of the cell surface markers Ly6c and CCR2 and secrete large quantities of the pro‐inflammatory cytokines TNFα, IL‐6 and IL‐1 as well as MMP9 [Daley et al., 2010; Mirza et al., 2013; Rodero et al., 2013; Willenborg et al., 2012]. Macrophages of the M2 type are found later in the repair process (day 7 post‐wounding) [Brown et al., 2014; Daley et al., 2005; Rodero et al., 2013]. They express only low levels of Ly6c but express arignase‐1, mannose receptor (CD206) and IL‐4 receptor. They secrete anti‐inflammatory cytokines, such as IL‐10 and TGFβ, as well as ECM components [Daley et al., 2010; Rodero et al., 2013]. 
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1.2.4 Macrophages are necessary to promote wound healing Immune cell mediated inflammation is a normal part of tissue repair and necessary to trigger subsequent healing stages. Yet, the role of neutrophils for this is conflicting within the literature. Neutrophil depletion using anti‐neutrophil serum had been shown to have no impact on skin repair in a guinea pig model [Simpson and Ross 1972] but accelerated wound closure in mice [Dovi et al., 2003]. However, there is evidence that defective neutrophil recruitment due to CXCR2 (receptor for IL‐8) knockout in mice leads to altered monocyte recruitment, delayed re‐epithelialisation and decreased neovascularisation [Devalaraja et al., 2000]. Another study using integrin β2 (CD18) knockout mice suggests that the failure to recruit neutrophils deprives macrophages from phagocytosing apoptotic neutrophils necessary for macrophage differentiation into the M2 type causing wound healing defects [Peters et al., 2005]. Early experiments depleting macrophages using anti‐macrophage serum in guinea pig skin healing models showed impaired clearance of wound tissue, reduced fibroblast accumulation and disturbance in the healing process [Leibovich and Ross 1975]. However, pleiotropic anti‐inflammatory effects due to the hydrocortisone used in the study cannot be excluded. Wound healing studies in mice, which have been depleted of the monocyte chemoattractant MIP‐1α (also known as CCL3), showed not only reduced collagen deposition but also impaired angiogenesis [DiPietro et al., 1998]. However, CCL3 does not only mediate macrophage but also neutrophil recruitment [Reichel et al., 2009]. Furthermore, knockout of MIP‐1α in mice had no effect on wound healing outcomes [Low et al., 2001]. Alternatively, in another murine wound healing model with reduced infiltration of neutrophils and macrophages, due to simultaneous knockout of the adhesion molecules ICAM‐1 and L‐selectin, there was a reported delay in wound repair [Nagaoka et al., 2000]. Advancement in our understanding of the diverse roles that macrophages play in wound repair has been achieved through temporal, rather than complete, depletion of this cell type during the different phases of the wound healing cascade [Lucas et al., 2010]. In a murine liver injury model, depletion of macrophages during injury reduces collagen deposition and improves fibrosis [Duffield et al., 2005]. Depletion of macrophages during recovery on the other hand leads to a persistent fibrotic response [Duffield et al., 2005]. Similar observations have been made in a murine cutaneous wound healing model where macrophages are temporally depleted. Depletion of macrophages early during the inflammatory phase of skin repair (days 0‐5) resulted in a minimised scar but impaired the rate of wound closure [Lucas et al., 2010]. However, 
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macrophage influx subsequent to early depletion rescues the wound closure rates showing that depletion of macrophages in the early stages improves wound healing quality without compromising wound closure [Rodero et al., 2013]. In contrast, depletion of macrophages during tissue formation (days 4‐9) had negative effects on 
wound closure and vascularisation due to decreased levels of TGFβ and VEGF, whereas depletion of macrophages during the late stage of tissue maturation (days 9‐14) had no significant impact [Lucas et al., 2010]. These studies show that macrophages have strong impact on different aspects of cutaneous repair, such as scar formation and wound closure, but that this is strongly time dependent. 
1.2.5 Excessive inflammation and increased numbers of macrophages 
compromise wound healing After neutrophils have apoptosed, macrophages are the predominant cell type to affect the level of inflammation. The kinetics of macrophage recruitment upon tissue damage, as described above, are representative of the normal wound healing processes. Alterations in this process can result in excessive inflammation and compromised wound healing outcomes, such as chronic non‐healing wounds or increased fibrosis [Rohl et al., 2015]. 
1.2.5.1 Inflammation and macrophages regulate scar formation In order to restore the integrity of the skin in a timely manner, wound healing processes have evolved to meet functional restoration over aesthetic or pre‐injury skin appearance. The result of this is the formation of a scar, which is comprised of parallel aligned collagen fibres, rather than the basket weave structures found in uninjured skin. Although reforming the barrier and closing the wound, the scarred tissue lacks the tensile strength of the surrounding normal skin. Dependant on localisation of the scar and the degree of scar formation, the functionality of the new tissue can also be compromised, additionally to the cosmetic problems they may cause. If present close to or over joints, scars can restrict and inhibit movement, especially in growing children. Excessive scar tissue deposition resulting in hypertrophic or keloid formations can cause further discomfort, tenderness, and possible irritation, ranging from itchy to painful. Evidence suggests that macrophage‐mediated inflammation determines the level of scar formation [Stramer et al., 2007] (Figure 1.3). Although macrophages are recruited to both adult and foetal wound sites, the numbers and persistence of these cells are lower in the foetus than in the adult. This results in scar‐free healing in the foetal mice (until the second trimester when the foetus begins to develop a full immune system) compared 
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to scar formation in the adult mice [Cowin et al., 1998]. Likewise, the healing process without excessive inflammation and scarring in mouse embryos perseveres as long as the monocyte lineage has not fully developed while the artificial induction of inflammation in foetal wounds will cause scar formation [Hopkinson‐Woolley et al., 1994]. Furthermore, the repair process of the oral mucosa is characterised by low levels of macrophages resulting in faster healing, reduced inflammation and less scarring when compared to cutaneous wounds [Szpaderska et al., 2003]. In further support of this, PU.1 transcription factor knockout mice (Sfp1‐/‐), which are lacking macrophages, neutrophils, B cells, mast cells and eosinophils, show scar‐free healing that is independent of inflammation [Martin et al., 2003]. Together with the results from the temporal macrophage depletion studies, this suggests that if we could reduce early macrophage‐mediated inflammation (days 0–5) it might prevent the formation of hypertrophic scars. 
 
Figure 1.3. Inflammation in wound healing (from Rohl et al., 2015). 
The time period and extend of the inflammatory phase of tissue repair under different wound 
healing conditions. 
1.2.5.2 High levels of inflammation and macrophages contribute to the chronicity of 
wounds Excessive macrophage‐mediated inflammation also plays a role in pathological tissue repair, as seen in chronic wounds, where proteolytic enzymes and pro‐
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inflammatory cytokines impede the healing process (Figure 1.3) [Bannon et al., 2013; Pierce, 2001]. While normal wound healing is characterised by transient macrophage infiltration of the tissue, macrophage numbers are highly elevated and their levels do not reduce over time in impaired wound healing models of obese (ob/ob) and diabetic (db/db) mice [Goren et al., 2003; Wetzler et al., 2000], as well as in chronic wounds of human venous and diabetic leg ulcers [Rosner et al., 1995; Loots et al., 1998]. Although neutrophil numbers in acute wounds are high, biopsies of human chronic wounds have shown that 80% of the cells in the wound margin are macrophages [Sindrilaru et al., 2011]. Interestingly, macrophages found within chronic wounds can be characterised as persistent pro‐inflammatory M1 macrophages rather than switching towards the healing‐promoting M2 type seen in acute wounds 5 days following wounding [Sindrilaru 
et al., 2011]. The phenotype of these M1 macrophages can be characterised through their expression of high levels of the pro‐inflammatory M1 markers TNFα, IL‐12p40 and CCR2 while only moderate levels of the M2 markers arginase, CD206, Dectin‐1, IL‐10, IL‐4Rα and CD36 [Sindrilaru et al., 2011]. The enhanced release of TNFα and hydroxyl radicals from these pro‐inflammatory M1 activated macrophages was shown to be responsible for compromised healing outcomes [Sindrilaru et al., 2011]. Together, this suggests that elevated numbers of macrophages with an unrestrained pro‐inflammatory response play a major role in the inflammation driving the chronicity in wounds. Thus, reducing macrophage numbers in chronically inflamed wounds is expected to improve healing outcomes. Accordingly, dampening inflammation by reduction of macrophages using antibodies has been shown to reinstate tissue repair in healing impaired obese mice [Goren et al., 2007]. Understanding inflammation in the context of wound healing has therefore become an important focus in the treatment of chronic wounds. The development of strategies to reduce tissue infiltration by macrophages, as well as limiting the amount of macrophage‐derived molecules that exacerbate inflammation, could help to break the vicious cycle of inflammation in non‐healing wounds. 
1.2.5.3 Strategies to reduce macrophage tissue infiltration and inflammation Excessive inflammation in wounds could potentially be reduced via a number of different approaches. These may include reducing macrophage infiltration of the wound tissue and mitigating or inhibiting the release of pro‐inflammatory cytokines and other factors that actively damage the wound environment and exacerbate inflammation. 
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Reducing macrophage tissue infiltration Monocytes are recruited from the blood to the wound site where they become activated and exhibit their inflammatory behaviour [Koh and DiPietro, 2011; Eming et 
al., 2007]. The initial step in this process is for monocytes to adhere to the endothelium of the inner blood vessel wall. They then move along the vessel wall in a rolling movement until they cross the endothelium and basement membrane in a process called diapedesis. Once in the tissue, macrophages have to migrate through the 3D environment of the interstitial tissue, which is composed predominantly of collagen I and other extracellular matrix (ECM) components. Adhesion of monocytes to endothelial cells of the blood vessel is facilitated via contact of adhesion molecules on the endothelium with integrins located on the cell surface of monocytes [Muller, 2003]. This interaction can be disrupted either by targeting selectins, which are adhesion molecules on the endothelium, or integrins, which are the cognate adhesion molecules on the cell surface of immune cells [Muller, 2003]. In a mouse model lacking P‐ and E‐selectins macrophage recruitment is significantly reduced [Subramaniam et al., 1997]. However, as macrophage infiltration in these acute wounds is disturbed throughout the entire healing process beneficial factors released by macrophages are subsequently unavailable and as a result, the overall healing is impaired. Alternatively, macrophage‐mediated inflammation was reduced in a rabbit model of burn injury by treatment with an anti‐integrin alpha L antibody during the first 24 h post‐injury to target the adhesion molecules on the immune cell [Bucky et al., 1994]. Moreover, in a rabbit burn model, targeting ICAM‐1 and 
integrin β2 has, likewise, shown improved healing [Bucky et al., 1994; Fuchs et al., 2006]. Treatment with ICAM‐1 antibodies also led to accelerated healing in human burn injuries when administered within 6 h of injury [Mileski et al., 2003]. Whether treatments such as these have a positive impact on scar formation or their impact on chronic wounds has not been determined and requires further investigation. Following successful adhesion of monocytes to the endothelium, these cells then migrate along the inner blood vessel wall in a 2D migration mode [Verollet et al., 2011]. For this, the macrophage polarises into an elongated shape with a flattened migration front at the leading edge, called a lamellipodium. Establishment of the lamellipodium is achieved through actin filament assembly. This process of migration involves the continual formation of adhesive contacts, with the substratum at the leading edge and the disassembly of these adhesion contacts at the rear of the cell (Figure 1.4). Integrins are the major cell surface receptors mediating the attachment of macrophages to the 
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underlying matrixle. Proteases, namely MMP14, are delivered to the leading edge to regulate the turnover of these adhesion sites [Muller, 2003]. Both, integrins and MMPs are localised to actin‐rich structures at the leading edge of macrophages, which are called podosomes, and spontaneously form upon matrix contact [Cornfine et al., 2010; Gawden‐Bone et al., 2010; Linder, 2007; Wiesner et al., 2010]. Ultimately, monocytes cross the endothelium in a process called diapedesis. The emigration of leukocytes from the blood stream involves the loosening of the endothelium, followed by the degradation of the basement membrane, which is partly achieved by the catalytic activity of MMPs, mainly MMP2 and 9 (Figure 1.4) [Le et al., 2007]. Once in the interstitial tissue, leukocytes migrate through the 3D ECM towards the wound site. Lymphocytes and neutrophils have been known to use the amoeboid migration mode, which is characterised by a rounded to ellipsoid cell shape, as these leukocytes can squeeze through pores of the ECM [Friedl and Weigelin, 2008]. However, macrophages are much larger than neutrophils and T cells and manoeuvre through the tissue using the protease‐dependent mesenchymal migration mode to create a path through the dense matrix material [Friedl and Weigelin, 2008]. Analogous to 2D migrating cells, macrophages form podosomes at the leading cell protrusion in 3D environments. These podosomes are the site for MMP secretion and help establish the migration path by localised matrix degradation (Figure 1.4) [Bjorklund and Koivunen, 2005; Verollet et al., 2011]. Therefore, targeting the activity or secretion of proteases, such as the MMPs, and MMP14 in particular, could regulate tissue infiltration by macrophages. Inhibiting MMP activity has had limited success so far, suggesting that reducing surface delivery might be an alternative strategy (section 1.3.4). 
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Figure 1.4. Macrophage tissue infiltration occurs through different migration processes 
and requires the activity of matrix metalloproteinases. 
Once attached to the endothelium, macrophages polarise to exhibit a leading edge where 
MMPs secreted at podosomes facilitate adhesion complex-turnover while detachment takes 
place at the trailing edge. During diapedesis, macrophages use MMPs to loosen the 
endothelium and degrade the basement membrane. To migrate through the dense interstitial 
tissue, macrophages form 3D podosomes where they secrete MMPs to create a path by matrix 
degradation. 
Reducing molecules in the wound that exacerbate inflammation As increased levels of inflammation has a deleterious effect on wound healing, targeting pro‐inflammatory cytokines has been considered a promising therapeutic approach to speed up the healing process and improve overall outcomes. Progress has been made in targeting the potent pro‐inflammatory cytokine TNFα. Deficiency of the inflammation‐mediating TNF receptor has been shown to reduce the number of wound macrophages and accelerate repair, but is not translatable as it involved the use of transgenic mice [Mori et al., 2002]. A TNF antibody (Infleximab) has been successful in clinical studies to reduce inflammation and improve healing outcomes of chronic wounds [Streit et al., 2006]. When applying antibodies against the pro‐inflammatory cytokines IL‐1β and IL‐17, wound healing is enhanced in normal mice as well as in mice with compromised healing [Rodero et al., 2013; Mirza et al., 2013]. Moreover, the inhibition of the IL‐1β pathway in wounds of diabetic mice, using a neutralising antibody, improved healing of these wounds [Mirza et al., 2013]. The treatment induced the shift from the pro‐inflammatory M1 phenotype towards the M2 type, which is associated with repair [Mirza et al., 2013]. This also confirms that macrophage maturation is critical for proper wound healing and can be polarised. Some of the chronic inflammation observed in non‐healing wounds can be attributed to the persistent and elevated levels of certain MMPs in the wound. The unrestrained activity of these MMPs causes extensive tissue damage by breaking down too much of the ECM. The damaged ECM subsequently activates macrophages to secrete more pro‐inflammatory cytokines and MMPs, which leads to a vicious cycle of inflammation. Hence, reducing MMP levels has long been a focus in the development of therapeutics to improve wound healing outcomes but has had limited success so far (section 1.3.4).   
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1.3 MMPs during wound healing 
1.3.1 The role of the extracellular matrix during wound healing The ECM is the acellular component that comprises the dermal tissue. It is a gel‐like matrix that is made up of fibrous structural proteins, such as collagens and proteoglycans, produced by the surrounding cells [Rozario and DeSimone, 2010]. The combination of these two components allows the skin to have both elasticity and compressibility. The ECM acts not only as a scaffold for the cells, but also regulates cell adhesion, chemotaxis and migration, as well as storing growth factors and cytokines [Rozario and DeSimone, 2010; Schultz and Wysocki, 2009]. The production of ECM proteins is also crucial to the wound healing process. During haemostasis, ECM proteins, such as fibrin, fibronectin and collagen, build a clot that stops the bleeding. It also acts as provisional matrix for cells infiltrating the wounded area, and contains factors to stimulate fibroblasts, epithelial cells and endothelial cells [Rozario and DeSimone, 2010; Schultz et al., 2011; Schultz and Wysocki, 2009]. Immune cells, fibroblasts and endothelial cells release enzymes, including MMPs, which can degrade this provisional matrix in order to facilitate cellular recruitment into the wound space and promote angiogenesis and remodelling of the tissue. Breakdown of the ECM, release of growth factors and activation of cytokines by proteases, such as MMPs, during tissue repair has to be appropriately regulated to allow efficient healing [Schultz and Wysocki, 2009]. While unrestrained synthesis of ECM and reduced degradation of the same can lead to increased scarring, uncontrolled degradation of the ECM through the activity of MMPs such as MMP9 and MMP14 leads to excessive tissue damage and delays the healing process [Schultz et al., 2011; Xue et al., 2006]. It is therefore important to understand how MMP activity is (dys)regulated during the wound healing process. 
1.3.2 MMPs degrade ECM and non-ECM components In their active form MMPs can cleave both ECM proteins, such as collagen, and certain non‐ECM proteins found within the tissue [Martins et al., 2013]. The proteolytic cleavage of ECM proteins by MMPs is very important during the wound healing process on multiple levels. During the inflammatory phase, the secretion of MMPs enables immune cells to infiltrate the wounded area, where these cells can release more MMPs to remove broken ECM. As broken collagen is unable to interact with newly produced fibres, MMP activity debrides the wounded area clearing it of damaged ECM to allow for an organised and strong new matrix [Schultz et al., 2011]. MMPs also facilitate the migration of various other cell types through the tissue by breaking down the ECM thus 
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creating a path through the dense material [Quaranta, 2000]. The degradation of different ECM components also alters their ratio within the wound environment, which in turn affects cell adhesion and migration [Vu and Werb, 2000]. Throughout the proliferative phase fibroblasts, endothelial cells and keratinocytes also utilise MMP activity to migrate to the wound site where they regulate the formation of granulation tissue, and re‐epithelialisation [Quaranta, 2000]. Furthermore MMPs can change the availability or function of signalling molecules like receptors, cytokines and chemokines [Vu and Werb, 2000]. The latter may occur through mechanisms, such as the release of these molecules out of the ECM network making them biologically available, reducing their levels through degradation or transformation of inactive precursors [Stamenkovic, 2003]. MMPs assist in angiogenesis by degrading the basement membrane of existing blood vessels in order to allow the sprouting of new capillaries [Rundhaug, 2005]. Remodelling of the provisional matrix is also dependent on the action of MMPs and they aid wound contraction as the scar tissue forms [Schultz et al., 2003; Stechmiller et al., 2010]. Together with the fact that active MMPs can also induce the conversion of zymogen MMPs to their active state, MMPs can have very diverse effects on cell behaviour and the microenvironment throughout the wound healing process [Loffek et 
al., 2011]. 
1.3.3 Structure, substrates and regulation of MMPs MMPs form a family of Zn2+‐ and Ca2+‐dependent endopeptidases produced as inactive precursor proteins, called zymogens, which share similar mechanisms of activation [Vu and Werb, 2006]. Activated MMPs are able to cleave many ECM components including collagen, elastin, fibronectin and laminin [Martins et al., 2013]. This is why MMPs play an important role in tissue remodelling. They can also cleave non‐ECM proteins to affect growth‐factor activation and cell‐cell and cell‐matrix signalling [Martins et al., 2013] (Table 1.1). Due to their proteolytic activity they are fundamental for many physiological processes like immune cell infiltration during wound repair and in the regulation of inflammation [Le et al., 2007; Loffek et al., 2011; Stamenkovic, 2003].  
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 Table 1.1. Classification of MMPs according to their substrate specificity (from Rohl and Murray, 2013). 
Agg, aggrecan; Dec, decorin; EL, elastin; Fib, fibrillin; FBN, fibrin; FN, fibronectin; Gel, gelatin; IGFBPs, insulin-like growth factor binding protein; LN, laminin; 
PG, proteoglycan-linked protein; TGF, transforming growth factor; TNFa, tumor necrosis factor alpha; VN, vitronectin. 
Class Common Name(s) MMP# ECM Substrates Non-ECM Substrates (examples) 
Collagenases Collagenase 1, Interstitial, 
Fibroblast, Tissue C 
MMP1 Col I, II, III, VI, VII, X, Agg, FN, Gel, LN, PG, VN IGFBPs, CXCL12, pro-TNFα 
 Collagenase 2, Neutrophil C MMP8 Col I, II, III, V, VII, VIII, Agg, EL, FN, Gel, LN CXCL5 
 Collagenase 3 MMP13 Col I, II, III, IV, VII, IX, X, XIV, Agg, FN, Gel, Fib CXCL12 
Gelatinases Gelatinase A, 
72-kDa gelatinase 
MMP2 Col I, III, IV, V, VII, X, XI, XIV, Agg, EL, FN, Gel, 
LN, PG, VN, Dec, Fib, 
CCL7, CXCL12, pro-TNFα, IGFBPs, 
pro-TGFβ, pro-IL-1β 
 Gelatinase B, 
92-kDa gelatinase 
MMP9 Col IV, V, VII, X, XIV, Agg, EL, Gel, LN, PG, VN, 
Dec, Fib, FBN, 
pro-TNFα, pro-IL-1β, IL-8, IL-2Rα, 
CXCL7, CXCL8, CXCL1, CXCL12 
Stromelysins Stromelysin 1, Transin 1 MMP3 Col III, IV, IX, X, XI, Agg, EL, FN, Gel, LN, PG, 
VN, Dec, Fib 
CXCL12, E-cadherin, pro-TGFβ1, 
pro-TNFα, IGFBPs, pro-IL-1β 
 Stromelysin 2, Transin 2 MMP10 Col III, IV, V, IX, X , Agg, EL, FN, Gel, LN, PG  
 Stromelysin 3 MMP11  IGFBPs 
Matrilysins Matrylisin, Matrin, PUMP-1 MMP7 Col IV, X, Agg, EL, FN, Gel, LN, PG, VN, Dec, Fib pro-TNFα, E-cadherin, β4-Integrin 
 Matrylisin-2, Endometase MMP26 Col IV, FN, Gel  
Membrane-type MT1-MMP MMP14 Col I, II, III, Agg, FN, gel CXCL12, CD44, pro-TNFα/TGFβ 
 MT2-MMP MMP15 Agg, FN, Gel, LN, FBN  
 MT3-MMP MMP16 Col III, FN, FBN, VN, LN, Gel  
 MT4-MMP MMP17 Fib, FBN Pro-TNFα 
 MT5-MMP MMP24 Gel  
 MT6-MMP, Leukolysin MMP25 Col IV, Gel, FN  
Other Enamelysin MMP20 Agg  
 Epilysin MMP28   
 Metalloelastase MMP12 Col I, IV, Agg, EL, FN, Gel, LN, PG, LN, Fib Latent TNF 
 RASI 1 MMP19 Col IV, I, FN, Gel, LN  
 Xenopus MMP MMP21   
 MMP23b/CA-MMP MMP23 Gel  
  MMP27    
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There are 23 human MMP members that show similarities in their domain organisation (Figure 1.5). All MMPs, but one (MMP23), have an N‐terminal signal (pre‐domain), which allows the protein to traffic to the endoplasmic reticulum (ER) and subsequently also the Golgi apparatus. This allows the protein to be either secreted or incorporated into the plasma membrane. Those MMPs that are not destined for secretion have a either a transmembrane domain, a glycosylphosphatidylinositol (GPI) anchor or a signal anchor that links them to cell‐membranes [Egeblad and Werb, 2002]. No matter if they are secreted or reside as transmembrane proteins, all MMPs contain a catalytic domain with three conserved histidines (HEXGHXXGXXH) coordinating a Zn2+‐ion involved in the hydrolytic mechanism [Martins et al., 2013]. In their zymogen form, a pro‐domain of about 80 amino acids containing a free thiol group (PRCKKPD) that can further complex the Zn2+‐ion blocks via a linker region the entry of the catalytically important water molecule into the active site [Martins et al., 2013] (Figure 1.6). To convert the zymogen form into the active protein, this interaction has to be disturbed and occurs through a ‘cysteine switch’ (Figure 1.6). In vivo, this can be achieved by proteolytic cleavage of the pro‐domain through the action of serine proteases or other MMPs [Bjorklund and Koivunen, 205; Loffek et al., 2011; Martins et al., 2013; Vu and Werb, 2000]. Additionally, zymogen activation can occur through conformational perturbation induced by chaotropic agents, such as SDS, or ROS, which chemically modify the cysteine within the pro‐domain, in vitro [Bjorklund and Koivunen, 2005; Loffek et al., 2011; Martins et al., 2013; Vu and Werb, 2000]. Cleavage‐mediated zymogen activation usually occurs after secretion of the pro‐MMP, as is the case for MMP9 [Stamenkovic, 2003]. However, some MMPs have a furin‐cleavage site within the pro‐domain, such as MMP14, which allows for them to be activated intracellularly before their delivery to the cell surface [Stamenkovic, 2003]. Once activated, substrate specificity for the individual MMPs is partly determined by small variances within the catalytic domain [Bjorklund and Koivunen]. Additional coordination of the substrate is accomplished through interactions mediated by a hemopexin‐like domain, which can be found in most MMPs [Bjorklund and Koivunen, 2005] (Figure 1.5).   
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Figure 1.5. Classification of MMPs according to their domain structure (from Rohl and 
Murray, 2013). 
Pro, pro-domain; Pre, N-terminal signal sequence, Zn2+, zinc; Fi, a gelatin binding domain that 
resembles collagen-binding repeats in fibronectin; Fu, furin; TM, transmembrane domain; Vn, 
vitronectin-like; SA, signal anchor; GPI, glycosylphophatidylinositol anchoring sequence; CA, 
cysteine array; Ig, immunoglobulin.   
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Figure 1.6. Mechanisms of pro-MMP activation (from Rohl and Murray, 2013). 
All MMPs contain a catalytic domain with three conserved histidines coordinating a Zn2+-ion 
involved in the hydrolytic mechanism. In their zymogen form, a pro-domain of about 80 amino 
acids containing a free thiol group that can further complex the Zn2+-ion blocks via a linker 
region the entry of the catalytically important water molecule into the active site. To convert 
the zymogen form into active protein this interaction has to be disturbed through a ‘cysteine 
switch’. In vivo, this can be achieved by proteolytic cleavage of the pro-domain through the 
action of serine proteases or other MMPs. Additionally, zymogen activation can occur through 
conformational perturbation induced by chaotropic agents, such as SDS, or ROS, which 
chemically modify the cysteine within the pro-domain, in vitro. Once activated, MMPs are highly efficient in the degradation of ECM material. To prevent excess tissue damage, it is important that MMP activity is controlled on multiple levels such as gene expression, cell surface delivery, localisation, zymogen activation and through specific endogenous inhibitors [Bjorklund and Koivunen, 2005]. Generally, the expression of MMPs, such as MMP9, is absent or minimal in normal tissues, but is found to be greatly enhanced during inflammation and wound healing [Opendakker et al., 2001]. Within the wound environment, ECM contact and cytokines can induce expression of MMP genes in keratinocytes, fibroblasts, endothelial cells and immune cells. In response to stimuli, the levels of MMPs produced by these cells can be further controlled through epigenetic modifications or mRNA (de)stabilisation [Martins et al., 2013]. After MMP synthesis, the enzymes need to be delivered to the cell surface in order to access their substrates, like the ECM components or molecules housed within. This occurs either through the secretion of soluble MMPs, as is the case for MMP9, or 
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incorporation of transmembrane MMPs, such as MMP14, into the plasma membrane. Intracellular trafficking machinery, such as specific SNARE and Rab proteins, regulate these discrete trafficking processes [Murray and Stow, 2014]. This also allows the polarised delivery of MMPs and limits their activity to areas of the cell where it is required, including structures necessary for migration and invasion through the ECM. MMP9 and MMP14 are delivered to membrane protrusions, such as filopodia, actin‐rich rod‐like structures at the leading edge of migrating cells. Particularly in macrophages, they are also found at podosomes, which are actin‐rich structures that give the cells the ability to invade dense material [Gialeli et al., 2011]. Association of membrane‐anchored MMPs like MMP14 to the plasma membrane restricts their activity to the immediate pericellular space. Soluble MMPs are also known to bind back to the cell surface via adhesion molecules or proteoglycans to focalise their 
enzymatic activity. MMP9, for example, binds to CD44, as well as the integrins α4β1, 
α5β1 and αvβ5 [Deryugina and Quigley, 2011]. Unless conversion of the zymogen form to the active enzyme has occurred intracellularly, as is the case for MMP14, activation of MMPs without a furin‐cleavage site, such as MMP9, occurs after secretion [Stamenkovic, 2003]. Interestingly, activation of MMP2 occurs through cell surface docking of the pro‐enzyme to TIMP2 and together they bind to the catalytic domain of MMP14, which results in its activation [Deryugina and Quigley, 2011]. Once activated this complex is responsible for the conversion of MMP9 to its active form [Itoh et al., 2001; Itoh and Seiki, 2004; Toth, 2003; Vandooren et al., 2013]. Although additional MMPs, as well as other proteases, have been implicated in the activation of MMP9 this docking mechanism, involving the MMP14/MMP2/TIMP complex, could increase efficiency of zymogen conversion and help concentrating MMP activity to the pericellular space. Once activated, MMP activity can be restricted through the presence of non‐
specific endogenous inhibitors, such as α2‐macroglobulin, or specific ones, which are the tissue inhibitors of metalloproteinases (TIMPs). Four TIMPs (TIMP1, TIMP2, TIMP3, TIMP4) are known and they are cysteine‐rich proteins of approximately 21‐28 kDa in size that reversibly associate to MMPs in a 1:1 ratio [Bjorklund and Koivunen, 2005; Stamenkovic, 2003]. The levels and ratios of MMPs and TIMPs within a wound has a strong influence on the wound healing outcome and alterations in this balance can influence wound chronicity (section 1.3.3). Interestingly, MMP9 levels can also be modulated through an endocytic clearance mechanism. Binding of MMP9 to low density lipoprotein receptor‐related protein 1 (LRP‐1) triggers the uptake of the complex, which 
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ultimately leads to its degradation within the lysosome, thereby reducing extracellular MMP9 [Van den Steen et al., 2006]. 
1.3.4 Pathological roles of MMPs during wound healing Through their activity of cleaving ECM and non‐ECM proteins, MMPs play many important roles during different phases of wound healing. However, when dysregulated, MMPs can cause excessive damage to the provisional matrix, inhibiting re‐epithelialisation in chronic wounds (Figure 1.7) [Beidler et al., 2008; Ladwig et al., 2002; Lobmann et al., 2002; Mwaura et al., 2006; Pirila et al., 2007]. These non‐healing wounds are understood to be locked in a vicious cycle of inflammation with elevated levels of neutrophils and macrophages and unable to progress to the granulation phase of healing [Gethin, 2012; Raffetto, 2013]. Wounds with little or no macrophages on the other hand heal faster, with reduced scarring [Martin and Leibovich, 2005]. It is believed that elevated MMP levels, as well as other pro‐inflammatory molecules released from macrophages and neutrophils, contribute to the persistent inflammation seen in these wounds [Le et al., 2007]. An imbalance of particular MMPs and TIMPs, with increased MMP1, 2, 8 and 9 expression and decreased TIMP1 and 2 levels, have been found in chronic ulcers and are considered accountable for unrestrained ECM breakdown, inflammation, altered cell growth and increased immune cell infiltration in wound tissue [Loffek et al., 2011; Martins et al., 2013] (Table 1.2; Figure 1.7). Proteolytic cleavage of the ECM by MMPs creates damage‐associated molecular patterns that cause activation of macrophages to secrete pro‐inflammatory cytokines as well as more MMPs further perpetuating the inflammatory state of non‐healing wounds [Olczyk et al., 2014].   
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Figure 1.7. Increased MMP levels in wounds contribute to poor wound healing 
outcomes. 
MMPs in chronic wounds cause uncontrolled matrix degradation, depletion of growth factors, 
and activation of pro-inflammatory cytokines, which prolongs inflammation and prevents re-
epithelialisation by keratinocytes. Macrophages are major secretors of MMPs during the 
inflammatory phase of wound healing. 
 
Table 1.2. Alterations in MMP and TIMP levels in chronic venous, diabetic, pressure and 
mixed ulcers (from Rohl and Murray, 2013). 
 Elevated levels Reduced levels Reference 
Chronic venous 
leg ulcers 
MMP1, MMP2, MMP3, 
MMP8, MMP9, MMP12, 
MMP13 
TIMP1, TIMP2 
[Beidler et al., 
2008; Mwaura 
et al., 2006] 
Diabetic ulcers 
 
MMP1, MMP2, MMP8, 
MMP9 TIMP2 
[Lobmann et 
al., 2002] 
Pressure ulcers 
 MMP9 TIMP1 
[Ladwig et al., 
2002] 
Ulcers (mixed 
group) 
 
MMP8, MMP26  [Pirila et al., 2007]  In particular, macrophage‐derived MMP9 has been considered the main protease responsible for unwanted matrix degradation as its levels correlate with chronic wound severity [Rayment et al., 2008; Tarlton et al., 1999]. It has been hypothesised that the negative impact of MMP9 levels on wound healing is due to the fact that MMP9 is highly efficient at degrading collagen [Mackay et al., 1990]. Additionally, MMP9’s substrates include non‐ECM molecules, such as cytokines and chemokines, which could have immunomodulatory potential and further perpetuate the inflammation and immune cell 
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recruitment [Marom et al., 2007; Okamura et al., 2001]. Hence, MMP9 levels, also in relation to its inhibitor TIMP1, within wound fluid are considered to be an indicator of the competence of wound closure [Ladwig et al., 2002]. This is confirmed through studies showing that adding high levels of MMP9 to acute wounds actually delays the wound healing process [Reiss et al., 2010]. This means that although MMP9 expression is temporally upregulated to assist in the wound healing process, persistent and elevated levels of this enzyme can delay healing [Reiss et al., 2010]. 
1.3.5 Strategies to reduce levels of matrix metalloproteinases in wounds As MMPs play a significant role in inflammatory diseases, like non‐healing wounds, they have been regarded important therapeutic targets. One approach to reducing the levels of MMPs in the wound environment is the use of highly absorbent foam dressings [Eming et al., 2008; Lobmann et al., 2006]. These dressings can soak up the wound fluid and thereby draw away detrimental MMPs, such as MMP9, as well as other pro‐inflammatory factors but also beneficial factors that could be present. They also have no influence on membrane anchored MMPs, such as MMP14. Their overall clinical effect on the microenvironment of non‐healing wounds remains to be tested. The application of pressure has been shown to reduce the levels of MMP3, MMP8 and MMP9, in chronic wound fluid either through compression bandages or by topical negative pressure therapy [Beidler et al., 2008; Moues et al., 2008]. However, the reduction of MMP3, MMP8 and MMP9 was not correlated with overall wound healing outcomes. Excessive MMP activity in chronic wounds has also been targeted through the use of broad‐spectrum MMP inhibitors like GM6001 (Galardin). This small molecule inhibitor works by chelating the zinc ion necessary for the catalytic activity of MMPs. Unfortunately, this inhibitor was found to negatively affect keratinocyte migration, myofibroblast differentiation and wound contraction [Barletta et al., 1996; Miratschijski 
et al., 2004; Schultz et al., 1992]. Being a broad spectrum inhibitor, the limited efficacy of this inhibitor on the overall wound healing outcome is owed to the fact that not all MMPs are detrimental to the wound healing process. Some MMPs, like MMP8, have important and beneficial roles during wound healing [Gooyit et al., 2014; Martins et al., 2013]. Fibroblasts, endothelial cells as well as keratinocytes use MMPs for their cell migration and as a result generally inhibiting MMPs will negatively affect important wound healing processes such as re‐epithelialisation and angiogenesis. Similar observations have been made when applying TIMPs onto chronic wounds [Miyoshi et al., 2005]. As such, broad‐spectrum inhibitors should be avoided and individual members of the MMP family that are thought to play a harmful role in non‐healing wounds should be targeted instead [Xue 
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et al., 2006]. Interestingly, doxycycline, which chelates the zinc or calcium ions in the catalytic domain of MMPs, appears to be an exception to this. When doxycycline is used at sub‐antimicrobial doses, improvement in wound healing for patients with diabetic or venous leg ulcers can be observed [Chin et al., 2003; Serra et al., 2013]. The design of specific inhibitors has proven difficult as the structures of the catalytic domain is similar amongst the individual members of the MMP family [Loffek et 
al., 2011]. Nonetheless, some more selective MMP inhibitors have been developed but have not yet been tested on non‐healing wounds [Dahl et al., 2012; Devy et al., 2005; Sina 
et al., 2009]. Functional blocking antibodies, such as one targeting MMP14, also have the potential to improve chronic wounds but this has also not been tested yet [Devy et al., 2009]. It is important to consider that treatments involving antibodies are very costly. Thus, there are currently no viable options available to inhibit MMP‐mediated tissue damage in chronic wounds. Therefore, identifying alternative targets to regulate MMP activity might lead to the development of better and more cost‐effective targeted treatments. This could be achieved by understanding the specific trafficking mechanisms involved in MMP cell surface delivery or secretion.   
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1.4 Intracellular trafficking of proteins To establish a border to the environment, all cells are surrounded by a membrane. In addition to this plasma membrane, eukaryotic cells are compartmentalised as they contain multiple membrane‐bound organelles with different shape, specialised function, and composition. This allows larger cells to be more efficient but requires a refined system that enables exchange between these organelles [Tokarev 
et al., 2009]. Between organelles, soluble and membrane‐bound cargo, such as proteins as well as lipids, are transported in membrane‐bound carriers called vesicles, which are often of tubular or pleiomorphic character [Lacy, 2015]. Directional transport between compartments requires the fusion of two separate lipid bilayers [Martens and McMahon, 2008]. Retrograde or ‘inwards’ transport is called endocytosis (section 1.4.1) and allows the uptake of nutrients and pathogens but also regulates cell signalling. By budding from the plasma membrane and subsequent inwards transport cell surface receptors with or without ligands can be internalised and fluids or particles be brought into the cell [Doherty and McMahon, 2009]. Anterograde or ‘outwards’ delivery of cargo to the cell surface on the other hand is achieved by exocytosis or secretion (section 1.4.2). Ultimately, vesicles fuse with the plasma membrane to release soluble cargo and incorporate membrane‐associated molecules into the cell membrane. This allows cell communication and also for cells to modulate the environment and their contact with other cells or the ECM [Stow et al., 2006]. Both pathways are connected by bi‐directional transport (section 1.4.3) and requires sophisticated machinery (section 1.4.4). Vesicle transport from one organelle or membrane to another involves four major steps [Stenmark, 2009]. Initially, a vesicle has to bud off from a donor membrane and this budding is facilitated by specific cytosolic coat proteins like COPI, COPII, or clathrin and their adaptors. The membrane‐bound cargo is then transported to the target membrane with the help of motor proteins that can move vesicles along microtubules and actin filaments. Tethering factors, such as the Rab proteins (see section 1.4.4.1), aid docking of the vesicle at the target membrane while other trafficking machinery, in particular SNARE proteins (see section 1.4.4.2), in conjunction with other regulators, ultimately enable membrane fusion [Stow et al., 2006]. Specific machinery and pathways have been identified in macrophages and other cell types and can be used to manipulate intracellular trafficking pathways of various effector molecules (see section 1.4.4.3). However, the pathways responsible for the cell surface delivery of important MMPs in 
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macrophages remain unclear (see section 1.4.4.4) and investigating these might allow the development of novel therapeutics. 
1.4.1 Endocytic pathways Endocytosis describes the retrograde transport of vesicles, which allows cargo to be internalised from the cell membrane and environment [Doherty and McMahon, 2009]. Phagocytosis, the engulfment of large particles, is one form of endocytosis that is limited to professional phagocytes such as macrophages and is a crucial mechanism for immune function and protection from pathogens [Greenberg and Grinstein, 2002]. Non‐specific bulk‐phase uptake of extracellular fluid as well as soluble macromolecules is accomplished by all cells when the plasma membrane ruffles fold back to internalise materials and is called micropinocytosis [Lim and Gleeson, 2011]. The actin cytoskeleton plays a major role for both, phagocytosis and macropinocytosis. Other endocytic mechanisms include clathrin‐mediated, caveolae‐mediated and alternative clathrin‐ and caveolae‐independent pathways. [Lopez and Arias, 2010]. These endocytic pathways are often receptor‐mediated to internalise specific extracellular macromolecules upon binding to their respective cell surface receptors, e.g. transferrin (Tfn) and transferrin receptor (TfR) or low density lipoprotein (LDL) and its receptor [Van der Goot and Gruenberg, 2006]. Following the endocytosis from the cell surface, membrane‐bound cargo is delivered to the sorting or early endosome. This membrane‐bound compartment is mildly acidic with a pH of about 6.2, which sometimes induces the release of ligands from their receptors (e.g. LDL) while other ligand‐receptor complexes remain associated (e.g. Tfn or TLR4 and LPS) [Luzio et al., 2005]. Detachment of ligand and receptor allows both of them to be trafficked separately in case the receptor is recycled back to the cell surface either directly or via other compartments [Van der Goot and Gruenberg, 2006]. The tether molecule Rab5 as well as the early endosomal antigen‐1 (EEA1) surround the early endosome and play important roles in endocytic trafficking. From the early endosome, vesicles can be trafficked to the late endosomes. The late endosome compartment is characterised by a growing number of intraluminal vesicles as well as an increasingly acidic pH (~5.5‐5.0) [Luzio et al., 2007; Van der Goot and Gruenberg, 2006]. These intraluminal membranes are enriched in lysobisphosphatidic acid (LBPA), while the limiting membrane contains lysosomal‐associated membrane protein 1 (LAMP1). The presence of tethering factor Rab5 in these organelles is lost while Rab7 is recruited instead. 
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Next in the endocytic pathway are lysosomes, which are the most acidic of these organelles (pH ~4.6‐5.0) and hold acidic hydrolases, such as Cathepsin D. Within the endocytic pathway, it is often the terminal degradation compartment. While lysosomes are also positive for LAMP1, they do not contain LBPA found in late endosomes [Luzio et 
al., 2007]. Transfer of endocytosed material from late endosomes to lysosomes involves heterotypic fusion of both organelles to form a transient hybrid organelle. Late endosomes and lysosomes re‐establish by selective retrieval of late endosome components [Luzio et al., 2007]. The reformation of late endosomes appears to be facilitated, in part, by LBPA [Van der Goot and Gruenberg, 2006]. Both, late endosomes and lysosomes often localise in clusters in the perinuclear region near the microtubule‐organising centre [Luzio et al., 2007; Van der Goot and Gruenberg, 2006]. 
1.4.2 Exocytic/biosynthetic pathways Exocytosis describes the anterograde transport of vesicles towards the cell surface, which ultimately allows soluble cargo to be secreted into the environment and membrane‐associated molecules, such as transmembrane proteins and lipids, to be incorporated into the plasma membrane [Lippincott‐Schwartz et al., 1998]. Exocytosis allows reestablishment of the plasma membrane with the appropriate lipids and cell‐surface proteins following endocytic events, expulsion of waste products but also enables transport and discharge of newly synthesised material into the environment to fulfil cell functions, such as the release of cytokines by macrophages to exert immune properties [Stow et al., 2006]. Classically, newly made proteins destined to be secreted are usually trafficked from the ER to the Golgi complex and then to the cell surface. However, it has to be noted that proteins, such as IL‐1, exist that are secreted by non‐classical pathways independent of ER or Golgi complex [Stanley and Lacy, 2010]. Also, not all proteins are produced for the release into the environment but remain for use inside of the cell. One third of all the newly synthesised proteins – secreted proteins, transmembrane proteins and proteins that will remain within intracellular organelles – are translocated into the ER [Ghaemmaghami et al., 2003]. The translocation process is initiated at the ribosome as detection of an N‐terminal signal peptide by the signal recognition particle halts translation [Rapoport, 1992]. The ribosome then attaches to the ER and translation of the emerging peptide chain through a translocon pore of the ER membrane is initiated. Once translation is finalised, signal peptidases will remove the signal sequence from the new protein [Rapoport, 1992]. The entry into the ER also marks 
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the start of the co‐ and post‐translational modification of the new protein. If the relevant consensus sequence (NXS/T) is present, N‐linked glycans are added en bloc to asparagine residues within the protein by oligosaccharyltransferase [Rapoport, 1992]. The oxidative environment inside the ER allows for the formation of disulphide bonds with the help of the oxidoreductase protein disulphide isomerase (PDI) [Kleizen and Braakman, 2004]. Chaperones aid in the folding process and quality control mechanisms ensure that only properly folded proteins leave the ER [Tokarev et al., 2009]. Correctly folded proteins leave the ER in vesicles at one of 100‐200 ER exit sites and are transported to the ER‐Golgi‐intermediate compartment (ERGIC) by COPII vesicles [Appenzeller‐Herzog and Hauri, 2006]. This process is regulated by activation of the Sar1 GTPase by ER‐associated guanine nucleotide exchange factor (GEF) sev12, guanine nucleotide activating protein GAP Sec23/24 and its regulator Sec13/31 complex [Beraud‐Dufour and Balch, 2002; De Matteis and Luini, 2008]. ER‐resident proteins, recognised by a KDEL motif, as well as misfolded proteins are shuttled back from the Golgi complex to the ER. Vesicles with cargo destined for retrograde transport to the ER are assembled by COPI coat proteins, a process that is regulated by ARF1 GTPase [De Matteis and Luini, 2008].  The Golgi complex is made up of four to eight tightly stacked disk‐like cisternae and takes up a peri‐centrosomal position within the cell. Proteins move from the cisternae nearest to the ER (cis‐Golgi) towards the opposite site (trans‐Golgi). While in the Golgi cisternae, proteins may be modified by O‐linked glycosylation to serine and threonine side chains without any known consensus sequences required for this process [De Matteis and Luini, 2008]. The trans‐Golgi network (TGN) is a sorting station that allows the exit from the trans‐Golgi cisternae where cargo is organised into different vesicles to be transported to various endosomes [De Matteis and Luini, 2008]. The TGN is also the place for final modifications of the newly synthesised protein, such as sialylation and fucosylation of N‑linked and O‑linked glycans and sulphation of glycosaminoglycans, as well as conversion of zymogen to mature protein forms [De Matteis and Luini, 2008]. As an example, processing of the inactive MMP14 pro‐form occurs in the TGN and is a prerequisite for the delivery of mature MMP14 to the cell surface as well as its function upon incorporation into the plasma membrane [Frittoli et 
al., 2011]. The sorting of cargo at the TGN is influenced by multiple mechanisms; recognition of tyrosine (NPXY or YXXO) or leucine ([DE]XXXL[LI] or DXXLL) consensus sequences within the protein, post‐translational modifications (glycosylation, ubiquitinylation, phosphorylation), affinity to micro‐domains of the TGN membrane and 
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sorting machinery proteins [De Matteis and Luini, 2008]. Sorted cargo is transported from the TGN to other organelles or the plasma membrane along microtubules [Luini et 
al., 2008]. Plus‐end‐directed movement of vesicles is mediated by kinesin motor proteins that use ATP‐hydrolysis for a conformational change that translates into movement along the microtubules [Caviston and Holzbaur, 2006; Soldati and Schliwa, 2006]. The interaction between these motor proteins and cargo can be influenced by further regulators like the Rabs and affect the destination of the vesicle [De Matteis and Luini, 2008]. 
1.4.3 Crosstalk between exocytic/biosynthetic and endocytic pathways While endocytosis and exocytosis are concepts to describe retrograde versus anterograde trafficking events, they do not actually occur independently of each other but are connected by bi‐directional transport. Endosomes act as mediating compartments that do not only facilitate degradation of internalised material but also the recycling of cargo and even the delivery of newly synthesised proteins to the cell surface [Stow et al., 2009]. For instance, following endocytosis of Tfn and TfR and after iron bound to Tfn has been released within the cell, receptor and ligand are recycled back to the cell surface via recycling endosomes for reuse [Maxfield and McGraw, 2004]. However, newly synthesised TfR also passes through the recycling endosome before being transported to the plasma membrane as shown in epithelial cells [Futter et al., 1995]. More recently, it was shown that the biosynthetic route of other proteins, such as TNF and IL‐6, also occurs via the recycling endosome in macrophages [Manderson et al., 2007; Murray et al., 2005]. The recycling endosome also participates in the retrograde transport of cargo back to the TGN [Mallard et al., 1998; Tran et al., 2007]. To allow this level of complexity of cargo sorting the recycling endosome is sub‐compartmentalised into multiple domains, which are differently enriched in the respective trafficking machinery. A further example for the connection of endocytic and exocytic pathways are the mechanisms that allow antigen presentation. The MHCII complex is assembled within the ER and Golgi complex before being transported to late endosomes/lysosome [Chow and Mellman, 2005; Geuze, 1998]. In the late endosomes/lysosomes the MHCII complex binds peptides, which originate from internalised pathogens as the phagosome fused with late endosomes/lysosome [van den Hoorn et al., 2011]. The peptide‐MHCII complex is then shuttled to the cell surface where antigen presentation can occur [Bertho et al., 2003; Boes et al., 2002; Chow et al., 2002; Kleijmeer et al., 2001; Vyas et al., 2007]. Thus 
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late endosomes/lysosomes are not exclusively for degradation of endocytosed material but cargo can traffic through them en route to the cell surface. In many haematopoietic cells, and some other cell types, such as melanocytes, secretory lysosomes or lysosome‐related organelles enable storage of pre‐produced proteins derived from the TGN and efficient release of the cargo from these compartments in response to a stimulus [Blott and Griffiths, 2002; Dell’Angelica et al., 2000]. This process is also called regulated exocytosis and is integral for important effector functions of different immune cells. For example, upon T cell receptor stimulus CTLs and NK cells release cytotoxic molecules, such as perforin and granzymes, to kill infected or transformed cells [Griffiths, 2003]. Mast cells and basophils secrete large amounts of histamines and other pro‐inflammatory molecules following Fc receptor stimulus, while the same stimulus triggers neutrophils to release chemoattractants [Blott and Griffiths, 2002; Clark and Griffiths, 2003; Stanley and Lacy, 2010]. Although also of haematopoietic lineage, macrophages do not possess this type of granules or secretory lysosomes but they are nonetheless able to export cargo to the cell surface via lysosomes in a constitutive fashion [Stanley and Lacy, 2010]. Macrophages can upregulate the required machinery and pathways in response to stimulation to increase the rate at which important inflammatory mediators are released into the environment [Murray et al., 2005; Pagan et al., 2003]. Proteins that are transported to the lysosomes for secretion or degradation may be derived from biosynthetic or endocytic pathways and sorting is influenced by a variety of signals. Proteins that are membrane‐associated often display a tyrosine‐based signal within their cytoplasmic tail, while soluble proteins may receive a mannose‐6‐phosphate moiety while in the Golgi complex, which binds to the mannose‐6‐phosphate receptor (M6PR) and targets the protein to the late endosome and then lysosome. Other cell‐specific pathways may exists to influence sorting of cargo to be delivered to these compartments [Blott and Griffiths, 2002; Clark and Griffiths, 2003; Luzio et al., 2007].   
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1.4.4 Trafficking machinery Vesicular transport requires budding, movement, docking and fusion of membrane‐bound cargo at every step of the trafficking pathway [Lacy and Stow, 2011]. To aid with vesicular trafficking eukaryotic cells are equipped with a range of trafficking machinery, which includes lipids and proteins. Initially, newly made proteins need to be sorted into the appropriate carriers, while cytosolic coat and adaptor proteins facilitate budding of the vesicle. Motor proteins drive the movement of the cargo to its target compartment along the cytoskeleton. The family of Rho GTPases, which are predominantly cytoplasmic, can regulate aspects of the intracellular actin network while the family of membrane‐associated Rab GTPases control vesicle docking at the target membrane [Stenmark, 2009]. Fusion of the vesicle and target membrane is dependent on the action of a family of membrane‐associated proteins called SNAP (soluble NSF attachment protein) receptors (SNAREs) [Stanley and Lacy, 2010]. 
1.4.4.1 Rabs Rab GTPases influence budding, movement and docking of vesicles during intracellular trafficking events [Stenmark, 2009]. Rab proteins are a family of small GTPases of the Ras superfamily and there are 70 known members in mammals [Bhuin and Roy, 2014]. Rabs switch between two conformational states as typical of GTPases. When inactive, Rabs are bound to GDP and found in the cytosol. Guanine nucleotide dissociation inhibitor (GDI) converts the Rab into its active, GTP‐bound state, which then becomes membrane‐associated through two hydrophobic geranylgeranyl groups that are attached to cysteine residues within the protein [Bhuin and Roy, 2014; Stenmark, 2009]. Individual members of the Rab family localise to distinct membranes within the cell [Stenmark, 2009]. While in the active state, Rabs recruit and/or activate effector molecules, such as sorting adaptors, kinases, phosphatases, motor proteins and other tethering factors [Stenmark, 2009]. Sorting of cargo is initiated through recognition of the cargo by adaptor proteins and assembly of coat proteins, such as clathrin or COPI and COPII, recruited from the cytosol [Cai et al., 2007]. Rabs can assist in cargo‐specific vesicle sorting by recruiting effector molecules to distinct intracellular membranes. For example, Rab9 recruits the adaptor protein TIP47 to late endosome, which enables the recycling of M6PR by transporting M6PR‐positive carriers back to TGN [Bhuin and Roy, 2014; Carroll et al., 2001; Stenmark et al., 2009]. Rab5 participates in the assembly of clathrin‐coated pits at the plasma membrane for the endocytosis of TfR [Bhuin and Roy, 2014; Liu and Storrie, 
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2012; McLauchlan et al., 1998; Stenmark, 2009]. Once a vesicle is established and budded from the donor membrane, Rabs can also help to remove coat proteins. This coat shedding is important as the presence of coat protein complexes inhibits membrane fusion. Rab5 is known to coordinate disassembly of the adaptor protein complex AP2 following endocytosis [McLauchlan et al., 1998]. Rabs also influence the motility of vesicles as they control interactions of the cargo with motor proteins that facilitate long‐range transport along elements of the cytoskeleton. Rab27 connects melanosomes, which are organelles that store melanin, e.g. in melanocytes, to the actin motor protein myosin Va [Bhuin and Roy, 2014; Liu and Storrie, 2012; Stenmark, 2009]. Once in proximity to the target membrane, Rabs facilitate vesicle docking often together with other tethering factors. Rab5 tethers endocytosed vesicles to the membrane of early endosomes in cooperation with EEA1 [Bhuin and Roy, 2014; Nielsen 
et al., 2000; Simonsen et al., 1998; Stenmark, 2009]. At the ERGIC, Rab1 first recruits the tether molecule p115 during COPII vesicle budding at the ERGIC, and then also binds to the Golgi matrix protein GM130 [Beraud‐Dufour and Balch, 2002; Stenmark, 2009].  Rabs specifically locate to particular membranes of different organelles; for instance, Rabs 5, 7, and 11 associate with early, late, and recycling endosomes, respectively, while Rab6 is found at the Golgi complex and Rab27a is known to regulate granule release in certain cell types [Lacy and Stow, 2011; Liu and Storrie, 2012; Stow and Murray, 2013; Stanley and Lacy, 2010]. If various Rab members associate with the same organelle, they are often found spatially segregated and occupy distinct membrane microdomains, which are sometimes referred to as Rab domains. These domains remain dynamic but do not significantly intermix to allow for their function in cargo sorting [Stenmark, 2009; Zerial and McBride, 2001]. While Rabs play many important roles for vesicular trafficking by influencing vesicle formation, movement and docking, fusion is ultimately achieved through the specific pairing of cognate SNARE proteins on the opposing membranes [Jahn and Scheller, 2006]. Rabs have been suggested to further influence this process as Rab effector proteins interact with SNARE machinery, SNARE priming machinery, and SNARE proteins themselves to increase efficiency as well as specificity of cargo transport [Bhuin and Roy, 2014; Zerial and McBride, 2001]. However, the exact mechanisms through which Rabs might regulate membrane fusion are not yet known [Bhuin and Roy, 2014].   
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1.4.4.2 SNAREs Ultimately, the delivery of membrane‐bound vesicles to the cell surface for secretion or incorporation into the plasma membrane requires membrane fusion between vesicles and organelles or the cell surface. A family of proteins known as the SNAREs (soluble N‐ethylmaleimide‐sensitive factor attachment protein receptor) regulate this process at multiple points along the trafficking pathway by providing the energy and specificity required [Jahn and Scheller, 2006]. SNAREs are small proteins of around 100–300 amino acids in length. Each member contains at least one evolutionally‐conserved SNARE motif of about 60‐70 residues, which participates in the formation of a helical SNARE complex important for the membrane fusion mechanisms [Hong, 2005]. 36 members of the SNARE family exist in humans to date and most of them possess a C‐terminal hydrophobic type II transmembrane anchor, while some of them associate to the cytoplasmic side of the membrane via prenylation, palmitoylation or interaction with another anchored SNARE member [Hong, 2005; Malsam et al., 2008; Murray and Stow, 2014]. Members of the SNARE family are in general ubiquitously expressed, with the exception of two neuronal specific SNAREs, Stx1, and SNAP25, and the immune specific SNARE Stx11 [Murray and Stow, 2014]. SNAREs are found on all organelle membranes, as well as the plasma membrane, and, similar to the Rabs, they are characterised by a precise subcellular distribution. The selective interaction of a SNARE on a donor membrane and two to three cognates SNAREs on a target membrane forms a trans‐SNARE complex that drives the fusion process (Figure 1.8) [Fasshauer, 2003]. 
 
Figure 1.8. SNARE‐mediated fusion (modified from Murray and Stow, 2014). 
The R‐SNARE (pink) together with the Q‐SNARE complex (aqua), pull vesicle and target 
membrane close together and potentially generate the force required for the fusion of the two 
lipid bilayers. After fusion the SNARE complex is located on the target membrane and called 
cis‐SNARE complex. It will then be disassembled.  
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In yeast, of about 300 possible combinations of SNARE proteins tested in an in 
vitro liposome fusion assays, only 9 of them were found to be fusogenic [Malsam et al., 2008]. This is because SNAREs are not all the same. According to the composition of their SNARE motif, SNAREs can be classified as either R‐ or Q‐SNAREs. R‐SNAREs, such as the VAMPs, carry an arginine (R) as central functional residue within SNARE motif and are usually found on the vesicle membrane [Jahn and Scheller, 2006]. Q‐SNAREs, such as the syntaxins (Stx), are characterised by a glutamine (Q) as the central functional residue of the SNARE motif and are typically on the target membrane. These conserved SNARE motifs facilitate the protein interactions in the trans‐SNARE complex, which forms a highly stable coiled‐coil superstructure [Jahn and Scheller, 2006]. Depending on their position in the trans‐complex, Q‐SNAREs can be further classified as Qa, Qb, Qc or Qbc SNAREs (Table 1.3). All R‐SNAREs, as well as most Q‐SNAREs (Qa, Qb, Qc), have one SNARE motif near their C‐terminal anchor to contribute to the trans‐SNARE complex. However, three Q‐SNAREs SNAREs, namely SNAP23, SNAP25 and SNAP29, contain two SNARE motifs (Qbc). Hence, the formation of functional trans‐complex with four SNARE motifs is established either through the interaction of four (R‐Qa‐Qb‐Qc) or three (R‐Qa‐Qbc) SNAREs [Stow et al., 2006]. 
Table 1.3. Q‐ and R‐SNARE family members. 
R-SNAREs Q-SNAREs Qa Qb Qc Qbc 
VAMP1, 
VAMP2, 
VAMP3, 
VAMP4, 
VAMP5, 
VAMP7, 
VAMP8, 
ERS24, YKT6 
STX1, STX2, 
STX3, STX4, 
STX5, STX7, 
STX11, STX13, 
STX16, STX17, 
STX18 
GS27, GS28, 
Vti1a, Vti1b 
STX6, STX8, 
STX10, GS15, 
BET1, SLT1 
SNAP23, 
SNAP25, 
SNAP29, 
SNAP47 
 The formation of the four‐chain helix that forms the trans‐complex is mediated by the hydrophobic side chain residues, which are positioned perpendicular to the helical axis [Beraud‐Dufour and Balch, 2002; Hong, 2005; Stanley and Lacy, 2010]. The zippering of this helix is initiated at the N‐terminus of the SNARE proteins and progresses toward the C‐terminus, which is closer to the membrane. This conformational change brings the two membranes in close proximity, deforms the membrane and provides the energy required to overcome repulsion of the opposing membranes due to the negative charges of phospholipid headgroups of the lipid bilayers [Hong, 2005]. This allows the formation of an aqueous fusion pore through which cargo can be discharged while transmembrane proteins and lipids of the donor membrane are incorporated into 
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the target membrane [Murray and Stow, 2014]. Alternatively, in a process called “kiss and run”, only some of the cargo is released and the pore might subsequently close again [Murray and Stow, 2014]. It is estimated that 3 to 15 SNARE complexes are required to catalyse a single fusion event [Jahn and Scheller, 2006]. As a result of the fusion event, all participating SNAREs are located on the same membrane, which is called a cis‐SNARE complex. This cis‐complex has to be disassembled to allow further fusion events and requires conformational rearrangement regulated by the NSF and α‐SNAP molecular chaperones [Jahn and Scheller, 2006]. As SNARE members have a precise distribution within the cell (Figure 1.9), and SNARE come together in specific combinations to form distinct SNARE complex, the process of membrane fusion for vesicular trafficking is highly specific [Murray and Stow, 2014]. Additionally, plasma‐membrane SNAREs are known to concentrate in nano domains rather than being randomly distributed within the membrane to allow polarised release of cargo at certain areas of the cell surface [Jahn and Scheller, 2006]. Further spatial and temporal regulation of SNARE‐mediated fusion is achieved through post‐translational modifications of SNARE proteins, as well as binding of regulatory proteins [Stow et al., 2006]. Sec1/Munc18 and Rab proteins are regulatory machinery that can influence assembly of the SNARE fusion‐complex [Beraud‐Dufour and Balch, 2002; Martens and McMahon, 2008; Stanley and Lacy, 2010]. As each type of organelle has distinct SNAREs sets that can only bind their equivalent SNARE partner on the respective target membrane, the absence or malfunction of just one of the participating SNAREs inhibits the fusion process [Stow et 
al., 2006]. Therefore, mutant forms or depletion of individual SNAREs block specific fusion steps and have been used to map transport pathways in macrophages [Stow and Murray, 2013]. Pathologically, SNAREs are targets of the zinc‐dependent endopeptidase activity of the clostridial neurotoxins [Pickett and Perrow, 2011]. These toxins enter the cell by endocytosis after binding to the cell surface of neuronal cells. Once within the cell, they can cleave certain members of the SNARE family and thereby inhibit membrane fusion. The defect in the release of the neurotransmitter acetylcholine causes the diseases tetanus and botulism and can be fatal. However, the toxin may be re‐engineered to target specific trafficking pathways in other cell types, such as macrophages [Pickett and Perrow, 2011]. 
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Figure 1.9. Intracellular trafficking pathways in macrophages and SNARE proteins 
associated with the different compartments. 
Endocytosed material transported to the early endosome (orange) is either targeted to the 
lysosome (green) or recycled back to the cell surface. There are at least two major exocytic 
pathways by which proteins can be delivered to the cell surface in macrophages. The classical 
pathway takes cargo from the Golgi complex (blue) to the plasma membrane (black) either 
directly or via the recycling endosome (purple). In the lysosomal secretory pathway, cargo is 
transported via lysosomes (green) or lysosome‐related organelles (brown) en route to the cell 
surface. Both pathways require cargo to be transported in membrane bound carriers, which 
must at each step fuse with the plasma membrane and is mediated by SNARE proteins. 
Individual SNARE members locate to distinct membranes (boxes) and the selective interaction 
of one R-SNARE (pink) on a donor membrane and two to three cognate Q-SNAREs (aqua) 
on a target membrane forms a trans‐SNARE complex that drives the fusion process.  
1.4.4.3 Trafficking pathways and machinery in macrophages To fulfil their various tasks during the immune response, macrophages extensively use their endocytic and exocytic pathways, which allows phagocytosis and the release of large amount of newly made inflammatory mediators into the extracellular space, as well as other important processes. Hence, SNARE proteins and other associated trafficking machinery have a great impact on macrophage function and the overall inflammatory response within tissues [Stow et al., 2006]. In unactivated macrophages, low levels of constitutive trafficking occurs to maintain basic functions of protein transport and cell homeostasis. Some proteins, such as cytokines, may be transported through to the cell surface for secretion, however the protein levels of certain SNAREs are rate‐limiting for these trafficking events [Murray et 
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al., 2005]. Upon activation, macrophages upregulate the expression of important SNAREs and other machinery to increase vesicular trafficking [Stow et al., 2006]. This is important to permit secretion of large quantities of cytokines within minutes to hours following activation as macrophages lack the ability to pre‐pack proteins to be released from granules as is the case in some other immune cells [Murray and Stow, 2014]. LPS‐stimulation for example up‐regulates the SNAREs Stx6‐Stx7‐Vti1b to accommodate for increased TNF transport [Murray et al., 2005]. The levels of specific SNAREs can also be changed experimentally in order to manipulate particular trafficking pathways. At least two major pathways are known in macrophages by which proteins can be delivered to the cell surface [Murray and Stow, 2014]. Proteins that have an N‐terminal signal sequence are targeted for synthesis in the ER. Proteins can then be shuttled through the Golgi apparatus and transported to the surface in membrane bound compartments or vesicles either directly or through the recycling endosome (Figure 1.9). This is known as the classical transport pathway. In the second major secretory pathway, the lysosomal secretory pathway, lysosomes or lysosome‐related organelles target proteins to the surface either directly from the cytosol or from the Golgi complex (Figure 1.9). Both pathways require cargo to be transported between organelles and to the cell surface in membrane bound carriers, which must at each step fuse with the organelles 
en route or the plasma membrane mediated by the appropriate trafficking machinery proteins [Stow and Murray, 2013]. Secretory mechanisms in macrophages are not fully elucidated yet but mapping of exocytic pathways have begun and are best understood for certain cytokines. Tumour 
necrosis factor α (TNFα) is trafficked from the Golgi to the recycling endosome through interaction of the Golgi SNARE complex Stx7/Vti1b/Stx6 with the Recycling Endosome SNARE VAMP3 and its secretion then mediated through association of VAMP3 with Stx4/SNAP23 at the plasma membrane in macrophages [Murray et al., 2005a; Murray et 
al., 2005b; Pagan et al., 2003]. In macrophages, VAMP3 is also required for secretion of IL‐10 and IL‐6. For the release of IL‐6, VAMP3 cooperates with Vti1b and Stx6 [Manderson et al., 2007; Stanley et al., 2012]. On the other hand, Stx11 has been shown to regulate the secretion of a protein called Flightless (Flii) via a late endocytic/lysosomal compartment in macrophages [Lei et al., 2012]. Generally, knowledge about other SNARE proteins still relies mostly on information obtained from other cell types and requires further investigation in macrophages. 
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1.4.4.4 Intracellular trafficking of MMP9 and MMP14 in macrophages There are currently no effective drugs that clinically alter MMP levels in wounds and as such there is a need for a greater understanding of how these enzymes are secreted in order to provide new therapeutic targets to treat chronic wounds. MMP9 is highly elevated in chronic wounds and linked to poor wound healing outcomes as they lead to excessive ECM degradation [Rohl and Murray, 2013]. Membrane‐associated MMP14 is believed to play a role in macrophage migration and infiltration of wound tissue, where they further contribute to the level of MMPs at the wound site [Linder, 2007]. The intracellular trafficking pathways responsible for secretion of MMP9 and the delivery of MMP14 to the cell surface are unknown in macrophages and unclear in other cell types. 
Intracellular trafficking of MMP9 In neuroblastoma cells, MMP9 has been found to traffic through a Golgi dependant pathway along microtubules and filaments to the cell surface in an anterograde and retrograde manner [Sbai et al., 2010]. In astrocytes, MMP9 was further demonstrated to co‐localise with the lysosome marker LAMP2 [Sbai et al., 2010] while in breast carcinoma cells [Bobrie et al., 2012] and neutrophils [Brzezisnka et al., 2008], a lysosome‐related GTPase, Rab27a, is involved in MMP9 secretion, suggesting MMP9 is stored in and trafficked via a lysosomal‐related organelle in these cell types. It is noteworthy that trafficking of MMP9 is cell type dependent [Vandooren et al., 2013] and this may depend on the pathways utilised although this has yet to be tested. Upon stimulation, mature neutrophils, which have MMP9 pre‐stored in granules, can release MMP9 within minutes [Chakrabarti et al., 2006]. Macrophages on the other hand, rely on 
de novo synthesis prior to the secretion of MMP9, a process that takes at least several hours [Opendakker et al., 2001]. In murine macrophages MMP9 has been shown to be trafficked in Golgi‐derived vesicles that are microtubule‐associated but do not co‐localise with markers for lysosomal degradation such as LAMP1, suggesting MMP9 is trafficked through a classical pathway [Hanania et al., 2012]. Furthermore, the SNARE VAMP3 (recycling endosome associated) together with the plasma membrane SNARE SNAP23 are required for secretion of MMP9 in fibrosarcoma cells, suggesting the classical pathways is used in these cells [Kean et al., 2009]. These contradictive findings suggest that MMP9 could be trafficked through the classical pathway via the recycling endosome in some cell types and secreted via a lysosomal pathway in other cells. The responsible 
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pathways for secretion of MMP9 in macrophages remain unclear and the machinery that regulates MMP9 secretion pathways is unknown. 
Intracellular trafficking of MMP14 Many studies have been undertaken to investigate the trafficking of MMP14. As MMP14 is believed to play a major role in cancer invasion, most of these studies have been conducted using breast adenocarcinoma and fibrosarcinoma cell lines and not macrophages [Poincloux et al., 2009]. Studies found that pro‐MMP14 processing occurs in the Golgi complex and is required for the delivery of mature MMP14 to the plasma membrane [Frittoli et al., 2011]. In resting fibrosarcoma cells, MMP14 is also continuously internalised and trafficked to early and late endosomes before being recycled back to the cell surface [Poincloux et al., 2009; Remacle et al., 2003]. As a result, a substantial amount of MMP14 is localised inside the cell with cell surface expression being weak in most cell types and thus, polarised secretion of pre‐existing MMP14 is highly regulated [Poincloux et al., 2009]. There are conflicting results about whether MMP14 could be trafficked to the cell surface via a classic pathway or through the lysosome. MMP14‐positive vesicles were found to localise in Rab7‐positive late endosomes [Williams and Coppolino, 2011; Yu et al., 2012] and to co‐localise with the lysosome‐related SNARE VAMP7 [Steffen et al., 2008; Williams and Coppolino, 2011] in breast adenocarcinoma and fibrocarcinoma cells. Controversially, it was found that polarised MMP14 exocytosis from the Golgi to the cell surface involves the recycling endosome‐associated GTPases Rab4 and Rab11 in fibrosarcoma cells [Remacle et al., 2005], suggesting it traffics through these organelles. Additionally, the endosomal SNAREs VAMP3 and Stx13 together with the plasma membrane SNARE SNAP23 mediate trafficking of MMP14 to the cell surface in fibrosarcoma cells [Kean et al., 2009] as does the cell surface SNARE Stx4 in gastric epithelia cells [Miyata et al., 2004]. This shows that there are contradictory results about whether MMP14 could be trafficked via a classical or lysosomal pathway for these cell types. In primary human macrophages, MMP14 endocytosis is regulated by Rab5a and recycled by Rab14 (early endosome to cell surface) and Rab22 (early endosome to recycling endosome), whereas newly synthesised MMP14 is proposed to be trafficked by a Rab8a‐dependant pathway from the Golgi apparatus to the cell surface [Wiesner et al., 2013]. But whether the transport in exocytic vesicles to the cell surface occurs directly or via the recycling endosome is not clear. It would be advantageous to expand the current knowledge of pathways for MMP14 surface delivery in macrophages and its influence on macrophage invasion.  
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1.5 Aims MMP14 may play a key role in macrophage migration and infiltration of wound tissue and therefore influences the level of inflammation within a wound. MMP9 may also promote macrophage mobility by degrading the extracellular matrix. In addition, MMP9 and MMP14 are highly elevated in chronic wounds further contributing to tissue damage and inflammation at the wound site. Their increased levels have been linked to poor wound healing outcomes and chronic wounds. Exactly how MMP9 and MMP14 are delivered to the cell surface in macrophages and whether they have an influence on macrophage mobility is mostly unknown. At present, there are no clinically viable drugs that reduce MMPs in wounds and as such there needs to be greater understanding of how these enzymes are secreted in order to provide new therapeutic targets to dampen inflammation and speed up the repair process in chronic wounds. Based on this, the following research questions were identified: 1. Which trafficking routes are used to deliver MMP9 to the cell surface and which are the key trafficking proteins involved in this process? 2. Which trafficking routes are used to deliver MMP14 to the cell surface and which are the key trafficking proteins involved in this process? 3. What influence does MMP14 and its surface delivery trafficking pathways have in the migration of macrophages through the extracellular matrix? This body of research aims to answer these questions and thereby elucidate the processes of MMP trafficking in macrophages, their influence on macrophage infiltration into wounded tissue and identify potential therapeutic targets to reduce MMP levels in chronic wounds. To investigate these research questions, the following aims were established: 
 Aim 1: Determine the specific intracellular trafficking pathways responsible for trafficking of MMP9 to the cell surface for secretion. 
 Aim 2: Determine the specific intracellular trafficking pathways responsible for trafficking MMP14 to the cell surface for incorporation into the plasma membrane. 
 Aim 3: Characterising MMP‐mediated macrophage migration in 3D. 
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Chapter 2: Materials and methods 
 
2.1 Cell culture and treatments 
2.1.1 Cell culture of RAW264.7 macrophages The mouse macrophage cell line RAW264.7 (American Type Culture Collection (ATCC); ATCC Number TIB‐71™) was maintained as semi‐adherent cultures on bacteriological Petri dishes (BD Biosciences) in RPMI1640 medium (Gibco®) supplemented with 10% (v/v) heat‐inactivated Foetal Bovine Serum (FBS; Sigma‐Aldrich) and 2 mM GlutaMAX™ (Gibco®). Cells were maintained in a humidified incubator at 37 °C and 5% CO2. Cells were passaged every 2‐3 days, up to passage 17, using a 10 ml syringe with an 18 gauge needle to resuspend the cells. The cells were then pelleted at 300 x g for 3 min and resuspended in 10 ml media for subculturing at a ratio of 1:5 to 1:20. For most experiments, cells were seeded at 1:10 onto tissue culture‐treated plates (Corning Incorporated), where they grow as adherent cells. For fluorescence microscopy analysis, cells were seeded onto round glass coverslips (diameter 10 mm, thickness 0.13‐0.16 mm; Menzel‐Gläser). In relevant experiments cells were plated onto coverslips that had been incubated for 2 h at 37 °C with 50 μg poly‐L‐lysine (Sigma‐Aldrich) in PBS and for a further 4 h at 37 °C with 10 μg fibronectin (Sigma‐Aldrich) in PBS. To record the dynamic movement of MMP‐containing vesicles by live cell imaging, cells were seeded into Matek dishes (Matek), which contain a 12‐mm diameter round glass coverslip inserted into the bottom of the plate. Prior to live imaging, the medium was changed to pre‐warmed CO2‐independent medium (Gibco®) supplemented with 10% FBS and 2 mM GlutaMAX™. 
2.1.2 Activation of RAW264.7 macrophages To classically activate macrophages, RAW264.7 cells were cultured with lipopolysaccharide (LPS), a component of the outer bacterial membrane of Gram‐negative bacteria, derived from Salmonella enterica serotype Minnesota (Sigma‐Aldrich), at a final concentration of 100 ng/ml for up to 18 h. For migration experiments macrophages were stimulated with the chemoattractant N‐formyl‐methionyl‐leucyl‐proline (fMLP; Sigma‐Aldrich) at a final concentration of 100 nM. 
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2.1.3 Disruption of protein synthesis and intracellular trafficking To stop protein synthesis, cycloheximide (Sigma‐Aldrich) was added to the medium of LPS‐stimulated cells (9 or 12 h depending on the experiment) at a final 
concentration of 1 μg/ml for the last 4 h, to block protein synthesis. Brefeldin A (Sigma‐Aldrich), which inhibits protein transport from the ER to the Golgi and leads to collapse of the Golgi stacks, was added to LPS‐stimulated (9 or 12 h depending on the experiment) cells at a final concentration of 5 μg/ml for the last 6 h. To disrupt microtubules, nocodazole (Sigma‐Aldrich) was added to LPS‐stimulated (9 or 12 h depending on the 
experiment) RAW264.7 cells at a final concentration of 5 μM for the last 3 h. Cytochalasin D (Sigma‐Aldrich), which disrupts filamentous actin, was added to LPS‐stimulated cells 
(9 or 12 h depending on the experiment) at a final concentration of 1 μM for the last 2 h. 
2.1.4 Transient overexpression of proteins The cationic lipid based transfection reagent Lipofectamine® 2000 (Invitrogen™) was used to transiently overexpress proteins (fluorescence‐labelled MMPs) in macrophages that had been plated onto tissue culture dishes with or without coverslips on the previous day. Macrophages were transfected with 0.1 μg DNA and 0.4 μl Lipofectamine® 2000 reagent diluted in 25 μl of Opti‐MEM® per cm2 of tissue culture surface area. The cells were incubated with the final transfection mix for 3 h at 37 °C and then with normal media at 37 °C for 3 h and were either imaged live (section 2.3.2), fixed and further immunofluorescence labelled (section 2.2.5) or lysed and subjected to SDS‐PAGE and immunoblotting analysis (section 2.2). The mammalian expression vectors used in this project are listed in Table 2.1. 
Table 2.1. List of plasmids used for this project. 
Protein Vector Obtained from 
MMP14-GFP peGFP Prof Jim Norman, The Beatson Institute for Cancer Research, Glasgow, UK 
MMP14-mCherry pcDNA3.1(+) Prof Jim Norman, The Beatson Institute for Cancer Research, Glasgow, UK 
MMP9-mCherry pCI-neo Dr Tyler Duellman, University of Wisconsin-Madison, USA 
ssT-Cad*-eGFP pCI-neo Dr Tyler Duellman, University of Wisconsin-Madison, USA 
* T-cadherin signal sequence 
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2.1.5 Targeted knockdown using siRNA To reduce the expression levels of SNARE proteins, double‐stranded short interfering RNA (siRNA) molecules were used (Table 2.2) according to the manufacturer’s instructions. In brief, RAW264.7 macrophages were transfected using a mix of 22.5 pmol siRNA and 0.45 µl Lipofectamine® 2000 (Invitrogen™) in 25 µl Opti‐MEM® (Gibco®) per cm2 tissue culture surface area. The transfection mixture was prepared by incubation of the Lipofectamine® 2000 in Opti‐MEM® for 5 min before the addition of the respective siRNA and incubating for a further 20 min. The cells were then incubated with the transfection mix for 3 h at 37 °C, the media was replaced with fresh RAW cell culture media and the cells cultured overnight. This process was repeated the following day. After the second transfection, cells were either incubated overnight or, if equal cell numbers were necessary, removed from the tissue culture plates 5 h after transfection. Detachment of cells was achieved by incubating them in 0.5 mM EDTA/PBS for 5 min at 37 °C, followed by gently scraping the cells off the plate using a rubber cell scraper. Cells were then counted and reseeded at equal densities.  
Table 2.2. siRNA sequences used to knockdown SNARE proteins. 
Target  ID* Sequence 
Negative 
Control 
Catalogue number: 
AM4635 
scrambled siRNA; no sequence information 
available for Silencer® Negative Control No. 1 
SNAP23 64778 5’-GGCAUGGACCAAAUAAAUAtt-3’ 3’-UAUUUAUUUGGUCCAUGCCtt-5’ 
Stx2 157352 5’-GGCGGAAAAAGUGGAUAAUtt-3’ 3-‘AUUAUCCACUUUUUCCGCCtg5’ 
Stx3 151904 5’-CGGCAGCUUGAAAUUACUGtt-3’ 3-‘CAGUAAUUUCAAGCUGCCGtt5’ 
Stx4 151036 5’-GGAAGCUGAUGAGAAUUACtt-3’ 3’-ctCCUUCGACUACUCUUAAUG-5’ 
VAMP2 186987 5’-GGAAGGAUCUAAUCUUUUUtt-3’ 3-‘AAAAAGAUUAGAUCCUUCCtc5’ 
VAMP3 186988 5’-CCUGCCGUGUUAUCGAGCUtt-3’ 3’-ttGGACGGCACAAUAGCUCGA-5’ 
VAMP4 184543 5’-GCUUCGAAGGCAAAUGUGGtt-3’ 3-‘CCACAUUUGCCUUCGAAGCtg5’ 
VAMP7 261085 5’-GGCACAAGUCUCCUUGUAAtt-3’ 3-‘UUACAAGGAGACUUGUGCCtt5’ 
VAMP8 188662 5’-GCCACGUCUGAACACUUCAtt-3’ 3-‘UGAAGUGUUCAGACGUGGCtt5’ 
* All purchased from Ambion®, Thermo Fisher Scientific 
2.1.6 Fluorescent gelatin degradation assay To perform fluorescent gelatin degradation assays, coverslips were prepared as follows. First, the coverslips were cleaned by incubation in 1 M HCl overnight, followed by rinsing in distilled water twice and 95% ethanol twice. To aid attachment of the Oregon Green® 488 conjugated gelatin (Molecular Probes™), the coverslips were 
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first coated with 50 μg poly‐L‐lysine (Sigma‐Aldrich) for 1 h at room temperature (RT). After removing the poly‐L‐lysine, the coverslips were washed three times with PBS. Next, 0.5% glutaraldehyde in PBS was added for 15 minutes at 4 °C to activate the poly‐L‐lysine surface for further protein attachment. Following removal of the glutaraldehyde, each coverslip was rinsed three times with PBS. Finally, coverslips were coated with 0.2 mg/ml gelatin in 2% sucrose/PBS and allowed to set for 15 minutes at RT, followed by two rinses in PBS. All steps including, and subsequent to, fluorescent‐gelatin coating were performed in low lighting or in the dark so as to protect the fluorophore from photobleaching. Any free aldehydes were quenched by incubation with amino‐acid‐containing growth medium at RT for at least 20 minutes. To prepare for cell plating, the coated coverslips were sterilised with 95% ethanol for 15 minutes at RT. After this step, coverslips were either used immediately or stored at 4 °C for up to two weeks. Macrophages were seeded on to the gelatin coated coverslips and incubated for 18 h in a humidified incubator at 37 °C. In relevant experiments MMP activity was inhibited with a broad spectrum MMP inhibitor, GM6001 (Sigma‐Aldrich) at a final concentration of 25 μM in DMSO and DMSO alone was added to control wells. MMP14 activity was also inhibited with a function blocking antibody [LEM‐2/63.1] specific to the catalytic domain of MMP14 (Abcam, ab78738). A matched isotype control was added to some wells at a final concentration of 10 μg/ml. Approximately 18 h after plating, the growth medium was removed and the cells on the coverslips were fixed and stained as described in section 2.2.5. Using ImageJ 1.46r software (National Institutes of Health, Bethesda, MD, USA), the mean grey value for the gelatin fluorescent signal (Oregon Green® 488 conjugated to gelatin) was determined for areas that were positive for phalloidin staining. Degradation was determined per cell by subtracting this mean grey value from the mean grey value of the background adjacent to the individual cell.   
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2.1.7 Inverted invasion assay Inverted invasion assays [Hennigan et al., 1994] were performed using either undiluted Matrigel (12 mg/ml) or gelled collagen plugs. To obtain gelled collagen, Bovine collagen I (Gibco®) was mixed with PBS (final concentration: 1 X), NaOH (final concentration: 0.02 N) and distilled water to a final concentration of 4 mg/ml. 100 μl of either Matrigel or collagen matrix was then transferred into a Transwell® insert (Corning) and allowed to set for at least 30 minutes at 37 °C. Inserts were then inverted, 5×105 cells were seeded directly onto the bottom side of the membrane and allowed to attach for at least 2 h. Inserts were reinverted, more growth medium was added to the bottom chamber, and medium supplemented with the chemoattractant 100 nM fMLP was added on top of the matrix (Figure 2.1). In some experiments the broad spectrum MMP inhibitor GM6001 (25 μM in DMSO) or an antibody specific for the catalytic domain of MMP14 [LEM‐2/63.1] (10 μg/ml) was added to the bottom chamber. Invading cells were fixed 72 h after seeding in 4% paraformaldehyde in PBS for 1 h at RT, washed once with PBS and were stored in PBS at 4 °C until analysis.  Permeabilisation of fixed cells within gel plugs was performed using 0.1% Triton X‐100 in PBS for 10 min at RT. Cells were washed twice and blocked with 0.5% (w/v) Bovine Serum Albumin (BSA, Sigma) in PBS for 10 min at RT. The cells were then incubated with phalloidin‐TRITC diluted in 0.5% BSA in PBS (see Table 2.3 for dilutions used) for 1 h at RT in the dark. After three washes, cells were stored in PBS at 4 °C until they were imaged. Imaging was conducted on a Leica SP5 confocal laser scanning microscope (see 2.3.1). After imaging the cells that did not cross the membrane by confocal microscopy, the membrane was removed to visualise those cells that had invaded the gel. Serial optical sections of the collagen gel were captured at 3‐15 µm intervals. The cell area for each section was measured by setting a high intensity threshold for the phalloidin signal and using the particle analysis function of ImageJ. The sum of all area measurements for each stack was determined and the mean of at least three technical replicates calculated. This index of invasion was normalised by comparing the treatment groups to a control. At least three independent experiments were performed for each sample unless stated otherwise.   
  46   Chapter 2: Material and methods 
 
Figure 2.1. Inverted Invasion Assay. 
Matrix material (Matrigel or collagen I) was allowed to set in a Transwell® insert (Corning) 
before cells were seeded onto the bottom side of the membrane and placed in growth medium. 
Medium supplemented with fMLP as the chemoattractant was added on top of the matrix. 
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2.2 Biochemistry assays 
2.2.1 Sample preparation To collect conditioned media, cell culture supernatant was collected and centrifuged at 2500 x g for 5 min to remove any cells and cell debris. The cell culture supernatant was transferred to a new tube and either used immediately or snap‐frozen in liquid nitrogen and stored at ‐20 °C until use. To prepare whole cell lysates, cells grown on tissue culture plates were placed on ice, washed once with ice‐cold PBS and scraped into ice‐cold lysis buffer (20 mM Tris/HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X‐100 and Complete™ protease inhibitors (Roche Applied Sciences)). Cells were lysed by sonication in a standard sonicating water bath for 2 x 5 min at 4 °C, with a 5 min incubation on ice. The lysate was then centrifuged for 20 min at 17,000 x g and the supernatant collected. Protein concentration was determined using the Bio‐Rad Bradford protein assay (Bio‐Rad Laboratories) according to the manufacturer’s instructions. Samples were either used immediately or stored at ‐20 °C. 
2.2.2 Gelatin Zymography (MMP9) Samples were mixed with 5 x Zymography sample buffer (5 x buffer: 200 mM Tris/HCl pH 6.7, 10% SDS, 50% glycerol, 0.025% bromophenol blue). Equal volumes (conditioned media) or equal amounts of protein (30‐100 µg lysates) were loaded onto 10% Ready Gel® Zymogram Gels (Bio‐Rad), along with a lane each of Benchmark™ prestained protein ladder (Invitrogen), and PagerRuler™ prestained protein ladder (Thermo Scientific™) markers to enable the visualisation of protein separation and to determine the size of protein bands. Gels were run at 125 V in buffer containing 25 mM Tris, 192 mM glycine and 0.1% SDS until the bromophenol blue tracking dye ran out of the bottom of the gel. After incubation with Renaturing Buffer (2.5% Triton) for 30 min with gentle agitation at RT the gels were equilibrated in Developing Buffer (50 mM Tris pH 7.6, 10 mM CaCl2, 50 mM NaCl) for 30 min at RT and then incubated in fresh Developing Buffer overnight at 37 °C. Gels were stained with 0.1% Coomassie Brilliant Blue in 50% methanol and 10% acetic acid overnight and destained in water or 50% methanol and 10% acetic acid. Gelatinase activity is revealed as clear bands in the blue gel, and the zymogen (105 kDa) or mature form of murine MMP9 (95 kDa) can be discriminated by molecular weight. FBS‐free conditioned media from the fibroblast cell line baby hamster kidney (BHK) cells overexpressing the human zymogen form of MMP9 (kindly provided by Dr Eliza Whiteside, QUT) was used as a positive control for the assay. Images of the gels were taken using the Bio‐Rad ChemiDoc™ XRS system. 
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2.2.3 SDS-Page and Immunoblotting Protein samples were denatured in Laemmli sample buffer (5 x buffer: 200 mM Tris/HCl pH 6.7 containing 10% SDS, 50% glycerol, 0.025% bromophenol blue, and 250 mM DTT) by boiling for 5 min at 95°C. Up to 100 μg of protein per lane was loaded onto SDS‐PAGE gels. Depending on the size of the proteins of interest, gels ranged from 10‐15% acrylamide (Bio‐Rad Laboratories). Gels placed in the Bio‐Rad Mini‐Protean gel apparatus (Bio‐Rad Laboratories) were electrophoresed in 25 mM Tris buffer containing 192 mM glycine and 0.1% SDS, at 90 V until the proteins had moved from the stacking gel into the separation gel, at which point the voltage was increased to 180 V. Benchmark™ prestained protein ladder (Invitrogen), and PagerRuler™ prestained protein ladder (Thermo Scientific™) markers were also loaded onto each gel. Gels were transferred onto methanol‐hydrated Immuno‐Blot® poly‐vinyl‐D‐fluoride (PVDF) membranes (0.2‐μm pore size; Bio‐Rad Laboratories). Proteins were transferred at 100 V for 90 min at 4 °C using the Bio‐Rad Mini‐Protean wet transfer system (Bio‐Rad Laboratories) and a standard transfer buffer (15 mM Tris buffer containing 120 mM glycine and 10% or 20% (v/v) methanol depending on protein size). Protein transfer was confirmed by staining the membrane with 0.1% Coomassie Brilliant Blue 50% methanol, and 10% acetic acid followed by destaining (50% methanol and 10% acetic acid) to visualise protein bands. Membranes were then dried and stored for later use or rehydrated and then blocked with 15% (w/v) skim milk powder (Woolworths Homebrand) in PBS containing 0.05% Tween‐20 (PBST) for 15 min at RT. Membranes were then incubated in primary antibody at an antibody dependant concentration (see Table 2.3 for individual dilutions) in 3% (w/v) skim milk in PBST for 1 h at RT or overnight at 4 °C depending on the antibody. Subsequently, membranes were washed three times in PBST, followed by incubation with HRP‐conjugated secondary antibody (Table 2.3) in 3% (w/v) skim milk in PBST for 1 h at RT. Membranes were then washed five times with PBST for 5 minutes each and incubated with a 1:1 mix of ECL solution 1 (100mM Tris pH 8.5, 2.5mM luminol, 0.4mM p‐coumaric acid) and ECL solution 2 (100mM Tris pH 8.5 containing 0.02% H2O2) for 5 min. Protein bands were detected by exposure of X‐ray film to the membrane for various times and the X‐ray film developed and scanned. Densitometry was performed using ImageJ 1.46r software. Protein bands of interest were normalised to the respective actin loading control band. To quantify changes in protein levels over time, the first time point was let equal 1 and the fold change was calculated for the following time points. To quantify changes in protein levels following treatment, the control was set to 1 and the respective fold change was calculated for the treatment group.  
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Table 2.3. Antibodies used for immunoblotting. 
 Antibody Host Dilution Source 
Primary 
Actin [C4] Mouse 1:20000 Millipore (MAB1501) 
MMP14 [EP1264Y] Rabbit 1:2000 Abcam (ab51074) 
MMP9* Rabbit 1:1000 Abcam (ab38898) 
MMP9 [E-11]† Mouse 1:500 Santa Cruz (sc-393859) 
SNAP23 Rabbit 1:2000 Synaptic Systems (111202) 
Stx2 Rabbit 1:1000 Synaptic Systems (110123) 
Stx3 Rabbit 1:1000 Synaptic Systems (110033) 
Stx4 Rabbit 1:1000 Synaptic Systems (110042) 
VAMP2 Mouse 1:1000 Synaptic Systems (104211) 
VAMP3 Rabbit 1:500 Synaptic Systems (104103) 
VAMP4 Rabbit 1:1000 Abcam (ab3348) 
VAMP7 Mouse 1:1000 Abcam (ab36198) 
VAMP8 Rabbit 1:1000 Synaptic Systems (104302) 
Secondary Anti-mouse-HRP Goat 1:3000 Novex™ (A16072) Anti-rabbit-HRP Goat 1:3000 Novex™ (G21234) 
* Only a limited number of experiments were performed with this polyclonal rabbit antibody as 
antibody from a new lot was no longer able to detect MMP9 in conditioned media or lysates 
from RAW264.7 macrophages. 
†Some later experiments were performed using this antibody as it became commercially 
available and was positively tested to detect MMP9 in lysates from RAW264.7 macrophages. 
 
2.2.4 Flow cytometry (MMP14) Cells were harvested by incubating them in 0.5 mM EDTA in PBS for 5 min at 37 °C, followed by gently scraping with a rubber cell scraper. Cells were pelleted at 300 x g for 3 min, washed twice in ice‐cold 2% FBS in PBS for 10 min and incubated for 5 min on ice with 10 µg/ml Fc Block (BD Biosciences). Cells were labelled for 30 min on ice with 5 µg/ml MMP14 antibody, isotype control antibody (  
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2.4) in 2% FBS in PBS or 2% FBS in PBS alone (unstained control). Cells were washed 3 x with 2% FBS in PBS, followed by 30 min incubation on ice with AlexaFluor® 647‐conjugated anti‐rabbit IgG in 2% FBS in PBS, or buffer alone (unstained control). Cells were then washed 2 x with 2% FBS in PBS followed by PBS. For analysis, cells were resuspended in PBS. Flow cytometry analysis was performed using the FACSAria cell sorter with the FACSDiva acquisition software (BD Biosciences). FlowJo software (FlowJo, LLC) version 10 was used for data analysis. Cell populations were gated based on forward and sideward scatter characteristics. Fluorescence intensity of each sample was assessed based on the mean fluorescence intensity (MFI) of the cell population, which was measured in arbitrary units and corrected for by subtracting the MFI of the isotype control. 
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Table 2.4. Antibodies used for flow cytometry. 
 Antibody Host Dilution Source 
Primary MMP14 [EP1264Y]  Rabbit 1:100 Abcam (ab51074) Rabbit Isotype [DA1E]  Rabbit 1:1000 CST (3900) 
Secondary Anti-rabbit AlexaFluor® 647  Goat 1:100 Novex™ (A21245) 
 
2.2.5 Immunofluorescence labelling 
2.2.5.1 Standard protocol Cells on glass coverslips were fixed for 30 min at RT in 4% paraformaldehyde solution in PBS, washed once with PBS and stored in PBS at 4 °C until required. Permeabilisation of fixed cells was performed using 0.1% Triton X‐100 in PBS for 5 min at RT. Cells were washed twice and blocked with 0.5% (w/v) BSA in PBS for 10 min at RT. The cells were then incubated with primary antibodies diluted in 0.5% BSA in PBS (Table 2.5) for 1 hour at RT. After three washes with 0.5% BSA in PBS, cells were incubated with secondary antibodies and non‐antibody fluorescent probes (Table 2.5) diluted in 0.5% BSA in PBS for 1 hour at RT in the dark, followed by another five washes with 0.5% BSA in PBS. The coverslips were mounted on glass slides in mounting media (PBS containing 25 mg/ml 1,4‐diazabiccyclo‐2,2,2‐octane (DABCO, Sigma‐Aldrich) and 80% glycerol), sealed with nail polish and stored at 4 °C.  
2.2.5.2 Cell surface labelling (MMP14) To label MMP14 on the surface of live non‐permeabilised cells, coverslips were placed on ice. Cells were washed twice, blocked with ice‐cold 0.5% BSA in PBS for 10 min. Cells were then incubated with MMP14 antibody ([EP1264Y], Abcam) diluted in 0.5% BSA in PBS for 30 min on ice. Cells were washed three times with 0.5% BSA in PBS and fixed in 4% paraformaldehyde solution in PBS for 30 min at RT. The remaining labelling procedure was performed as described in section 2.2.5.1. 
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Table 2.5. Antibodies and fluorescent probes used for immunofluorescence labelling. 
 Antibody/Probe Host Dilution Source 
Primary 
EEA1 Rabbit 1:100 Pierce™ (PA1-063A) 
GM130 [35/GM130] Mouse 1:100 BD Biosciences (610822) 
LAMP1 [1D4B] Rat 1:100 Abcam (ab25245) 
LBPA Mouse 1:100 
Jean Gruenberg, 
University of Geneva, 
Switzerland 
MMP9 Rabbit 1:1000 Abcam (ab38898) 
MMP14 [LEM-2/63.1] Mouse 1:100 Abcam (ab78738) 
MMP14 [EP1264Y] Rabbit 1:100 Abcam (ab51074) 
TfR [H68.4] Mouse 1:100 Novex™ (13-6800) 
PDI [1D3] Mouse 1:100 Abcam (ab190883) 
SNAP23 Rabbit 1:100 Synaptic Systems (111202) 
Stx4 Rabbit 1:100 Synaptic Systems (110042) 
α-tubulin Mouse 1:100 Invitrogen 
Secondary 
Anti-mouse 
AlexaFluor® 488 Goat 1:100 Novex™ (A11029) 
Anti-mouse 
AlexaFluor® 647 Goat 1:100 Novex™ (A21236) 
Anti-rabbit 
AlexaFluor® 488 Donkey 1:100 Novex™ (A21206) 
Anti-rabbit 
AlexaFluor® 647 Goat 1:100 Novex™ (A21245) 
Anti-rat AlexaFluor® 
488 Goat 1:100 Novex™ (A11006) 
Anti-rat AlexaFluor® 
647 Goat 1:100 Novex™ (A21247) 
Fluorescent 
probes 
DAPI  1:1000 Sigma-Aldrich (D9542) 
Phalloidin-FITC  1:200 Sigma-Aldrich (P5282) 
Phalloidin-TRITC  1:200 Sigma-Aldrich (P1951) 
Phalloidin- 
AlexaFluor® 647  1:100 
Molecular Probes™ (A-
22287) 
 
2.2.6 ELISA The commercially available mouse Total MMP9 DuoSet® ELISA (R&D Systems) and MMP9 ELISA Kit (biosensis) were used according to the manufacturer’s instructions. In brief, standards and undiluted conditioned media samples were added to wells of the pre‐coated plates and incubated overnight at 4 °C. The next day, the plate was washed five times with PBS before adding the biotinylated antibody diluted in the provided dilution buffer for 3 h. After washing the plate three times with PBS, the Avidin‐Biotin‐Peroxidase Complex solution provided was added for 1 h followed by five washing steps 
with PBS. For colour development, 3,3′,5,5′‐tetramethylbenzidine substrate was added, and after 20 min the reaction was terminated using the provided stop solution. The plate was then read immediately at 450 nm with a microplate reader. 
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2.3 Microscopy and image analysis 
2.3.1 Fixed cell imaging Fixed cells were imaged using one of the following microscopes: Nikon® Eclipse Ti‐S epifluorescence microscope fitted with a CFI S Plan Fluor ELWD ADM 20x (MA 0.45), 40x (NA 0.60) dry objective lens, with a CFI Plan Fluor 60XS Oil (with iris) and a CFI Plan 100X Oil immersion lens. The system was operated using the NIS‐Elements BR software (Version 4.11.00). Pictures were captured using a DigitalSight DS‐Qi1Mc colour camera. Leica TCS SP5 laser scanning confocal microscope (Leica Microsystems GmbH, Wetzlar, Germany) fitted with a HCX PL APO CS 20x (NA 0.70), 40x (NA 1.25) and 60x (NA 1.4) oil immersion lens. The system was operated using the Leica Application Suite Advanced Fluorescence software (Version 2.6.3.8173).  Olympus BX63F motorised upright fluorescence microscope (Olympus, Hamburg, Germany) fitted with a UPLSAPO100XO (NA 1.40) oil immersion lens. The system was operated using the cellSens software. Pictures were captured using a Dual‐CCD DP80 Microscope Digital Camera. 
2.3.2 Live cell imaging Live cell imaging was carried out using a Leica AF6000LX microscope fitted with a HCX PL APO CS 63x (NA 1.30) glycerol immersion lens. The system was operated using the Leica Application Suite Advanced Fluorescence software (Version 2.6.3.8173). Pictures were captured using a DFC 350 FX digital camera. To record the dynamic movement of MMP‐containing vesicles, images were acquired at rates of one frame every 5 s for 5 min. Time‐lapse series were constructed, cropped, and adjusted using ImageJ 1.46r. 
2.3.3 Image analysis Images were merged, analysed, cropped and optimised using ImageJ 1.46r, and Adobe Photoshop CC 2015 (Adobe Systems, San Jose, CA, USA). In some instances images were pseudo‐coloured using an intensity‐coded palette in ImageJ. Intensity profiles were produced by measuring the fluorescence intensity along a line scan within an image and displaying the values in a scatter plot that was graphed in Microsoft Excel. 
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2.4 Statistics All graphs present means of at least three independent experiments unless stated otherwise. Error bars show the standard error of the mean (SEM).  One‐way ANOVA with either Tukey’s or Dunnett’s post‐hoc test was performed for multiple comparison of data with more than two groups while unpaired, two‐tailed Student’s t‐test was carried out for data with two groups using a confidence interval of 95%. P‐values <0.05 were considered significant (*P<0.05, **P≤0.01, ***P≤0.001, 
****P≤0.0001). 
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Chapter 3: Identifying intracellular 
trafficking pathways for secretion of 
MMP9 
 
3.1 Introduction MMPs are a family of enzymes that in concert are responsible for the degradation of most extracellular matrix proteins. Their proteolytic activity during the repair process has to be tightly controlled as increased levels of certain MMPs lead to excessive tissue damage and impairs the wound healing process. MMP9 is highly elevated in chronic wound fluid and elevated levels correlate with poor wound healing outcomes [Beidler et 
al., 2008; Lobmann et al., 2002; Liu et al., 2009; Mwaura et al., 2006]. Macrophage‐secreted MMP9 is thought to be one of the main enzymes responsible for ECM degradation in chronic wounds [Rayment et al., 2008; Wall et al., 2002]. Thus, being able to reduce MMP9 secretion from macrophages may lead to a new therapeutic to treat chronic wounds. However, the secretory pathways and intracellular trafficking steps involved in the cell surface delivery and secretion of MMP9 in macrophages are still poorly understood. Multiple pathways exist in macrophages for the exocytosis of proteins. Most secreted proteins, as is the case for MMP9, have an N‐terminal signal sequence that targets them for import into the ER during biosynthesis, from which they are then shuttled through to the Golgi apparatus. From the Golgi apparatus, proteins may be directly transported to the cell surface in membrane bound compartments. However, more recently it has become clear that transport en route to the cell surface can also occur via other organelles, such as recycling endosomes. For example, TNFα is secreted via these endosomes in macrophages [Murray et al., 2005a; Murray et al., 2005b]. Proteins destined for secretion can also be trafficked through late endosomes/lysosomes, which can function as secretory compartments releasing their contents upon fusion with the cell surface. For example, IL‐1β is secreted via lysosomes [Andrei et al., 1999]. Delivery of MMP9 within membrane‐bound vesicles to the cell surface for secretion requires membrane fusion that is mediated by the SNARE proteins at all points in its trafficking pathway. There are currently 38 mammalian SNARE proteins, with some of them being differentially expressed in different cell types. These SNARE proteins are associated with distinct membranes within the cell, for example, 
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VAMP3 is found on recycling endosomes and VAMP4 is found in the Golgi complex in macrophages. It is the selective pairing of three to four SNARE proteins that mediates membrane fusion between vesicles, organelles and/or the plasma membrane to regulate discrete transport pathways. For this reason, they can be used to map intracellular transport pathways. Identifying the specific SNAREs that facilitate MMP9 secretion in macrophages will identify the intracellular transport pathways and also provide targets to prevent secretion of the enzyme from macrophages that could be useful for the treatment of chronic wounds. Therefore, this chapter begins with the optimisation of methods to detect intracellular MMP9 and MMP9 secreted from macrophages*. Next, the subcellular localisation of MMP9 in macrophages is determined and intracellular compartments that might form part of its secretory route in these cells characterised. Finally, levels of SNARE proteins are reduced by siRNA knockdown to test for their involvement in MMP9 secretion and to identify trafficking pathways and machinery that might regulate MMP9 secretion.   
                                                          
* Note, a number of immunoblots throughout this chapter were performed using a polyclonal rabbit antibody to MMP9 that was able to detect MMP9 at the correct size. Along the way, the same antibody was repurchased but the received product was from a different batch with a new lot number and antibody from this batch no longer recognised MMP9. The old lot no longer exits. Data obtained from using the original batch of this antibody is shown but in some cases there was only 1 immunoblot (conditioned media samples). Where this is the case the results have been repeated using a second method (ELISA) with at least three biological replicates. 
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3.2 Results 
3.2.1 Detecting secreted MMP9 in RAW264.7 cell culture supernatants 
The influence of FBS concentration on RAW264.7 macrophage cell growth To identify the specific intracellular trafficking pathways that are responsible for the surface delivery and secretion of MMP9, an assay was needed that could detect changes in intracellular and secreted MMP9. MMP levels are typically determined using zymography, where their proteolytic activity is detected on the basis of the degradation of a substrate incorporated into an SDS‐PAGE gel [Vandooren et al., 2013]. In the case of MMP9 that substrate is gelatin. Typically, MMP levels in conditioned media are measured by zymography in the absence of FBS, which has been found to contain high levels of gelatinolytic activity [del Zoppo et al., 2012]. RAW264.7 macrophages are usually maintained in the presence of 10% FBS in their cell culture media. Thus, the effect of removing or reducing FBS levels was first tested to determine whether it would have any detrimental effects on macrophage growth. For this, RAW264.7 cells were cultured in five different concentrations, ranging from 0‐10%, of FBS (in RPMI) and the effect on cell numbers was initially evaluated using phase contrast microscopy under low magnification (Figure 3.1A). The growth of RAW264.7 macrophages was found to be considerably retarded under low FBS conditions relative to control cells grown in the presence of 10% FBS (Figure 3.1A). To quantify the reduction in growth, cells were counted using a haemocytometer (Figure 3.1B). A significant reduction (31±6%) in macrophage cell numbers was observed for cells cultured in serum‐free medium, compared to control cells grown in 10% FBS‐containing media (*P<0.05). Macrophages grown in low‐serum conditions (1.25, 2.5 or 5% FBS) had approximately 15% less cell numbers than those grown in 10% FBS‐containing media. These results reflect the changes in cell confluency observed by microscopy (Figure 3.1A). To determine whether reduced FBS levels altered cell morphology, macrophages grown in normal (10%) or low serum (1.25%) conditions were carefully examined by microscopy. The RAW264.7 macrophages grown under low serum conditions had large vacuoles typically not present in control cells grown in 10% serum (Figure 3.1C). Additionally, in the presence of low serum many cells presented with two or more nuclei, which was typically not the case for macrophages grown in normal serum conditions (Figure 3.1C). Thus, reduced serum conditions appear to have a deleterious effect on macrophages and as such are not compatible with RAW264.7 cells.  
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Figure 3.1. The FBS concentration in the cell culture media influences RAW264.7 
macrophage cell numbers and morphology. 
Equal numbers of RAW264.7 cells were seeded in media containing 10% FBS and allowed to 
attach to the dish for 2 h. Media was then replaced with media containing different FBS 
concentrations (0, 1.25, 2.5, 5 or 10%) and cells were incubated for a further 18 h. (A) 
Representative images from the cell cultures grown in the presence of different FBS 
concentrations taken with low-magnification phase contrast microscopy. Scale bar is 50 μm. 
(B) Cell counts of macrophages grown in reduced FBS conditions were calculated as a 
percentage of cells grown in 10% FBS-containing media and represented in a bar graph; mean 
± SEM (n=3), *P<0.05 (One-way ANOVA with Tukey’s post-hoc test). (C) Cells grown on 
coverslips in 10% (control) or 1.25% FBS (low serum) conditions were fixed and their nuclei 
labelled with DAPI. Representative overlaid images (top row) from Bright-field (grey) and DAPI 
fluorescence (blue) channel, as well as single-channel images for the insets, are shown 
(bottom row). Scale bar is 20 μm. 
Zymography of RAW264.7 macrophage conditioned media As reducing the serum concentration in the growth medium of RAW264.7 macrophages negatively influences cell numbers and morphology, it was then determined if gelatin zymography could detect MMP9 secreted from RAW264.7cells into serum‐containing media (conditioned media). MMP levels in serum can vary so it was determined whether the FBS used in RAW264.7 cell culture media had detectable proteolytic activity in gelatin zymography assays (Figure 3.2A). Media containing 0‐10% FBS was assayed using zymography, along with control conditioned FBS‐free media from BHK cells overexpressing human pro‐MMP9 and endogenously expressing pro‐MMP2. The lanes loaded with the BHK conditioned media control displayed bands of the predicted size for pro‐MMP9 (92 kDa) and pro‐MMP2 (72 kDa). Media without FBS (0%) showed no proteolytic activity in the zymography assays, as expected (Figure 3.2A). However, media supplemented with 1.25‐10% serum showed a concentration‐dependant increase in gelatinase activity for both pro‐MMP9 and pro‐MMP2, respectively (Figure 3.2A). As bovine and murine MMP9 are a similar molecular weight, bovine MMP9 is most likely masking detection of mouse MMP9 secreted in the conditioned media. A method to upregulate MMP9 expression was needed to test whether the mouse MMP9 activity could be upregulated and detected above that of bovine MMP9. MMP expression has been found to be upregulated upon stimulation with the strong Toll‐like receptor (TLR) agonist lipopolysaccharide (LPS) [Newby, 2008] and MMP9 secretion from LPS‐activated RAW264.7 macrophages can be detected in conditioned media from as early as 8 h post‐stimulation [Yang et al., 2015]. Thus, it was examined whether LPS activation of macrophages leads to a noticeable upregulation in MMP9 levels that would allow discrimination between bovine and murine MMP9 by zymography. Comparing the gelatinase activity in FBS‐containing media and FBS‐containing conditioned media from macrophages stimulated in the absence or presence of LPS for 9 h shows that the level of FBS‐originated bovine gelatinolytic activity in media 
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masks any detectable changes in macrophage‐secreted MMP9 levels after LPS stimulation (Figure 3.2B). Next, it was tested whether increasing the length of stimulation could lead to the secretion of MMP9 levels above those found within the FBS by incubating RAW264.7 cells with LPS over an 18 h time course (Figure 3.2C). However, after stimulating the cells for 18 h the gelatinase activity of conditioned media did not reach an intensity level significantly above that found in medium containing 10% FBS (Figure 3.2C). Overall, these results show that high bovine MMP activity in FBS‐containing medium masks any macrophage‐secreted MMP9 activity, making it very difficult to measure gelatinase levels in FBS‐containing conditioned media by zymography. This method is still suitable to measure intracellular MMP9 as only mouse MMP9 will be present in the cells. However, a different approach was needed to detect changes in secretion of MMP9 into the FBS‐containing cell culture supernatant of RAW264.7 macrophages.   
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Figure 3.2. Bovine MMP9 found in FBS masks the gelatinase activity of MMP9 secreted 
by macrophages. 
(A) RAW264.7 cell culture media containing increasing concentrations of FBS (0, 1.25, 2.5, 5 
or 10%) were analysed by gelatin zymography. Conditioned media (without FBS) from human 
pro-MMP9-secreting BHK cells was used as a positive control (PC) and shows bands for pro-
MMP9 (92 kDa) and pro-MMP2 (72 kDa). (B) RAW264.7 cell culture media containing 10% 
FBS and FBS-supplemented conditioned media (CM) from cells that were stimulated with 100 
ng/ml LPS (+LPS) for 0 h and 9 h were analysed by gelatin zymography. Conditioned media 
from human pro-MMP9-secreting BHK cells was used as a positive control (PC) (C) 
RAW264.7 cell culture media with and without 10% FBS and FBS-supplemented conditioned 
media from cells that were stimulated with 100 ng/ml LPS 0-18 h were analysed by gelatin 
zymography. Conditioned media from human pro-MMP9-secreting BHK cells was used as a 
positive control (PC).  
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MMP9 ELISAs and RAW264.7 macrophage conditioned media Since the serum‐derived and macrophage‐secreted MMPs originate from different species (bovine and mouse, respectively), it was tested whether a commercially available ELISA kit against mouse MMP9 (mouse Total MMP9 DuoSet® ELISA, R&D Systems) could specifically detect murine RAW264.7 macrophage‐originated MMP9 in the presence of FBS. To first assess whether the sample itself might interfere with the ability of the assay to detect the target protein (matrix effect), known amounts of the recombinant mouse MMP9 standard (1000 pg/ml) were spiked into i) dilution buffer provided in the kit, ii) culture media with and without 10% FBS and iii) conditioned media from cells incubated in the presence or absence of LPS for 9 h. The spiked samples were then analysed along with standards using the mouse MMP9 ELISA kit and the percentage of the expected concentration (recovery) was calculated from a standard curve. As expected, almost all (97%) of the spiked 1000 pg/ml of MMP9 standard was recovered when made up in the kit dilution buffer (Figure 3.3A). However, the recovery of MMP9 spiked in media that lacked FBS was reduced to 75% of that spiked in the kit dilution buffer. The recovery of MMP9 in media containing 10% FBS was lower again at 44% of that spiked in the kit dilution buffer. The low recovery of murine MMP9 spiked into media containing FBS suggests that the assay is specific for murine MMP9 but the sample matrix, both RPMI media and FBS, individually have a negative impact on the assay itself. Additionally, the recovery of MMP9 spiked in conditioned media from LPS stimulated and unstimulated macrophages was with 59% and 55%, respectively. This is less than the recovery of MMP9 from buffer or media without FBS but was higher than the recovery from media with FBS that had not been conditioned by cells. This could be due to macrophage‐derived MMP9 being present in the conditioned media, which is detected by the ELISA and therefore increases the apparent recovery. Nevertheless, the recovery in these samples remained reduced due to the above mentioned matrix effects. One way to reduce matrix effects is to dilute samples in dilution buffer to greatly reduce the amount of media and FBS and thus their effect during the assay. To test whether this would reduce the matrix effect, buffer and media with and without FBS were spiked with 5000 pg/ml MMP9 and serially diluted with the kit dilution buffer (Figure 3.3B). The matrix effect of both RPMI media and FBS decreased as the samples were increasingly diluted and disappeared completely at 8‐fold or higher dilutions of the matrix (Figure 3.3B). However, when samples of LPS‐conditioned media were similarly diluted there was no detectable secreted MMP9 signal within the range of the standard curve (not shown). This suggested that when the conditioned media is diluted to remove 
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the matrix effects then the concentration of secreted MMP9 is below the sensitivity range of the kit and/or there is a factor(s), secreted by the cells, that is further interfering with the assay. Since the dilution of sample in the buffer provided with the kit was no longer an option, it was next tested whether MMP9 recovery could be improved by diluting both the MMP9 standards and samples in media containing FBS (Figure 3.3C). Murine MMP9 was detected in undiluted conditioned media samples at levels equivalent to the FBS‐containing media spiked with 5000 pg/ml of the MMP9 (Figure 3.3C). However, when the sample was serially diluted in FBS media it can be seen that the recovery of the MMP9 in the conditioned media samples is much lower. This suggests that a factor(s) in the conditioned media might be interfering with the assay. Based on these results, it was decided to discontinue the optimisation of this particular assay for measuring mouse MMP9 in RAW264.7 conditioned media samples. 
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Figure 3.3. The MMP9 ELISA Kit (R&D) is unsuitable for assaying MMP9 in RAW264.7 
cell culture supernatants. 
(A) MMP9 (1000 pg/ml) was spiked into ELISA kit dilution buffer, into RPMI media with and 
without 10% FBS, and into conditioned media (CM) from RAW264.7 macrophages stimulated 
with or without 100 ng/ml LPS for 9 h. MMP9 levels were then measured using the mouse total 
MMP9 DuoSet® ELISA (R&D Systems), according to the manufacturer’s instructions. The 
amount of MMP9 recovered was calculated from the standard curve as a percentage of the 
expected concentration and graphed. The graph shows the mean of two technical replicates, 
n=1. (B) A MMP9 standard (5000 ng/ml in dilution buffer) was prepared in dilution buffer (), 
media without () and media with 10% FBS () and subsequently serially diluted with dilution 
buffer and assayed using the mouse total MMP9 DuoSet® ELISA according to the 
manufacturer’s instructions. The graph shows the standard curves as a function of the Optical 
density (OD) dependent on the concentration of the standard. Dilution of the top standard in 
diluents other than buffer results in deviation from the curve. The graph shows the mean of 
two technical replicates, n=1. (C) MMP9 levels in cell culture supernatant from cells that had 
been conditioned (CM) with 100 ng/ml LPS for 18 h (undiluted) were compared to a standard 
curve that was produced through dilution of the standard in media with 10% FBS. The sample 
was further diluted in media with 10% FBS. MMP9 concentrations in the diluted samples were 
compared to the standard curve and relative recovery of diluted samples was expressed as a 
percentage of that and graphed. The graph shows the mean of two technical replicates, n=1. 
 A second commercially available ELISA kit (Biosensis) with a broader concentration range (156 pg/ml ‐ 10,000 pg/ml) was subsequently trialled. To test whether the new ELISA kit had any matrix effects, media with and without FBS, and cell culture supernatants (conditioned media) from LPS‐stimulated macrophages were spiked with known amounts of the MMP9 standard and the recovery determined as a percentage of the expected concentration. For all sample matrices tested, recovery of MMP9 was similar but significantly lower than the expected value, with an average MMP9 recovery of ≈63% (Figure 3.4A), which was slightly higher than the R&D ELISA kit. This suggested that there may again be some sort of matrix effect occurring. However, unlike the R&D ELISA kit, the matrix effects found with the Biosensis kit predominantly come from the media alone, with FBS and factors in the conditioned media having little to no additional effect (Figure 3.4A). The same kit was further tested for linearity by spiking media containing FBS and conditioned media with 1250 pg/ml MMP9, then serially diluting this in dilution buffer. It can be seen in Figure 3.4B that it is linear in this range. Hence, despite the non‐optimal recovery of spiked MMP9 in cell culture media, this assay was considered suitable to detect fold changes in the amount of MMP9 secreted by macrophages and was used for subsequent experiments.   
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Figure 3.4. The Biosensis MMP9 ELISA Kit is suitable to assay changes in MMP9 levels 
in RAW264.7 cell culture supernatants. 
(A) Media with and without 10% FBS , and conditioned media (CM) containing 10 % FBS from 
cells stimulated with 100 ng/ml LPS for 18 h were spiked with 1250 pg/ml recombinant MMP9 
standard protein provided in the kit and MMP9 was measured using the Biosensis mouse 
MMP9 ELISA Kit according to the manufacturer’s instructions. The graph shows the MMP9 
recovered as a percentage of the expected concentration calculated using the MMP9 standard 
curve. The graph shows the mean of four technical replicates, n=1. (B) Media containing 10% 
FBS and conditioned media (CM) containing 10 % FBS from cells stimulated with 100 ng/ml 
LPS for 18 h were each spiked with 1250 pg/ml recombinant MMP9 standard protein and 
subsequently serially diluted with dilution buffer. Recovery determined as a percentage of the 
expected concentration was graphed. The graph shows the mean of two technical replicates, 
n=1. 
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3.2.2 MMP9 expression and secretion is upregulated after LPS stimulation 
in RAW264.7 macrophages In order to be able to determine any changes in MMP9 secretion following the disruption of trafficking pathways, it was first necessary to establish the ideal time points for such experiments. To investigate the kinetics of LPS‐induced MMP9 synthesis and secretion from RAW264.7 macrophages, cells were stimulated with 100 ng/ml LPS over an 18 h time course, and their conditioned media and cell lysates were analysed at 3‐hourly time points. MMP9 was measured in conditioned media using the Biosensis ELISA kit (Figure 3.5). Mouse MMP9 was absent in unstimulated samples (0 h) but could be detected by ELISA in the conditioned media of LPS‐stimulated samples as early as 3 h post‐stimulation and continued to increase over the 18 h time course (Figure 3.5A).  Figure 3.5A). MMP9 levels 18 h post‐stimulation were significantly increased from 0 h and 3 h post‐stimulation (*P<0.05). MMP9 secretion did not plateau in the timeframe tested. To confirm the results obtained from the ELISA, an MMP9 antibody was sourced and tested for detection of mouse MMP9 by immunoblotting in RAW264.7 macrophages conditioned media. This antibody did not react with bovine MMP9, as is apparent by the lack of bands in the unstimulated samples (Figure 3.5B). It was able to detect one band in conditioned medium, which most likely is the fully glycosylated zymogen form of MMP9 and runs at 105 kDa (Figure 3.5B). Secreted MMP9 was detected by immunoblotting as early as 6 h post‐stimulation and the levels continue to increase over the time course in a similar manner as observed by ELISA analysis (Figure 3.5B). Intracellular MMP9 levels were also assessed over the same 18 h time course. Pro‐MMP9 was seen as a single band around 105 kDa by zymography (Figure 3.5C) while two MMP9 bands were detected by immunoblotting (Figure 3.5D). The higher one of the two bands is most likely representing fully glycosylated MMP9 (105 kDa) and the lower molecular weight band, detected only in activated samples (3 to 18 h), is possibly an underglycosylated form of MMP9 (98 kDa) that occurs during its de novo synthesis [Olson et al., 2000]. Figure 3.5C and 3.5D show MMP9 in lysates from unstimulated macrophages (0 h), suggesting there is a low basal MMP9 level present in unstimulated RAW264.7 macrophages. As with the secreted form, intracellular MMP9 levels increase after LPS stimulation (Figure 3.5C and D). Together these results show that MMP9 secretion greatly increases in response to LPS stimulation and that time points between 9 h and 18 h were the most suitable for measuring changes in MMP9 levels.  
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Figure 3.5. MMP9 secretion and expression is increased in response to LPS stimulation. 
(A) RAW264.7 macrophages were stimulated with 100 ng/ml LPS over an 18 h time course 
and the conditioned media collected. MMP9 was quantified by ELISA. The graph shows the 
mean ± SEM (n=3); *P<0.05 (One-way ANOVA with Tukey’s post-hoc test). (B) The same 
conditioned media was analysed by immunoblotting for mouse MMP9 (105 kDa) confirming 
this result (C) Cell lysates taken over the same time course were collected and analysed by 
gelatin zymography. A representative gel image shows the increase in MMP9 activity over 
time (D) Cell lysates taken over the same 18 h time course were collected and analysed by 
immunoblotting for MMP9. Actin was used as a loading control. A representative immunoblot 
is shown.  
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3.2.3 MMP9 secreted from LPS-activated macrophages is newly made The increase in secreted MMP9 from LPS‐stimulated macrophages could predominantly be due to MMP9 de novo synthesis, as suggested in Figure 3.5, rather than it being due to the release of intracellular pools, as would be expected with neutrophils, or by the inhibition of the degradation of intracellular MMP9. To confirm this, RAW264.7 macrophages were LPS‐stimulated for 12 h and treated with 1 μg/ml cycloheximide to inhibit protein synthesis during the final 4 h. Treatment with cycloheximide over the whole 12 h led to abnormal cells and eventually cell death, so 4 h treatment was chosen as a sound compromise. Cells on coverslips were stained for F‐actin to define the cell surface and with DAPI to label nuclei. Activated RAW264.7 macrophages cultured in the absence of cycloheximide showed the typical macrophage morphology (Figure 3.6A), where cells are spread out, with what appears to be a leading edge on one side in many cells. In the presence of cycloheximide, macrophages are elongated as previously observed [Liu et al., 2010] and the leading edge is less visible (Figure 3.6A). Conditioned media and cell lysates from the same cycloheximide treatment were analysed for MMP9. The ELISA results for conditioned media revealed a significant decrease (44±6%; **P≤0.01) in the level of secreted MMP9 when compared to media from the control cells (Figure 3.6B). A similar reduction in MMP9 was found when the same samples were immunoblotted for MMP9 (Figure 3.6C). Inside the cell, MMP9 proteolytic activity was also reduced in the cycloheximide‐treated cell lysates as shown by zymography (Figure 3.6D), confirming that the reduction in MMP9 secretion was due to reduced intracellular MMP9 levels. The same lysates were also immunoblotted for MMP9 and it was found that the underglycosylated nascent precursor form of MMP9 typically found in the ER is almost absent in lysates from cells treated with cycloheximide (Figure 3.6E). Actin remained unaffected over the time course (Figure 3.6E). Together, these results suggest that LPS‐stimulation strongly induces the de novo synthesis of MMP9 and that the MMP9 secreted from activated macrophages is predominantly newly synthesised rather than a stored form.   
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Figure 3.6. MMP9 is newly synthesised and secreted upon LPS stimulation. 
(A) RAW264.7 macrophages grown on coverslips were stimulated with 100 ng/ml LPS for 8 h, 
then the cells were incubated in the absence (control) or presence of 1 μg/ml cycloheximide 
(CHX) for a further 4 h. Cells were fixed, permeabilised and stained for F-actin (red) and nuclei 
were labelled using DAPI (blue). Overlay images of typical macrophage morphologies are 
shown. Scale bar is 20 μm. (B) Macrophages were stimulated with 100 ng/ml LPS for 8 h, then 
the cells were incubated in the absence (control) or presence of 1 μg/ml cycloheximide (CHX) 
for a further 4 h. Conditioned media was collected and the total secreted MMP9 levels were 
quantified using an ELISA kit (Biosensis). Bar graph of the mean value ± SEM shows the 
changes in MMP9 levels (n=3). **P≤0.01 (unpaired, two-tailed Student’s t-test). (C) The same 
conditioned media was collected and MMP9 levels were analysed by immunoblotting (n=1) 
(D) Cell lysates were collected and intracellular MMP9 levels were analysed by gelatin 
zymography (n=1) (E) Cell lysates were collected and intracellular MMP9 levels were analysed 
by immunoblotting for MMP9 and Actin (n=3). A representative image is shown. 
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3.2.4 Expression of mCherry-tagged MMP9 to study intracellular 
trafficking pathways Localisation of a protein in a cell can give an indication of what pathways might be used for its secretion. Four MMP9 antibodies (one rabbit polyclonal, two different goat polyclonal and one mouse monoclonal) were tested for use in immunofluorescence microscopy, of which only one (rabbit polyclonal) was able to detect MMP9. However, a second batch of this antibody was unfortunately no longer able to detect MMP9. Hence, RAW264.7 cells were transfected with a fluorescently (mCherry)‐tagged MMP9 as an alternative approach to immuno‐labelling endogenous MMP9 with an antibody. Cells were transiently transfected for 6 h with the MMP9‐mCherry construct and lysates from these cells were immunoblotted for MMP9 (Figure 3.7A). Both the control and MMP9‐mCherry overexpressing cells show a band at around 105 kDa, representing endogenous mouse MMP9 (Figure 3.7A). The MMP9‐mCherry expressing cells had an additional higher molecular weight band at about 120 kDa, representing human MMP9 (92 kDa) plus the mCherry tag, which is 28 kDa (Figure 3.7A). To determine whether the mCherry tagged form of MMP9 behaves similarly to endogenous MMP9, macrophages were grown on coverslips and transiently transfected with MMP9‐mCherry. Cells were fixed at 3, 6, 9, 12, 15 and 18 h after transfection and imaged by fluorescence microscopy (Figure 3.7B). MMP9‐mCherry can be observed from as early as 6 h post‐transfection with the peak fluorescence intensity occurring between 9 and 12 h (Figure 3.7B). At 6 h post transfection MMP9‐mCherry locates predominantly to the perinuclear region but over time more MMP9‐mCherry is seen in peripheral structures (Figure 3.7B). A pseudo‐coloured image using an intensity‐coded palette, where blue is low and red/pink is high, shows MMP9 in the perinuclear region and a punctate staining pattern in periphery of the cell (Figure 3.7B right hand panel). Co‐immunostaining for endogenous MMP9 shows both endogenous and overexpressed MMP9 are colocated in the perinuclear region and in punctate structures in the periphery of the cell (Figure 3.7C). This suggests that MMP9‐mCherry is being trafficked in the same vesicles as endogenous MMP9 and the punctate structure at the periphery of the cells suggest that MMP9 might not be trafficked directly from the Golgi apparatus to the cell surface for secretion. All subsequent localisation studies were performed using MMP9‐mCherry transiently transfected cells.  
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Figure 3.7. MMP9-mCherry localises to the same places as endogenous MMP9 in 
RAW264.7 macrophages. 
RAW264.7 cells were transfected to transiently express MMP9-mCherry. (A) Cell lysates from 
control macrophages (mock) and macrophages transiently expressing MMP9-mCherry were 
collected and analysed by immunoblotting for MMP9 and Actin. (B) Cells transiently 
expressing MMP9-mCherry grown on coverslips were fixed at the appropriate time points and 
MMP9-mCherry fluorescence was imaged (grey scale or pseudo-coloured using an intensity-
coded palette). Scale bar is 20 μm. (C) Cells transiently expressing MMP9-mCherry grown on 
coverslips expressing MMP9-mCherry (red) were fixed, permeabilised and immunolabelled for 
endogenous MMP9 (green). Scale bar is 20 μm. 
 
3.2.5 MMP9 secretion is not dependent on intact microtubules or actin 
filaments Microtubules can assist with the ‘long‐distance’ bi‐directional movement of vesicles to and from the plasma membrane. Association of protein cargo to microtubules can be an indication of microtubule‐dependent vesicle transport. Hence, RAW264.7 macrophages grown on coverslips were transiently transfected with MMP9‐mCherry 
and immunostained for α‐tubulin to label microtubules (Figure 3.8A). In the periphery of macrophages, fluorescently‐labelled MMP9 locates in punctate structures, some of which appear to localise along microtubules (see arrows in Figure 3.8A). To examine whether the secretion of MMP9 is dependent on intact microtubules, RAW264.7 cells were stimulated with LPS for 12 h and nocodazole was added for the last 3 h to block microtubule polymerisation and disrupt the microtubule network. Successful 
microtubule destabilisation was confirmed through immunofluorescence staining of α‐tubulin (Figure 3.8B). In untreated macrophages, microtubule networks are observed emerging from the microtubule‐organising centre near the nucleus radiating towards the cell surface (Figure 3.8B). In nocodazole treated cells tubulin‐levels appear to remain unaffected with equal fluorescence intensity. However, the tubule network is disrupted and tubulin staining is punctate and dispersed throughout the cell body (Figure 3.8B right hand panel). Disruption of the microtubule network affects cell shape and macrophages appear unorganised with multiple protrusions (Figure 3.8B right hand panel). MMP9 levels in RAW264.7 macrophage conditioned media and cell lysates were analysed in these cells following nocodazole treatment to determine whether the microtubule network might regulate MMP9 secretion. The level of secreted MMP9 was determined by ELISA (Figure 3.8C) and confirmed using immunoblotting (Figure 3.8D) of the conditioned media. MMP9 secretion was unaffected after disruption of microtubules (Figure 3.8C and D) (P>0.05). Similarly, intracellular levels of MMP9 measured from lysates of the same treated cells remained unchanged following nocodazole treatment, as seen by gelatin zymography (Figure 3.8E) and by 
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immunoblotting for MMP9 (Figure 3.8 F). These results suggest that MMP9 secretion under such conditions is not dependent on transport along microtubules. Vesicle transport towards the cell surface not only occurs along microtubules but can also track along actin filaments. Furthermore, actin‐rich podosomes found on the outer surface of the plasma membrane of macrophages are believed to play a role in MMP secretion and migration [Linder 2007]. Thus, to determine whether MMP9 secretion occurs via actin based structures, LPS‐stimulated macrophages (12 h) were treated with actin‐disrupting drug cytochalasin for the last 2 h. In general, RAW264.7 cells treated with cytochalasin exhibited a less pronounced actin cortex and shortened actin filaments than the control cells (Figure 3.9A). Treated cells also appeared more spread out and flatter in comparison (Figure 3.9A) as published previously [Otto et al., 2015]. To determine whether disrupting actin altered MMP9 secretion, levels of MMP9 in conditioned media and the corresponding cell lysates were analysed. Surprisingly, cytochalasin treatment resulted in a small increase in secreted MMP9 as determined by ELISA (Figure 3.9B) and by immunoblotting (Figure 3.9D) of the same samples. Intracellular MMP9 was also analysed from the same samples by zymography (Figure 3.9D) and immunoblotting (Figure 3.9E). The intracellular MMP9 appeared to remain unaffected at the 12 h time point. Thus, MMP9 secretion does not require microtubules or actin for secretion under the conditions analysed.     
Figure 3.8. MMP9 secretion is not dependent on microtubules. 
(A) Cells grown on coverslips expressing MMP9-mCherry (red) were fixed, permeabilised and 
co-labelled for α-tubulin (green). Lower panels show zoom in regions of upper panels and the 
arrows indicate MMP9 staining along microtubules. Scale bar is 10 μm. (B-F) RAW264.7 
macrophages were stimulated with 100 ng/ml LPS for 12 h. After 9 h, the cells were incubated 
in the absence (control) or presence of 5 μM/ml nocodazole (Noc) for further 3 h. (B) Cells on 
coverslips were fixed and stained for α-tubulin (green), F-actin (red) and the nuclei (blue). 
Scale bar is 20 μm. Lower panels show zoomed in regions of upper panels to allow comparison 
of microtubule structures. (C) Total MMP9 levels in cell culture supernatants were quantified 
by ELISA and the fold change in secretion is shown in the graph; mean ± SEM (n=3), 
n.s. P>0.05 (unpaired, two-tailed Student’s t-test). (D) Conditioned media (secreted fraction) 
was collected and analysed by immunoblotting for MMP9 to confirm the ELISA data (n=1). (E) 
Cell lysates (cellular fraction) were collected and analysed by gelatin zymography (n=1). (F) 
Cell lysates were also analysed by immunoblotting for MMP9 using actin as a loading control. 
A representative blot is shown (n=3). 
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Figure 3.9. Disruption of actin filaments with cytochalasin does not reduce MMP9 
secretion. 
RAW264.7 macrophages were stimulated with 100 ng/ml LPS for 12 h. For the last 2 h, the 
cells were incubated in the absence (Control) or presence of 1 μg/ml cytochalasin (Cyto). (A) 
Cells grown on coverslips were fixed and stained with phalloidin to label F-actin (red) and 
nuclei were labelled using DAPI (blue). Scale bar is 20 μm. (B) Total MMP9 levels in 
conditioned media were quantified by ELISA. The graph shows the fold change in MMP9 
levels; mean ± SEM (n=3), n.s. P>0.05 (unpaired, two-tailed Student’s t-test). (C) Conditioned 
media (secreted fraction) was collected and analysed by immunoblotting for MMP9 (n=1). (D) 
Cell lysates (cellular fraction) were collected and analysed by gelatin zymography (n=1) and 
(E) by immunoblotting for MMP9 and with actin as a load control (n=3). 
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3.2.6 Newly synthesised MMP9 is trafficked via the Golgi MMP9 has an N‐terminal signal sequence that targets it for import into the ER during biosynthesis [Egeblad and Werb, 2002]. Most secreted proteins are then shuttled through the Golgi apparatus from where they can be transported to the surface in membrane bound compartments or vesicles either directly or through other organelles such as recycling endosomes or late endosomes [Stow and Murray, 2013]. However, some proteins can bypass the Golgi complex and are shuttled directly from the ER to the plasma membrane [Stow and Murray, 2013]. To determine whether MMP9 localises to the Golgi complex, macrophages transiently transfected with MMP9‐mCherry for a period of 6 h were fixed, permeabilised and immuno‐labelled for the cis‐Golgi marker GM130. Figure 3.10A shows that some MMP9 localises to the Golgi complex.  To confirm that newly synthesised MMP9 transits through the Golgi complex, macrophages were stimulated with 100 ng/ml LPS for 12 h with the final 6 h being in the presence of brefeldin A. Brefeldin A inhibits protein transport from the ER to the cis‐Golgi leading to the collapse of the Golgi complex stacks [Lippincott‐Schwartz et al., 1989]. Immunofluorescence staining of brefeldin A treated RAW264.7 macrophages using the cis‐Golgi marker GM130 shows that, as expected, treatment with brefeldin A disrupts the Golgi stacks in RAW264.7 macrophages (Figure 3.10B). Next, RAW264.7 cells were co‐transfected with MMP9‐mCherry and a secreted form of GFP (ssGFP), and were cultured with LPS for 6 h in the absence or presence of brefeldin A. Cells were analysed by flow cytometry and gated for double‐positive cells and the intracellular median fluorescence intensities (MFI) for MMP9‐mCherry and ssGFP compared (Figure 3.10C). The secreted form of GFP (ssGFP) does not traffic through the Golgi complex and thus should not be affected by brefeldin A (Duellman et al., 2014). Figure 3.10C confirms that this is the case for ssGFP, but the level of intracellular MMP9‐mCherry increased over 4‐fold compared to untreated cells. Thus, the disruption of anterograde ER‐Golgi transport leads to a substantial accumulation in the mCherry tagged MMP9 within the cell suggesting MMP9 must traffic through the Golgi complex en route to the cell surface.  To confirm endogenous MMP9 also traffics through the Golgi complex, the level of endogenously secreted MMP9 was measured by ELISA in conditioned media from macrophages that had been stimulated with LPS for 12 h and treated in the presence or absence of brefeldin A for the final 6 h (Figure 3.10D). The secretion of endogenous MMP9 was significantly decreased (84%; *0**P≤0.0001) in the presence of brefeldin A compared to control cells (Figure 3.10D). Cell lysates from the same experiment were analysed by zymography (Figure 3.10E) and by immunoblotting (Figure 3.10F). Both, 
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intracellular proteolytic activity (Figure 3.10E) and MMP9 protein levels (Figure 3.10F) were strongly increased after BFA treatment macrophages compared to the control suggesting a build‐up in the cell. Levels of non‐secreted proteins, such as actin, remain unaffected by the BFA treatment (Figure 3.10F). These results, along with the localisation of MMP9 to the Golgi complex, confirm newly synthesised MMP9 traffics through a Golgi complex en route to the cell surface.           
Figure 3.10. Newly synthesised MMP9 is trafficked to the cell surface via the Golgi 
complex. 
(A) RAW264.7 cells transiently expressing MMP9-mCherry (red) were fixed on coverslips, 
permeabilised and immunostained for the cis-Golgi marker GM130 (green). The lower panels 
show a zoomed in region where MMP9 and GM130 co-localise. Scale bar is 10 μm. (B) 
RAW264.7 macrophages were stimulated with 100 ng/ml LPS for 12 h. For the last 6 h the 
cells were incubated in the absence (control) or presence of 5 μg/ml brefeldin A (BFA). Cells 
on coverslips were fixed and stained for GM130 (green), F-actin (red) and the nuclei (blue). 
Scale bar is 20 μm. (C) RAW264.7 cells were co-transfected with MMP9-mCherry and a 
secreted form of GFP (ssGFP). Cells were stimulated with 100 ng/ml LPS for 6 h in the 
absence (control) or presence of 5 μg/ml brefeldin A (BFA). After BFA treatment macrophages 
were analysed by flow cytometry and the macrophages were gated for double-positive cells. 
The graph shows the mean fluorescence intensity (MFI) of ssGFP and MMP9-mCherry in the 
double positive cells following brefeldin A treatment relative to the control (n=1). (D) RAW264.7 
macrophages were stimulated with 100 ng/ml LPS for 12 h. For the last 6 h the cells were 
incubated in the absence (control) or presence of 5 μg/ml brefeldin A (BFA). Total MMP9 levels 
in cell culture supernatants were quantified by ELISA; mean ± SEM (n=3), ****P≤0.0001 
(unpaired, two-tailed Student’s t-test). (E) Cell lysates were collected and analysed by gelatin 
zymography (n=1) (F) Cell lysates were collected and analysed by immunoblotting for MMP9 
and actin. A representative image is shown (n=3).  
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3.2.7 MMP9 localises to late endosomes/lysosomes Both the endogenous and overexpressed MMP9 are located in the perinuclear Golgi complex and as punctate structures in the periphery of the cell (Figure 3.7). Protein cargo that is to be secreted but not directly transported to the plasma membrane can be trafficked via other organelle structures, such as the late endosome to the cell surface [Stow and Murray, 2013]. To test whether MMP9 is trafficked via late endosome/lysosomal compartments en route to the cell surface in RAW264.7 cells, macrophages were transfected with MMP9‐mCherry for 6 h and co‐stained with known organelle markers (Figure 3.11). Lysosome‐associated membrane protein 1 (LAMP1) is a structural glycoprotein integrated into the limiting membranes of late endosomes and lysosomes and is a commonly used marker for these compartments [Chen et al., 1985; Eskelinen et al., 2003]. Immunostaining of LAMP1 in cells expressing MMP9‐mCherry show MMP9 and LAMP1 are found on the same structures (Figure 3.11). LAMP1 appears as a punctate ring surrounding MMP9, suggesting that MMP9 is enclosed in LAMP1‐positive membranes (see arrows in Figure 3.11A). As LAMP1 is a marker for both late endosomes and lysosomes, cells were next stained for a late endosome marker to determine whether MMP9 was present in both structures. Lysobisphosphatic acid (LBPA) is a lipid that accumulates within intraluminal membranes of late endosomes but not lysosomes [Kobayashi et al., 1999; Matsuo et al., 2004] and is commonly used as a late endosome marker. MMP9‐mCherry is located in enlarged vesicles in the periphery of the cell and partially colocalised with LBPA‐positive endosomes (Figure 3.11B). Again the LBPA‐positive stained membranes often appeared to surround the MMP9 (arrows in Figure 3.11B). These results suggest that MMP9 could be trafficked from the Golgi complex to the late endosome and lysosome prior to secretion. 
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Figure 3.11. MMP9 localises to late endosomes and lysosomes. 
Cells expressing MMP9-mCherry (red) grown on coverslips were fixed, permeabilised and 
immunostained for either (A) late endosome/lysosome marker LAMP1 (green) or (B) the late 
endosome marker LBPA (green). The lower panels show zoomed in regions of the upper 
panels. Arrows indicate LAMP1- or LBPA-positive membranes surrounding the MMP9 cargo. 
Scale bar is 20 μm.  
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3.2.8 Targeting specific SNARE proteins alters MMP9 levels in conditioned 
medium Having shown that MMP9 is transported through the Golgi complex but can be found in late endosomes/lysosomes, possibly en route to the cell surface, it was next determined which SNARE proteins might regulate this transport to the cell surface. SNARE proteins will regulate every point of membrane fusion in the transport of MMP9 to the cell surface and can be used to map transport pathways. Each of the 38 mammalian SNARE proteins has a precise subcellular distribution and as such regulates distinct fusion events. These proteins regulate fusion events such as late endosome/lysosome membrane fusion with the cell surface and thus identifying which SNAREs alter secretion will help identify the transport pathways. Identification of the trafficking machinery proteins involved in the exocytosis of MMP9 would not only further pinpoint the intracellular trafficking pathways for this protein, but might also provide novel therapeutic targets to reduce proteolytic degradation and inflammation in chronic wounds. 
Targeting surface Q-SNAREs As each type of organelle has distinct SNARE sets that can only bind their equivalent SNARE partner on the respective target membrane, the absence or malfunction of just one of the participating SNAREs inhibits the fusion process. Therefore, mutant forms or depletion of individual SNAREs block specific fusion steps and are commonly used to map transport pathways [Stow and Murray, 2013]. To identify possible regulators of MMP9 secretion from macrophages the four main Q‐SNAREs (Stx2, Stx3, Stx4 and SNAP23) found on the macrophage cell surface, and most likely to mediate secretion, were targeted for knockdown with specific siRNA (Figure 3.12). RAW264.7 macrophages were transfected with siRNA to these SNARE proteins on day 1, this was repeated on day 2 and then cells stimulated with LPS for 15 h. Knockdown was successful for all four tested surface SNARE proteins and it can be seen that the individual knockdowns were specific for the targeted SNARE and did not lead to changes in the levels of other surface non‐targeted SNAREs (Figure 3.12A). To measure the effectiveness of the protein knockdown for each individual SNARE, the levels of the remaining protein were quantified by densitometry of immunoblots from multiple experiments (n=3) and compared to the amount of that particular protein in control cells transfected with scrambled siRNA (Figure 3.12B). Stx2, Stx3 and Stx4 were significantly reduced following knockdown, with knockdown rates of 74% (**P≤0.01), 50% (*P<0.05) 
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and 55% (*P<0.5) respectively. Protein levels for SNAP23 were reduced by 20% (P>0.05). It is expected that if a specific SNARE protein is essential for MMP9 delivery to the cell surface then knockdown of that SNARE would lead to a reduction in secretion and MMP9 might accumulate within the cell. Reductions in SNAREs not involved with MMP9 delivery would be expected to have no effect on secretion. Conditioned media was collected from cells treated with siRNA to Stx2, Stx3, Stx4 or SNAP23, as well as from cells treated with control scrambled siRNA. The fold change in MMP9 levels were then determined by ELISA (Figure 3.12C). None of the surface SNARE knockdowns led to a decrease in MMP9 in the conditioned media compared to the control cells. On the contrary, knockdown of surface SNAREs Stx2 and SNAP23 lead to about strong enrichment of MMP9 in cell culture supernatants (*P<0.05), while knockdown of Stx3 and Stx4 had only minor effects on MMP9 levels (P>0.05) (Figure 3.13C). Partial knockdown of SNAP23 had a very striking effect, increasing MMP9 levels in conditioned media by almost three‐fold, although SNAP23 protein levels where only reduced by 20% (*P<0.05). Secreted MMP9 levels were more than three times as high as the control when Stx2 levels where reduced to a quarter of the levels in control cells (*P<0.05). Levels of intracellular MMP9 were also measured in the same cells (Figure 3.12A) and quantified by densitometry (Figure 3.12C). MMP9 levels remained mostly unaffected following knockdown of Stx2, Stx3 and Stx4 with changes of less than 10% (P>0.05). However, intracellular MMP9 levels decreased by 14% in macrophages that had reduced SNAP23. These results together suggest that Stx2, Stx3, Stx4 and SNAP23 do not directly mediate delivery of MMP9 to the cell surface but Stx2 and SNAP23 might regulate another process that can alter the level of MMP9 in the media. 
Targeting endosome and Golgi associated R-SNAREs Q‐SNAREs must form complexes with R‐SNAREs to regulate fusion at each point in the intracellular transport pathways. Five R‐SNARE proteins, VAMP2, VAMP3, VAMP4, VAMP7 and VAMP8, which mediate fusion of distinct intracellular transport pathways, were targeted using siRNA (Figure 3.13). RAW264.7 macrophages were transfected with siRNA to these SNARE proteins on day 1, this was repeated on day 2 and then cells stimulated with LPS for 15 h. As with the surface SNAREs, knockdown was successful (38‐71%) and specific for all four tested R‐SNARE proteins (Figure 3.13A). VAMP4 is located in the Golgi complex in RAW264.7 macrophages [Lei et al., 2012] and known to regulate fusion both to and from the Golgi in other cell types. As 
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newly synthesised MMP9 destined for secretion was found to be trafficked via the Golgi (Figure 3.10) VAMP4 was considered a potential regulator for MMP9 trafficking from the Golgi complex. Surprisingly, siRNA knockdown of VAMP4 by 38% (**P≤0.01) increased MMP9 levels in cell culture supernatants by 150% while reducing intracellular levels by 42% (P>0.05) (Figure 3.13C). Apart from the Golgi complex, MMP9 was also found to localise to late endosomal/lysosomal compartments (Figure 3.11). VAMP8 regulates homotypic fusion of late endosomes and VAMP7 regulates late endosome to lysosome fusion [Pryor et al., 2004]. In macrophages VAMP7 has also been shown to deliver late endosome/lysosome membrane to the cell surface during phagocytosis [Braun et al., 2004]. In other cells VAMP7 has been shown to regulate the delivery of exosomes from late endocytic compartments (multivesicular bodies) to the cell surface for secretion [Fader et al., 2009]. After siRNA treatment, VAMP7 and VAMP8 protein levels were reduced by 58% (****P<0.0001) and 71% (****P<0.0001), respectively. Again, an enrichment of MMP9 levels, rather than a reduction, was seen following knockdown of VAMP7 or VAMP8 (Figure 3.13D). After VAMP7 knockdown, MMP9 levels in the cell culture supernatants increased by 170% (n.s. P>0.5) and this was accompanied by a significant reduction in intracellular MMP9 (46% (*P<0.05)). The same effect, albeit to a lesser extent, was observed in macrophages with reduced VAMP8, where MMP9 levels in the conditioned media increased by 78% and decreased by 37% intracellularly (P>0.5). The reduction in secreted MMP9 seen when key SNAREs are reduced and the localisation of MMP9 to late endosomal/lysosomal compartments could also be a result of the internalisation of secreted MMP9, thus R‐SNAREs involved in endocytic pathways were also investigated for a role in altering MMP9 levels. VAMP2 is located on early endosomes in macrophages [Veale et al., 2010] and has been found to regulate endocytic events in neuronal and HeLa cells [Miller et al., 2011; Koo et al., 2011]. Reduction of VAMP2 levels by about 38% led to a small enrichment of MMP9 in the conditioned media (38% (p>0.05)), while intracellular levels remained mostly unaffected. Newly made MMP9 could also be trafficked via the recycling endosome to then be delivered to the plasma membrane for secretion. VAMP3 is located on the recycling endosome and has been shown to regulate the delivery of protein cargo, such as TNF and IL‐6 to cell surface in macrophages [Manderson et al., 2007; Murray et al., 2005]. It can also regulate the recycling of internalised cargo, such as the integrins, back to the cell surface [Veale et al., 2010]. With only 30% VAMP3 remaining (****P<0.0001), MMP9 levels in the cell culture supernatants increased by more than 220% and were reduced by 24% within the cell. 
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In summary, none of the tested SNAREs can conclusively be attributed to mediate secretion of MMP9 in macrophages. Surprisingly, knockdown of Stx2, SNAP23, VAMP2, VAMP3, VAMP4, VAMP7, VAMP8 but not Stx3 or Stx4 lead to an increased release of MMP9 levels in the extracellular environment rather than reducing its secretion. The most substantial enrichment of MMP9 (more than 2.5‐fold) in conditioned media was detected in macrophages with reduced levels of VAMP7, Stx2 and SNAP23. However, most of the changes observed only represent a trend and a significant effect could only be determined for VAMP7 knockdown. This might reflect the fact that the level of SNARE protein could not be completely ablated. Yet, the unanticipated results still suggest that there might be other mechanisms influencing MMP9 levels in cell culture supernatants apart from MMP9 secretion itself and that this mechanism could be mediated by these SNARE proteins.   
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Figure 3.12. Knockdown of the surface Q-SNAREs Stx2 and SNAP23 but not Stx3 and 
Stx4, leads to an increase in MMP9 levels in cell culture supernatants. 
RAW264.7 macrophages were transfected with scrambled (scr), Stx2, Stx3, Stx4 or SNAP23 
siRNA, re-transfected 24 h later and then stimulated with 100 ng/ml LPS for 15 h. (A) Whole 
cell lysates were immunoblotted for Stx2, Stx3, Stx4, SNAP23, MMP9 and also for actin as a 
loading control. Representative images are shown (n=3). (B) Bar graph showing the remaining 
SNARE protein levels relative to that present in control cells (scrambled siRNA) after SNARE 
knockdown as determined through densitometry of immunoblots; mean ± SEM (n=3), *P<0.05, 
**P≤0.01 (one-way ANOVA with Dunnett’s post-hoc test). (C) Bar graphs showing fold change 
in MMP9 levels in conditioned media (n=3) as determined by ELISA (red) and intracellular 
MMP9 levels as determined through densitometry of immunoblots (n=3) from lysates (grey) 
following SNARE knockdown; mean ± SEM, *P<0.05, (one-way ANOVA with Dunnett’s post-
hoc test). 
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Figure 3.13. Knockdown of VAMP2, VAMP3, VAMP4, VAMP7 and VAMP8 increases the 
level of MMP9 in cell culture supernatants. 
RAW264.7 macrophages were transfected with scrambled (scr), VAMP2, VAMP3, VAMP4, 
VAMP7 or VAMP8 siRNA, re-transfected 24 h later and then stimulated with 100 ng/ml LPS 
for 15 h. (A) Whole cell lysates were immunoblotted for VAMP2, VAMP3, VAMP4, VAMP7, 
VAMP8, MMP9 and actin, representative images shown. (B) Bar graph showing the remaining 
SNARE protein levels relative to control (scrambled siRNA) after SNARE knockdown as 
determined through densitometry of immunoblots; mean ± SEM (n=3 with exception of VAMP2 
where n=1), **P≤0.01, ****P≤0.0001 (one-way ANOVA with Dunnett’s post-hoc test). (C-E) 
Bar graphs showing fold change in MMP9 levels in conditioned media as determined by ELISA 
(red) and intracellular MMP9 levels as determined through densitometry of immunoblots from 
lysates (grey) following SNARE knockdown; mean ± SEM (n=3), *P<0.05, otherwise n.s. 
P>0.05 (one-way ANOVA with Dunnett’s post-hoc test). 
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3.3 Discussion MMP9 has a detrimental role in non‐healing wounds but specific inhibition of the enzyme’s activity as a therapy has been mostly unsuccessful so far, most likely due to their broader specificity. Preventing secretion of this enzyme from macrophages, which are major producers of MMP9 in chronic wounds, could represent a different approach to reduce proteolytic activity in those wounds that appear to be stuck in an inflammatory state. Thus, this chapter aimed to identify key organelles and machinery involved in the intracellular transport and secretion of MMP9. Results showed that in macrophages secretion of MMP9 is upregulated upon stimulation with LPS and that unlike neutrophils, where MMP9 is stored in tertiary granules prior to secretion, the released MMP9 is newly synthesised as needed. MMP9 was located in the Golgi complex, in late endosomes and lysosomes in macrophages. Brefeldin A disruption of the Golgi complex confirmed MMP9 is transported through the Golgi compartment but other drug treatments showed that microtubules and actin were not necessary for MMP9 surface delivery and secretion under the conditions used. SiRNA knockdown of R‐SNARE proteins involved in both, classical and non‐classical pathways, did not reveal which pathways were involved in MMP9 secretion but instead suggest that MMP9 might also be regulated by an endocytic mechanism making it difficult to distinguish the exocytic pathways. Inhibiting the function of the four major surface Q‐SNARE proteins did not reduce MMP9 secretion. This suggests that another SNARE at the cell surface is likely to be responsible for the final delivery of membrane bound MMP9 to the cell surface or that alterations in endocytic pathways are masking its identity. 
3.3.1 Detecting MMP9 To monitor any changes in the intracellular levels and secretion of MMP9, it was necessary to optimise assays to detect MMP9 in RAW264.7 whole cell lysates and cell culture supernatants. Many publications use gelatin zymography to determine MMP9 levels but the cells are usually cultured in the absence of FBS due to the intrinsic gelatinolytic activity from the bovine MMP9 in the serum. Unfortunately, removal of FBS from the cell culture media had detrimental effects on RAW264.7 macrophages cell growth and morphology. As FBS is used as a growth supplement in cell culture media because of its high content of growth promoting factors, the negative influence on macrophage cell numbers grown in the absence of FBS is not unexpected. RAW264.7 macrophages have a doubling time of about 11 h and the exhibited reduced growth rates and cell death upon starvation has been shown previously [Sakagami et al., 2009]. Importantly, cells growing in the low serum conditions showed distinct morphological 
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changes. Starvation has previously been shown to induce bi‐nucleation in HeLa cells due to cytokinesis failure [Nishimura et al., 2015] and accordingly increased numbers of bi‐nucleated macrophages were observed when serum concentration were reduced. Macrophages grown in low‐serum media also contained large vacuoles, most likely autophagic vacuoles, which are another known marker for starvation [Mizushima 2007]. Immunostaining for specific autophagy markers could determine whether these observed structures are in fact autophagic vacuoles or denote other compartments. As a consequence, reducing FBS in the culture medium of RAW264.7 macrophages was not an option. Unfortunately, the levels of bovine MMP9 in the FBS‐containing media were high enough to mask any macrophage‐originated MMP9 activity in zymography assays despite stimulation with the strong TLR agonist LPS over extended time periods to increase MMP9 production. Thus, while MMP9 could be measured in cells lysates from cells grown in 10% FBS, another method for detecting MMP9 in media was required.  Commercially available ELISA kits and an antibody raised against mouse MMP9 for immunoblotting were tested and were able to specifically detect the murine form of the protein in culture media. Two ELISA kits were tested but one (R & D) was ruled out due to what appeared to be a factor(s) secreted by the RAW264.7 cells that interfered with the assay. This specific ‘factor’ was not an issue with the second ELISA kit (Biosensis). However, the recovery of the MMP9 levels (Biosensis) was not 100% due to matrix effects from the RPMI media, which means that the MMP9 concentrations observed in cell culture supernatants do not represent an accurate quantification of absolute MMP9. But the absolute concentrations are not necessary to determine changes in MMP9 levels and this assay was linear across the concentration range used. It is important to note that the ELISA kits do not allow discrimination between zymogen and active MMP9, as it detects both of these forms. From the immunoblots of MMP9 in the conditioned media it became clear that only the zymogen form of MMP9 is present in cell culture supernatants. However, the ELISA kit was the more sensitive technique of the two as MMP9 could be detected in cell culture supernatants from as early as 3 h post‐stimulation, whereas MMP9 was only seen from 6 h post‐stimulation by immunoblotting.  Immunoblotting of cell lysates allowed for differentiation between the different forms of MMP9. Zymography of cell lysates was also utilised in some instances to detect intracellular MMP9 since the FBS, which was shown to mask macrophage‐originated MMP9 activity in cell culture supernatants, is absent in those samples. However, this technique appeared to be less sensitive and also only detected one form of MMP9. Hence, immunoblotting for MMP9 in cell lysates and immuno‐detection of murine MMP9 in 
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conditioned media using a commercially available ELISA kit were considered most suitable for the investigation of intracellular trafficking and secretion of MMP9. Unfortunately, only a limited amount of experiments were performed with the anti‐MMP9 polyclonal rabbit antibody as antibody from a newly purchased batch with a different lot number was subsequently unable to detect MMP9 in conditioned media or lysates from RAW264.7 macrophages. The batches from the old lot number were no longer available. Some later experiments were performed using a monoclonal mouse MMP9‐antibody as it became commercially available towards the end of the PhD and was positively tested to detect mouse MMP9 in lysates from RAW264.7 macrophages. However, detection of MMP9 in fixed, permeabilised cells for fluorescence microscopy analysis using this antibody was poor. Instead, fluorescently‐tagged MMP9 protein, which appears to locate to the same vesicles as endogenous MMP9 in RAW264.7 macrophages and allows for better detection in microscopy assays, was used for these experiments. 
3.3.2 MMP9 expression and secretion in RAW264.7 macrophages  MMP9 levels are typically low in normal tissue but greatly enhanced during the wound healing process [Opendakker et al., 2001]. Spatio‐temporal control of MMP9 activity is crucial in order to avoid excessive tissue damage as seen in chronic wounds. Endotoxins, tissue debris and other signalling molecules can activate macrophages to produce cytokines, proteases and other pro‐inflammatory factors in vivo. Macrophages are major producers of MMP9 during the inflammatory phase of the wound healing process and studies have shown that the MMP9 gene is strongly up‐regulated in LPS‐activated human blood monocytes and RAW264.7 macrophages in vitro leading to a temporal upregulation of MMP9 secretion into the environment [Huang et al., 2012; Rhee 
et al., 2007; Yang et al., 2015]. Accordingly, unstimulated RAW264.7 macrophages showed only basal levels of intracellular MMP9 but levels where strongly upregulated after stimulation with LPS, and secreted MMP9 was only detectable post‐stimulation. The time‐dependant upregulation of MMP9 expression and secretion observed was generally in agreement with previous studies where MMP9 secretion from LPS stimulated RAW264.7 macrophages was detected from 8‐12 h post‐stimulation [Rhee et 
al., 2007; Woo et al 2004; Yang et al., 2015]. However, MMP9 was also detected in conditioned media from as early as 3 h post stimulation. This may be due to a higher temporal resolution of this experiment as the first time point considered in the above mentioned previous studies was not until 6, 8 or 12 h post‐stimulation, respectively for the individual studies. In addition MMP9 levels were assessed using zymography or 
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immunoblotting techniques in these studies, whereas the analysis by ELISA is much more sensitive and could therefore detect MMP9 at 3 h post stimulation. In fact, MMP9 secretion was only detectable from 6 h post‐stimulation when using immunoblotting techniques for this time series confirming that detection limits can vary for different techniques. Furthermore, the temporal patterns for MMP9 upregulation do not only depend on the resolution of the time series and sensitivity of the assay that is used to measure MMP9 levels but are also affected by the concentration of the LPS used to stimulate MMP9 secretion [Yang et al., 2015]. MMP9 secretion from RAW264.7 macrophages can also be instigated through stimulation with IL‐1β or LPS in combination with IFNγ [Hanania et al., 2012; Yoo et al., 2003]. MMP9 secretion in LPS‐stimulated RAW264.7 has been shown to peak around 24 h post‐stimulation [Rhee et al., 2007; Yang et al., 2015]. Future work could determine whether the upregulation of MMP9 follows a similar temporal pattern after stimulation with these factors. A plateau for MMP9 secretion was not observed in this study as the time series was only assessed over an 18 h time frame but could be expected at later time points due to timely downregulation of MMP9 expression. The later time points were not considered in this study as sufficient levels of MMP9 were achieved for 9‐18 h LPS stimulation to be able to measure changes in MMP9 transport and secretion. MMP9 is synthesised as an inactive precursor (pro‐MMP9) and activation of the zymogen can occur through cleavage of the pro‐peptide upon rebinding at the cell surface following secretion. Hence, non‐cleaved pro‐MMP9 (zymogen) as well as processed MMP9 (active) could be expected to be present in the conditioned media. The ELISA results represent total MMP9 levels as the assay does not discriminate between pro‐MMP9 and the cleaved form. The active and zymogen form are, however, distinguishable by molecular weight. Immunoblots of conditioned media detected only one band for MMP9, most likely, from its size, the non‐cleaved zymogen form of MMP9 (105 kDa). This indicates that processing of pro‐MMP9 to active MMP9 might not occur under these in vitro conditions. It is known that in vitro pro‐MMP9 rapidly dissociates again following its rebinding to the surface and this dissociating would prevent it to be activated [Fridman et al., 2003]. Additionally, the culture media may also dilute any soluble activators, such as plasmin/MMP3, that might be present in the cell culture supernatant [Fridman et al., 2003]. This, together, might explain why the active form (98 kDa) cannot be detected. This is probably not representative of in vivo conditions, where activators and MMP9 molecules are expected to be much more concentrated, particularly within chronic wound fluid. In vivo regulation of MMP9 activity is not only limited to a 
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transcriptional regulation, secretion and activation but is also achieved through the presence of endogenous activators and inhibitors, such as the TIMPs. While short‐lived neutrophils are known to produce and prepack MMP9 in tertiary granules for rapid release [Van den Steen et al., 2002], macrophages do not have granules for the storage and release of pre‐made proteins. Hence, the upregulation of MMP9 secretion might be expected to stem mostly from newly synthesised protein or from the inhibition of MMP9 degradation. As with the majority of proteins destined to be secreted, MMP9 has a signal‐peptide targeting it to the ER during translation [Egeblad and Werb, 2002]. Indeed, a previous study was able to show that MMP9 co‐localises with the ER markers protein disulfide‐isomerase (PDI) and calreticulin in classical activated RAW264.7 macrophages [Hanania et al., 2012]. MMP9 is heavily glycosylated with both N‐ and O‐glycosylation sites. N‐glycosylation of fully unglycosylated MMP9 (98 kDa) to a short‐lived intermediate form (102 kDa) occurs in the ER, whereas O‐glycosylation of the rapidly processed 102 kDa‐sized intermediate form to the fully glycosylated protein with a molecular weight of 105 kDa form takes place in the Golgi complex [Duellman et 
al., 2015; Hanania et al., 2012; Olson et al., 2000]. By immunoblotting two bands can be seen in stimulated samples; one just below 100 kDa, most likely representing the underglycosylated (98 kDa) form of MMP9, and a band above 100 kDa detectable in stimulated, as well as unstimulated samples, which is likely the fully glycosylated zymogen form of MMP9 (105 kDa) [Olson et al., 2000]. The increasing presence of the underglycosylated form in LPS‐stimulated samples suggests that increased levels of MMP9 in cell culture supernatants of LPS‐stimulated RAW264.7 macrophages originate from newly made protein. This was confirmed when macrophages were treated with cycloheximide to stop protein synthesis where reduced levels of MMP9 were seen in the cellular and the secreted fraction. Correspondingly, the underglycosylated precursor (98 kDa) form of MMP9 that occurs during the de novo synthesis of the protein becomes almost absent in lysates from cells treated with cycloheximide. The reduction of MMP9 levels observed for cycloheximide treated macrophages is quite substantial considering protein synthesis was only inhibited for the last 4 h of LPS stimulation. This might be due to the fact that MMP9 secretion over time is not linear but appears to continually increase. It is likely that some MMP9 might be internalised and regulated by degradation, as implied in the SNARE knockdown experiments, as the time course progresses leading to a greater effect that anticipated when MMP9 production is inhibited at these later time points. 
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3.3.3 The cytoskeleton and MMP9 secretion The cytoskeleton can assist in the anterograde transport of cargo‐containing vesicles for their secretion [Anitei and Hoflack, 2012]. Microtubules have previously been reported to facilitate MMP9 secretion in RAW264.7 macrophages stimulated with LPS and IFNγ [Hanania et al., 2012]. In this study, MMP9 localised to stable microtubules in immunofluorescence microscopy as well as kinesin isoforms KIF5B and KIF3B [Hanania et al., 2012]. Disruption of microtubules with 10 μM nocodazole reduced secretion of MMP9 into cell culture supernatants. Concurrently, stabilisation of microtubules with taxol or low‐doses of nocodazole (0.1 μM) increased secretion of MMP9 [Hanania et al., 2012]. In RAW264.7 macrophages stimulated with LPS alone, MMP9 was also found to distribute along microtubules. Yet, disrupting microtubule networks with 5 μM nocodazole did not change intracellular or secreted levels of MMP9. A lack of an effect could be due to the fact that nocodazole also causes the separation of the Golgi complex from its central position resulting in the formation of scattered mini‐stacks, which are nevertheless competent for maintaining protein transport and secretion [Cole et al., 1996]. To add to this, microtubules only increase the probability for a cargo vesicle to encounter the target membrane, which means that the secretion in nocodazole‐treated samples is only slowed and not fully blocked [Wacker et al., 1997]. The treatment with nocodazole was present for the last 3 h of 12 h LPS stimulation whereas treatment in the above mentioned study was for the last 3 h of only 9 h LPS stimulation so any effect could have been too small to be detected given the large amounts of MMP9 being secreted during the absence of nocodazole. Using a lower nocodazole concentration might have added to this. The actin skeleton has been reported to have both supporting as well as hindering roles during the secretion process [Porat‐Shliom et al., 2013]. On the one hand, actin filaments can assist in the guidance of exocytic vesicles to fusion sites. On the other hand, actin can also act as physical barrier for any cargo trying to access the plasma membrane [Porat‐Shliom et al., 2013]. Disruption of cortical F‐actin in RAW264.7 macrophages led to an increase of secreted MMP9 levels. This suggests that MMP9 secretion may not be dependent on transportation along actin filaments but that the cytochalasin‐induced breakdown of cortical actin filaments allows for an easier access of MMP9‐containing vesicles to the cell surface for release, thus explaining the slight increase in secreted MMP9 after cytochalasin treatment detected by ELISA. Yet, there were no detectable changes by immunoblot. Cytochalasin treatment of macrophages was only performed for the last 2 h of the 12 h LPS‐stimulation period so changes in 
  94  Chapter 3: Identifying intracellular trafficking pathways for secretion of MMP9 
intracellular MMP9 levels might be too small to be detected with less sensitive techniques applied as immunoblotting and zymography. 
3.3.4 Trafficking pathways for MMP9 in RAW264.7 macrophages 
MMP9 in the Golgi Intracellular trafficking pathways responsible for the release of newly made MMP9 were also investigated. Following translation into the ER, most secreted proteins are then shuttled through the Golgi apparatus. Co‐localisation with GM130, a known Golgi organelle marker, indicated that newly made MMP9 is trafficked via the Golgi. Treatment of macrophages with brefeldin A causes blockage of anterograde traffic from the ER to the Golgi complex [Lippincott‐Schwartz et al., 1989]. The significantly reduced secretion seen after drug treatment verified that MMP9 is trafficked via this organelle en 
route to the cell surface. This blockage led to the accumulation of intracellular MMP9, seen by both immunoblotting and zymography. The intracellular accumulated MMP9 was approximately 100 kDa, slightly lower than the fully glycosylated MMP9 (105 kDa) and higher than the unglycosylated form of MMP9 (98 kDa) seen in control samples. This intermediate form of MMP9 has previously been reported as a short‐lived underglycosylated MMP9 version of the size of 102 kDa. MMP9 (98 kDa) is N‐glycosylated in the ER to produce a 102 kDa form which is usually short‐lived and undetectable, as its transport to the Golgi complex leads to MMP9 being rapidly O‐glycosylated to produce the 105 kDa MMP9 form [Duellman et al., 2015; Hanania et al., 2012; Olson et al., 2000]. The accumulation of this band is consistent with the disruption of the anterograde transport from the ER to the Golgi complex. Interestingly, the accumulated underglycosylated 102 kDa form of MMP9 but not the completely unglycosylated form of MMP9 (98 kDa) is able to degrade gelatin suggesting that N‐glycosylation alone is necessary for the proteolytic mechanism. N‐glycosylation of MMP9 is also known to be crucial for efficient secretion [Duellman et al., 2015a; Duellman et al., 2015b]. 
MMP9 in late endosomes/lysosomes Secretion of MMP9 has previously been demonstrated to be dependent on Rab3D, a trafficking machinery protein regulating exocytosis from the TGN, in macrophages [Hanania et al., 2012; Millar et al., 2002; Pavlos et al., 2005]. But the exact pathway Rab3D regulates in macrophages is unclear. Proteins destined for secretion can be trafficked via other organelles such as late endosomes/lysosomes, which can function as secretory compartments releasing their contents upon fusion with the cell surface. 
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However, in osteoclasts, which can be differentiated from macrophages, the Rab3D pathway is non‐endosomal/lysosomal [Pavlos et al., 2005]. To determine if MMP9 traffics through lysosome it was tested whether MMP9 would co‐localise with known markers for late endosomes/lysosomes in RAW264.7 macrophages. Surprisingly, MMP9 was found to co‐localise with both, late endosomal marker LBPA and late endosome/lysosome maker LAMP1. While most LAMP1‐positive vesicles contained MMP9 some punctate non‐perinuclear MMP9 staining could be seen that did not co‐localise with LPBA. These staining patterns therefore suggest that MMP9 locates to both, lysosomal and late endosomal compartments. The localisation of MMP9 to late endosomal/lysosomal compartments in macrophages could suggest that newly made MMP9 is trafficked via these organelles for secretion. The lysosomal trafficking machinery protein Rab27a does regulate MMP9 secretion in neutrophils [Brezinska et 
al., 2005]. However, this represents the release of stored pools of MMP9 from granules, which do not exist in macrophages. It has been shown using RAW264.7 macrophages 
stimulated with LPS and IFNγ that there is very low recruitment of endogenous MMP9 to LAMP1‐positive vesicles [Hanania et al., 2012]. This might be due to the fact that quantification of the co‐localisation between MMP9 and LAMP1 might only lead to a very small overlap as LAMP1 is only located in the limiting membrane of lysosomes. Another reason why MMP9 would not have been located to LAMP1‐positive compartments in that study could be that activation of RAW264.7 macrophages was achieved through simultaneous stimulation with LPS and IFNγ. Intracellular MMP9 levels were found to peak at 9 h following this stimulation regime [Hanania et al., 2012]. When RAW264.7 macrophages are stimulated with LPS alone intracellular MMP9 levels do not decrease until after 18 h of treatment [Woo et al., 2004]. This represents a significant difference in the temporal expression profile of MMP9. Co‐localisation studies in LPS/IFNγ‐activated macrophages were performed in cells that were fixed 9 h post‐stimulation when expression levels begin to decline, which could affect the distribution of the protein within the cell [Hanania et al., 2012]. Although the co‐localisation studies herein were achieved through transient overexpression of fluorescently labelled MMP9, alterations to trafficking pathways as a result of protein overexpression is not likely to be an explanation for any observed inconsistencies as MMP9‐mCherry localises to the same vesicles as the endogenous protein. Overexpression of proteins can sometimes lead to aggregation and clearance of these ‘aggresomes’ is facilitated via lysosomal mediated degradation [Ovádi and Orosz, 2008]. However, these structures would show a much brighter fluorescence signal and would expect to be LBPA‐negative. Together, this 
  96  Chapter 3: Identifying intracellular trafficking pathways for secretion of MMP9 
supports the data herein that MMP9 can indeed locate to late endosomal/lysosomal structures in macrophages.  MMP9 in late endosomal compartments could also represent pools of previously released MMP9 that had been endocytosed again for clearance. Endocytosis of secreted MMP9 would represent another level for the regulation of its activity and it is known that MMP9 is actively endocytosed. MMP9 is a ligand of low density lipoprotein receptor‐related protein 1 (LRP‐1) and binding of MMP9 to LRP‐1 on the plasma membrane mediates its endocytosis leading to degradation of the protease [Hahn‐Dantona et al., 2001; Van den Steen et al., 2006]. Degradation of MMP9 as a consequence of this process would take place within the lysosome and trafficking to the lysosomal compartment from the early endosome after endocytosis would occur via the late endosome. Therefore, some or all of the MMP9 found in any of these structures could be a result of this clearance mechanism. The increase in MMP9 in the media when specific SNARE proteins are inhibited might suggest that not only do they regulate this degradation pathway but also that MMP9 downregulation can occur by this pathway in macrophages. More work would be needed to determine whether trafficking of MMP9 via these organelles is necessary for its secretion or its degradation. 
Targeting SNARE proteins The delivery of MMP9 within membrane‐bound compartments to the cell surface for secretion requires membrane fusion mediated by SNARE proteins at all points in its trafficking pathway. To identify trafficking machinery proteins that could be involved in the trafficking of MMP9 to the cell surface for secretion, individual protein levels of a range of SNARE proteins were reduced through targeted siRNA knockdowns. Differences in knockdown efficiency between the individual tested SNAREs were seen and might be due to altered stability or half‐life for the individual SNARE protein. For some SNAREs, such as SNAP23, the average knockdown efficiency was as low as 20%. This is owed to the fact that SNAREs play a crucial role for many cellular and biological processes. This is also the reason why knockout mice for most SNAREs, e.g. SNAP23, are lethal and hence unavailable [Suh et al., 2011]. It was also found that the level of knockdown of any one SNARE was variable between biological replicates, occasionally to a large extent, which ultimately also had an effect on the extent of any occurring changes in MMP9 levels. The major surface Q‐SNAREs, Qa‐SNAREs Stx2, Stx3, Stx4 and Qbc‐SNARE SNAP23, which could potentially mediate the final secretion trafficking step at the plasma membrane were tested by siRNA knockdown for their involvement in MMP9 secretion. Disrupting intracellular trafficking pathways by reducing the levels of a key SNAREs involved in 
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fusion of vesicles with the cell surface should lead to a reduction in secreted MMP9 and a build‐up of intracellular MMP9. Surprisingly, a three‐fold increase in secreted MMP9 was observed for macrophages treated with siRNA to Stx2 or SNAP23. This unexpected result suggests that perhaps an additional mechanisms, such as endocytosis, might also influence the levels of extracellular MMP9. Other SNARE proteins that might be found at the plasma membrane should in future be tested for a role in MMP9 secretion. Q‐SNAREs must form complexes with R‐SNAREs to regulate fusion at each point in the intracellular transport pathways. Multiple R‐SNAREs from different pathways in macrophages were also tested for their involvement in MMP9 trafficking. At first, VAMP4 was considered a potential regulator for MMP9 trafficking. Trafficking of MMP9 via the Golgi complex was shown to be essential for MMP9 secretion (Figure 3.10) and VAMP4 can be found in the Golgi complex in RAW264.7 macrophages [Lei et al., 2012]. MMP9 is also known to be sorted into vesicles positive for VAMP4 in breast cancer cells [Jacob et 
al., 2013]. Surprisingly, siRNA knockdown of VAMP4 increased MMP9 levels in cell culture supernatants. This suggests that VAMP4 is not necessary for MMP9 secretion. Yet, it does seem to affect MMP9 levels through another mechanism. VAMP4 can regulate retrograde transport as well as anterograde transport from the Golgi complex and it can be found on early endosomes [Mallard et al., 2002]. Thus, the knockdown of this SNARE could potentially have disrupted endocytosis of MMP9 rather than its secretion, leading to the increase MMP9 seen in the media. The requirement of other Golgi complex SNARE machinery, such as Stx6, in MMP9 release should in future be investigated. Apart from the Golgi complex, MMP9 was also found to localise to late endosomal/lysosomal compartments. As these compartments can have secretory functions in macrophages this could suggest that MMP9 is trafficked to the cell surface via these organelles or degraded via these organelles. To further characterise the role of these compartments for intracellular trafficking of MMP9 the function of the late endosome/lysosome SNAREs VAMP7 and VAMP8 were attenuated in RAW264.7 macrophages using siRNA. Knockdown of VAMP7 and VAMP8 led to the enrichment of MMP9 in cell culture supernatants with a more significant effect observed in cells with reduced VAMP7. This suggests that neither of these two SNAREs is involved in secretion of MMP9 from a late endosomal/lysosomal compartment but nonetheless appear to regulate extracellular MMP9 levels. VAMP7 regulates late endosome to lysosome fusion [Pryor et al., 2004] and could hypothetically mediate the delivery of MMP9 cargo to the lysosome for its degradation. The localisation of MMP9 to late endosomal/lysosomal compartments could be indicative of a pool of MMP9 to be targeted for degradation. It is 
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known that MMP9 levels can regulated through endocytic events, which would also lead to accumulation of this protein within late endosomes and lysosomes. To allow for a more comprehensive investigation of the intracellular trafficking routes of MMP9 in macrophages machinery involved in recycling pathways were also considered. If a substantial amount of MMP9 is in fact endocytosed in macrophages pools of the protein would locate to early endosomes. Co‐localisation studies with an early endosome marker such as Early Endosome Antigen 1 (EEA1) could add valuable insights. VAMP2 locates to early endosomes in macrophages [Veale et al., 2010] and has been found to regulate endocytosis in other cell types [Miller et al., 2011; Koo et al., 2011]. Yet, changes in MMP9 levels following VAMP2 knockdown were only minimal in comparison to other tested SNARE proteins. Other SNAREs that could mediate endocytosis in macrophages should be further investigated.  Endocytosed surface cargo that is not targeted for degradation can be delivered to the cell surface via the recycling endosome, which is known to be the case for integrin 
α5β1 [Caswell et al., 2008; Jones et al., 2006; Powelka et al., 2004]. The recycling of integrin α5β1 to the cell surface is regulated by VAMP3 in macrophages [Veale et al., 2010; Veale et al., 2011]. At the same time, VAMP3 has also been shown to regulate the delivery of newly made cargo such as TNF and IL‐6 from the Golgi complex to the cell surface via the recycling endosome in macrophages and so VAMP3 can function in endocytic and exocytic pathways [Manderson et al., 2007; Murray et al., 2005]. Knockdown of VAMP3 led to increased MMP9 levels in cell culture supernatants, suggesting that it is most likely not regulating delivery of newly made or recycled MMP9 to the cell surface.  Extracellular MMP9 levels can be regulated through endocytosis by binding to LRP‐1 at the cell surface [Hahn‐Dantona et al., 2001; Van den Steen et al., 2006]. Based on LRP‐1‐dependant uptake of other proteins, MMP9 is expected to remain associated with LRP‐1 in early endosomes facilitating the transit of MMP9 from early to late endosomes where the complex dissociates [Laatsch et al., 2012]. MMP9 would then be targeted to the lysosome for degradation while LRP‐1 may be recycled back from late endosomes to the plasma membrane [Laatsch et al., 2012]. The machinery involved in the recycling of LRP‐1 is unknown but it is possible that some or all of the SNAREs that were tested and led to an increase in extracellular MMP9 levels following knockdown are involved in the LRP‐1 recycling process and hence influencing MMP9 levels through altering the cells ability to recycle the receptor involved in MMP9 endocytosis 
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(Figure 3.14). VAMP4 and VAMP3 could be involved in the cell surface delivery of unloaded LRP‐1, which could be either newly made originating from the Golgi or recycled from the plasma membrane. If this were true then knockdown of VAMP4 or VAMP3 could potentially lead to less LRP‐1 being available at the cell surface for the binding and uptake of secreted MMP9, resulting in more MMP9 being present in cell culture supernatants. This is one potential explanation for the results seen when the level of certain SNARE proteins are reduced. When normal levels of LRP‐1 exist at the cell surface, endocytosis of MMP9 associated with LRP‐1 could be mediated by the early endosome VAMP2, whose knockdown lead to increased extracellular MMP9. After internalisation of the LRP‐1‐MMP9‐complex MMP9 would then be delivered to late endosomes and lysosome resulting in MMP9 degradation and the delivery of LRP‐1 to the cell surface to repeat the process. These final stages could be mediated by VAMP7 and/or VAMP8 and the results provided herein are consistent with this, although further experimentation would be required to confirm this theory.  In summary, knockdown of the SNAREs VAMP3, VAMP4, VAMP7, VAMP8, Stx2 and SNAP23 increased the level of extracellular MMP9. This suggests rather than mediating secretion of newly made MMP9 these SNAREs appear to influence other pathways that can alter the level of MMP9 in the cell culture supernatant. Of course, other SNAREs that have not been investigated could also be tested for their involvement in MMP9 trafficking and for their potential to reduce MMP9 secretion. If MMP9 activity cannot be reduced through the inhibition of the enzyme’s secretion it is possible that regulating MMP9 activation through inhibiting surface delivery of components of the MMP14/MMP2/TIMP2 complex, which activates the zymogen at the cell surface, could be used to target its extracellular activity [Itoh et al., 2001; Itoh and Seiki, 2004; Toth, 2003]. The intracellular trafficking and protein machinery involved in the cell surface delivery of MMP14 is the subject of investigation of the next chapter.   
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Figure 3.14. Hypothetical schematic of LRP-1-mediated endocytosis of MMP9. 
MMP9 is secreted after transiting the Golgi complex via an unidentified pathway. VAMP4 and 
VAMP3 could be involved in the cell surface delivery of LRP-1, which could be either newly 
made originating from the Golgi (blue arrows) or recycled from the plasma membrane (purple 
arrows). At the cell surface LRP-1 binds secreted MMP9. Endocytosis of MMP9 associated to 
LRP-1 could be mediated by VAMP2 or VAMP4. Upon successful endocytosis of the LRP-1-
MMP9-complex the subsequent delivery to late endosomes and disassociation of the complex 
therein occurs. Targeting of MMP9 cargo to the lysosome would result in its degradation while 
now unloaded LRP-1 is recycled back to the cell surface. Transport through these latter stages 
could be mediated by VAMP7 and/or VAMP8. A hypothetical VAMP7/Stx2/SNAP23 complex 
could possibly be a regulator of recycling of unloaded LRP-1 from the late endosome to the 
cell surface but this requires further investigation. 
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Chapter 4: Identifying intracellular 
trafficking pathways for cell surface 
delivery of MMP14 
 
4.1 Introduction MMP14 belongs to the group of membrane anchored MMPs and is active at the cell surface. As such, MMP14 is not found in chronic wound fluid but its expression appears to be highly elevated in biopsies of chronic wounds, where they contribute to enhanced matrix turnover [Norgauer et al., 2002]. As part of a complex with TIMP2 and MMP2, MMP14 also regulates the activation of MMP9, which has a detrimental role in non‐healing wounds as it further facilitates collagen breakdown [Itoh et al., 2001; Itoh and Seiki, 2004; Toth 2003]. MMP14 is further thought to play a role in macrophage infiltration of wound tissue [Matias‐Roman et al., 2006; Verollet et al., 2001; Wiesner et 
al., 2014]. As high numbers of macrophages contribute to prolonged inflammation and wound chronicity it would be advantageous to elucidate the pathways for MMP14 surface delivery in macrophages and its influence on macrophage invasion. Understanding how MMP14 is delivered to the cell surface might provide new therapeutic targets to reduce inflammation and improve wound healing. In cancer cells, two pathways have been reported for MMP14 transport from the Golgi complex to the cell surface: one pathway is via the recycling endosome [Bravo‐Cordero et al., 2007; Kean et al., 2015 Remacle et al., 2005] and the other via a late endosome/lysosome pathway [Loskutov et al., 2014; Macpherson et al., 2014; Marchesin 
et al., 2015; Monteiro et al., 2013; Steffen et al., 2008; Williams & Coppolino, 2011; Williams et al., 2014; Yu et al., 2012]. However, these studies represent recycling pathways for MMP14 that has been delivered to the surface, endocytosed and recycled back to the cell surface. This recycling mechanism is the major pathway for controlling surface MMP14 levels in these cell types. In macrophages MMP14 has been shown to be upregulated 13 fold at the RNA level after LPS activation. Thus, it is expected that the majority of MMP14 that is delivered to the cell surface is newly made in macrophages.  Like other transmembrane proteins possessing a signal peptide, MMP14 is translated in the ER and it is then transported to the Golgi complex. Transport through the Golgi complex has been confirmed as essential for processing of pro‐MMP14 to the 
  102 Chapter 4: Identifying intracellular trafficking pathways for cell surface delivery of MMP14 
mature form in the TGN, which is a requisite for successful incorporation into the plasma membrane [Mazzone et al., 2004]. From the Golgi complex, it is unclear what pathway is used to transport MMP14 to the cell surface in macrophages for them to be able to regulate inflammation. To date there is only one study that investigated trafficking pathways of MMP14 in macrophages. This study looked at Rab proteins that regulate MMP14 trafficking to the cell surface [Wiesner et al., 2013]. Rab proteins, like the SNAREs, typically regulate distinct transport steps within the cell. This macrophage study, mainly using overexpressed MMP14, suggested that MMP14 delivery to the cell surface from the Golgi complex occurs in a Rab8 dependent manner. Although the exact route is unclear, the authors suggest MMP14 might be transported directly in Rab8a positive vesicles or via the recycling endosome, in a Rab8a dependent manner, to the cell surface [Wiesner et al., 2013]. However, no overlap of MMP14 with Rab11, which is typically located on the recycling endosome, could be seen [Wiesner et al., 2013]. Rabs that regulate the late endosome/lysosome (Rab7 and Rab9) were not tested in this study. Typically, monocytes/macrophages entering sites of injury and inflammation become activated en route to the site or on entering it. This activation alters the function of the macrophage, such as it might switch on the production and secretion of distinct cytokines and enzymes. Therefore, this chapter begins to establish MMP14 expression and cell surface levels in response to macrophage activation. Next, the subcellular localisation of MMP14 in macrophages is defined to pinpoint and characterise intracellular compartments that form part of the route for MMP14 exocytosis in these cells. Finally, levels of candidate SNARE proteins are reduced by siRNA to identify trafficking pathways and machinery that regulate incorporation of MMP14 into the plasma membrane.   
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4.2 Results 
4.2.1 MMP14 levels increase upon stimulation of RAW264.7 macrophages MMP14 expression has been shown to be upregulated at the RNA level in human and mouse monocytes/macrophages following 2, 6, 18 h or 24 h of LPS stimulation [Hald 
et al., 2012; Ming et al., 2012; Murray et al., 2013; Reel et al., 2011] and is upregulated at the protein level in human macrophages after 24 h of IFN and LPS activation [Johnson et 
al., 2014]. In order to determine the route by which MMP14 is delivered to the cell surface after activation the timing of its upregulation and delivery first needed to be characterised. Hence, to determine the time course for MMP14 protein upregulation, RAW264.7 macrophages were stimulated with 100 ng/ml LPS over an 18 h time course and cell lysates were analysed for MMP14 protein by immunoblotting (Figure 4.1A). MMP14 is initially synthesised as a zymogen (66 kDa) with the pro‐peptide covering the active site that then requires conversion to the mature active form (54 kDa). This process occurs intracellularly through the cleavage of the pro‐peptide by furin after exit from the Golgi complex but before reaching the cell surface [Mazzone et al., 2004]. Figure 4.1 shows that an MMP14 band around 54 kDa was observed in cell lysates of both stimulated and unstimulated macrophages, which most likely represents the mature processed form of MMP14. Post LPS activation the level of MMP14 was found to continually increase over time (Figure 4.1A). Quantification of MMP14 levels from multiple experiments (n=5) revealed that its protein expression is increased 2.7‐fold (±0.63) at its peak around 15 h post‐stimulation. Thus, LPS upregulates MMP14 expression in RAW264.7 macrophages, with levels peaking around 15 h after LPS activation. Unlike MMP9, MMP14 is not secreted but is a membrane‐bound MMP and contains a trans‐membrane domain. Therefore, the protein levels detected in whole cell lysates represent total MMP14, which includes the intracellular pools, as well as any MMP14 anchored in the plasma membrane. As such, discriminating between these two fractions is not possible by immunoblotting of whole cell lysates. Hence, the distribution of MMP14 in stimulated and unstimulated RAW264.7 macrophages was assessed by immunofluorescence microscopy to compare surface and internal MMP14 (Figure 4.1B). Macrophages were stimulated with LPS, fixed at the indicated time points, permeabilised and immunostained for MMP14. In agreement with the immunoblotting results, unstimulated macrophages (0 h) showed low basal levels of MMP14 expression and the levels were markedly upregulated following LPS stimulation (Figure 4.1B). The MMP14 fluorescence signal was most intense in regions around the nucleus and some surface 
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MMP14 was also apparent in LPS stimulated macrophages, although the ratio of the level of MMP14 in the perinuclear region reduced in comparison to that in the periphery over the time course (Figure 4.1B). This suggests that LPS stimulates the production of nascent MMP14 and its delivery to the cell surface.   
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Figure 4.1. MMP14 levels increase upon stimulation of murine macrophages. 
(A) RAW264.7 macrophages were stimulated with 100 ng/ml LPS for the indicated times. 
Following LPS stimulation, cell lysates were collected and analysed by immunoblotting for 
MMP14 and actin. A representative immunoblot is shown. Bar graph shows the increase of 
total MMP14 levels relative to the loading control (actin) over time; n=5, mean ± SEM, n.s. 
P.0.05 (one-way ANOVA with Tukey’s post-hoc test). (B) RAW264.7 macrophages grown on 
coverslips were LPS stimulated for 0, 9 and 18 h, fixed at the indicated time points and 
immunostained for total MMP14 (permeabilised cells) following LPS stimulation. Scale bar is 
20 μm.  
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4.2.2 MMP14 is incorporated into the plasma membrane upon stimulation Due to the intensity of MMP14 intracellular staining it is difficult to clearly distinguish the cell surface MMP14 pool by fluorescence microscopy, as the surface levels are typically lower. In order to better differentiate this surface pool an assay was developed to look at only surface MMP14, where cells were immunostained live on ice for MMP14 prior to fixation. With the membrane integrity remaining intact only the extracellular cell surface MMP14 is then accessible for antibody labelling, which recognises the extracellular domain, and cells can then be fixed and co‐stained as appropriate. Performing the assay on ice prevents any MMP14‐antibody complexes being internalised as endocytosis is halted at 4°C. Firstly, RAW264.7 macrophages grown on coverslips were stimulated with LPS over an 18 h time course and cells were immunostained live for surface MMP14, as described above. After immunofluorescence labelling of this surface MMP14 pool, these cells can be analysed by microscopy and flow cytometry (Figure 4.2). Only very low levels of surface staining can be seen on unstimulated cells but upon stimulation with LPS there is an increase in surface MMP14 that can be observed from around 6 h post‐stimulation (Figure 4.2A). Surface MMP14 continued to increase over the remaining 12 h. It is important to note that fluorescence intensities varied between cells. This is not unusual for macrophages, for example, when looking at TNF post LPS stimulation, typically around 70‐80% of the cells express TNF at 2 h and levels vary in those cells that do express TNF [Murray et al., 2005b]. In addition, not every cell appeared to have increased levels of MMP14 at the cell surface following LPS stimulation. Next, LPS stimulated macrophages were immunostained live for MMP14 and the level of MMP14 at the cell surface quantified over an 18 h time course using flow cytometry. Analysis showed a strong upregulation of MMP14 cell surface delivery in response to LPS activation (Figure 4.2B). Again, it is clear from the histogram that MMP14 surface levels after LPS activation varied from cell to cell (Figure 4.2B), which is consistent with the observations made by immunofluorescence microscopy. Less than 20% of macrophages (0 h) were positive for surface MMP14 in the absence of LPS. This number increased dramatically to around 70% of cells being positive for surface MMP14 following LPS stimulation (9 or 18 h), representing a significant increase of 3.5‐fold (**P<0.01) (Figure 4.2C). More strikingly, median fluorescence intensities (MFI) of surface MMP14 for the total cell population were increased by 8.8‐fold on macrophages stimulated with LPS for 9 h and 10.3‐fold on those stimulated for 18 h (Figure 4.2D). These results confirm that although basal levels of MMP14 are present in unstimulated 
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macrophages, and most cells do not have MMP14 at the cell surface, their activation with LPS strongly induces the delivery of MMP14 to the cell surface for incorporation into the plasma membrane. This together with the results in Figure 4.1 showing total MMP14 levels are increased suggesting that MMP14 at the cell surface might stem mainly from newly made protein. Levels of MMP14 are not only influenced by the presence of endotoxins or cytokines. While low levels of surface MMP14 due to increased MMP14 recycling have been observed for breast adenocarcinoma cells that had been seeded on glass, seeding on collagen abolished endocytosis of MMP14 and increased its levels at the cell surface [Bravo‐Cordero et al., 2007; Lafleur et al., 2006]. A general increase in MMP14 expression was also reported for human peripheral blood mononuclear cells seeded onto fibronectin but surface levels of the protein were not assessed [Jacob et al., 2002; Reel et 
al., 2011]. To investigate the effect of fibronectin on MMP14 surface levels, RAW264.7 
macrophages were seeded onto coverslips that had been coated with 0, 5 or 10 μg fibronectin and unpermeabilised cells were immunostained for MMP14 after 18 h of culture (Figure 4.2E). Only very low levels of MMP14 were detected at the cell surface of macrophages that were grown in the absence of fibronectin. When macrophages were grown on fibronectin, MMP14 surface levels were greatly enhanced in comparison to macrophages grown on uncoated glass coverslips. MMP14 surface levels of macrophages 
grown on 10 μg fibronectin appeared slightly higher than cells that were seeded onto lower (5 μg) concentrations of fibronectin. The effect of growing RAW264.7 macrophages on coverslips coated with 200 μg gelatin, the hydrolysed form of collagen, for 18 h on MMP14 surface levels was also investigated. Figure 4.2F shows that contact with gelatin in the absence of LPS stimulus leads to MMP14 surface levels that are equal to those on macrophages that had been stimulated with LPS. Together these results suggest that matrix components will also affect the surface levels of MMP14.   
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Figure 4.2. MMP14 is incorporated into the plasma membrane upon stimulation. 
(A) RAW264.7 macrophages grown on coverslips were stimulated with 100 ng/ml LPS for the 
indicated times. Macrophages were immunostained live on ice for surface MMP14 
(unpermeabilised cells) and then fixed. Scale bar is 20 μm. (B) Macrophages stimulated for 0, 
9 and 18 h with LPS were immunostained live (unpermeabilised cells) with anti-MMP14 
antibody or with an isotype control antibody, fixed and then analysed using the FACSAriaII 
flow cytometer. The overlaid histogram shows surface MMP14-immunostained cell 
populations over time following LPS stimulation in comparison to the control population 
immunostained with an isotype antibody. (C) Bar graph shows percentage of cells positive for 
surface MMP14 or (D) fold change of relative MMP14 surface levels (MFI), n=3; mean± SEM, 
**P≤0.01 (one-way ANOVA with Tukey’s post-hoc test). (D) RAW264.7 macrophages grown 
on coverslips coated with different concentrations of fibronectin for 18 h were immunostained 
live (unpermeabilised cells) for surface MMP14. (E) RAW264.7 macrophages grown on 
gelatin-coated coverslips (200 μg) for 18 h in the absence or presence of LPS were 
immunostained live (unpermeabilised cells) for surface MMP14. 
 
4.2.3 MMP14 incorporated into the plasma membrane is newly 
synthesised upon LPS stimulation To verify that the increased surface MMP14 represents mostly de novo protein, RAW264.7 macrophages were LPS stimulated for 12 h and treated in the presence or absence of 1 μg/ml cycloheximide for the final 4 h to inhibit protein synthesis. Cell lysates were then immunoblotted for MMP14 to determine the effect of inhibiting protein synthesis on total MMP14 levels (Figure 4.3A). Overall MMP14 levels were strongly reduced following cycloheximide treatment (Figure 4.3A). Next, cells treated with cycloheximide were immunostained live for surface MMP14 and imaged by fluorescence microscopy (Figure 4.3B). The cycloheximide‐treated cells appeared elongated in comparison to control cells and had very low levels of surface MMP14 in comparison to control cells, suggesting the pool at the cell surface after LPS activation is newly synthesised MMP14 (Figure 4.3B). The change in MMP14 surface levels was quantified by flow cytometry (Figure 4.3C). The population of cycloheximide‐treated macrophages showed a strong shift to the left (indicating lower levels) on the histograms for surface MMP14 signal (Figure 4.3C). While some cycloheximide‐treated cells had residual levels of surface MMP14, an increasing portion of the population possessed no MMP14 at the surface at all (Figure 4.3C). The number of macrophage positive for surface MMP14 was reduced from 62% (control) to 38% after cycloheximide treatment (*P≤0.05) (Figure 4.3D). When the surface MMP14 median fluorescence intensity was analysed, the overall levels were found to be reduced by more than half (**P≤0.01) (Figure 4.3E). This confirms that the majority of MMP14 into the plasma membrane after LPS activation requires the de novo synthesis of the protein. 
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Figure 4.3. MMP14 incorporated into the plasma membrane upon LPS stimulation is 
newly synthesised. 
(A) RAW264.7 macrophages were stimulated with 100 ng/ml LPS for 12 h and treated with 
cycloheximide (CHX) for the last 4 h to stop protein synthesis. Cell lysates were collected and 
were immunoblotted for MMP14 and actin. (B) RAW264.7 macrophages grown on coverslips, 
stimulated with 100 ng/ml LPS for 9 h and treated with cycloheximide (CHX) for the last 4 h to 
stop protein synthesis were immunostained live (unpermeabilised cells) for surface MMP14 
and fixed. Scale bar is 20 μm. (C) Macrophages stimulated with 100 ng/ml LPS for 9 hours 
and treated with cycloheximide (CHX) for the last 4 h to stop protein synthesis were 
immunostained live (unpermeabilised cells) with anti-MMP14 antibody or with an isotype 
control antibody, fixed and analysed using a FACSAriaIII flow cytometer. The overlaid 
histograms show surface MMP14-immunostaining for cycloheximide treated and control cells. 
(D) Bar graph shows the percentage of cells positive for surface MMP14, n=3; mean± SEM, 
*P<0.05 (unpaired, one-tailed Student’s t test). (E) Bar graph shows the relative MMP14 
surface levels (MFI), n=3; mean± SEM, **P≤0.01 (unpaired, one-tailed Student’s t test). 
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4.2.4 Live imaging of MMP14 transport in macrophages To visualise live the dynamics of intracellular transport and MMP14 surface delivery two different constructs encoding MMP14, one with a GFP tag and the other with a mCherry tag, were sourced. RAW264.7 macrophages were transiently transfected for 6 h with either MMP14‐GFP or MMP14‐mCherry and lysates from these cells were immunoblotted for MMP14 (Figure 4.4A). A band can be seen around 55 kDa in the transfected and control cells, most likely representing endogenous MMP14 (Figure 4.4A). In lysates of cells transfected with MMP14‐GFP a strong higher molecular weight band was detected between the 75 and 100 kDa markers consistent with it being MMP14 (54 kDa) tagged with GFP (27 kDa) (lane 2, Figure 4.4A). An additional band of a similar size was also observed in lysates from MMP14‐mCherry‐transfected cells signifying MMP14 fused to mCherry (28 kDa) (lane 3, Figure 4.4A). However, its expression level was much lower than MMP14‐GFP. It was therefore decided that MMP14‐GFP was more suitable for monitoring trafficking events in macrophages.  To determine the ideal time point for live imaging experiments RAW264.7 macrophages were transfected with the MMP14‐GFP construct and fixed at 0, 3, 6 or 9 h post transfection and MMP14‐GFP expression examined by fluorescence microscopy (Figure 4.4B). Low levels of MMP14‐GFP fluorescence were noticeable from 3 h but MMP14‐GFP fluorescence was most intense between 6 and 9 h post‐transfection. The majority of tagged‐MMP14 localised to perinuclear structures but it could also be found in punctate structures in the cell periphery (Figure 4.4.B). It was thus decided to use 6 h post transfection as a suitable time point to examine intracellular transport of MMP14‐GFP. To record the dynamic movement of MMP14‐GFP containing vesicles by live cell imaging, images of macrophages were acquired at rates of 1 frame every 1 s over 1 min (Movie 1 and Figure 4.4C). Tracking of individual vesicles shows directed transport of MMP14 from the perinuclear region to the periphery of the macrophage (Movie 1 and Figure 4.4C). Directionality was measured by comparing the displacement (Euclidean distance) and track length (accumulated distance), where a directionality of 1 equals a straight‐line from start to endpoint and is usually indicative that direction of movement is coupled to an external cue. Movement of MMP14 vesicles was not random but showed high directionality (0.93±0.01). The average velocity of these moving vesicles was 0.65±0.16 μm/s. Tracking these long‐distance movements showed MMP14 appeared to follow a direct path towards the cell surface. Together this suggests that the transport of MMP14 cargo could potentially involve the cytoskeleton for a polarised delivery. 
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Figure 4.4. Fluorescently-labelled MMP14 can be transiently overexpressed to monitor 
MMP14 trafficking in live macrophages. 
(A) Cell lysates from macrophages transfected with the MMP14-GFP or MMP14-mCherry and 
control cells were immunoblotted for MMP14 and actin. (B) Cells grown on coverslips were 
transiently transfected with MMP14-GFP and fixed at 0, 3, 6 and 9 h post transfection. MMP14-
GFP fluorescence intensity, as well as distribution, were assessed by microscopy (grey scale). 
Right hand panel shows the pseudo-colouring using an intensity-coded palette where black is 
low and white is high. Scale bar is 20 μm. (C) Cells grown on Matek dishes, which contain a 
12-mm diameter round glass coverslip built into the bottom of the plate, were transiently 
transfected with MMP14-GFP. At 6 h post transfection cells were imaged to record the 
dynamic movement of MMP14-GFP containing vesicles. Images were acquired at rates of one 
frame every 1 s for 1 min. A selection of images are shown and localisation of a MMP14-GFP 
positive vesicle moving from the cell body to the periphery is indicated. Scale bar is 10 μm. 
The movie is available at the following web address:   
https://mediawarehouse.qut.edu.au/QMW/player/?dID=40717&dDocName=QMW_032392  
 
4.2.5 MMP14 cell surface delivery is not dependent on intact microtubules 
or actin filaments The high level of directionality observed for MMP14‐containing vesicles that appeared to move along linear tracks from the cell body towards the cell periphery suggested involvement of MMP14 positive vesicles along the cytoskeleton. Thus, the effect of disrupting the cytoskeleton on MMP14 cell surface delivery was next tested. First, RAW264.7 macrophages stimulated with 100 ng/ml LPS for 12 h were treated with nocodazole for the last 3 h to disrupt microtubule networks (Figure 3.10B and Figure 4.5). Successful microtubule disruption was confirmed (as seen in Figure 3.10B). Cell lysates were collected and immunoblotted for MMP14 and actin. It can be seen that the total level of MMP14 is unaffected by microtubule disruption (Figure 4.5A). The surface delivery of MMP14 was next tested by again treating cells in the presence or absence of nocodazole. The delivery of MMP14 to the plasma membrane appears to be unaffected by the disruption of the microtubule network as MMP14 surface levels are very similar to those on control cells (Figure 4.5B). This was confirmed using flow cytometry, where histograms of MMP14‐labelled macrophages following nocodazole‐treatment looked similar to those in control cells (Figure 4.5C). The number of cells positive for surface MMP14 was identical for treated and control macrophages (62%) (Figure 4.5D) and the median fluorescence intensities did also not differ significantly between the two populations (P>0.05) (Figure 4.5E). Together, this suggests that disruption of microtubules under these conditions does not affect the trafficking of MMP14 to the cell surface in macrophages. In cancer cells, MMP14 has been reported to localise to actin‐rich structures at the cell surface thought to assist migration [Poincloux et al., 2009]. To determine whether this is the case in macrophages, RAW264.7 cells grown on coverslips and 
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stimulated with 100 ng/ml LPS for 9 h were costained for MMP14 and F‐actin (Figure 4.6A). Some MMP14 was located along ruffles, sheet‐like protrusive actin structures but there was also a large pool of MMP14 that did not appear to locate close to actin structures. To test the requirement of actin filaments for MMP14 surface delivery, RAW264.7 macrophages stimulated with 100 ng/ml LPS for 12 h were treated with cytochalasin for the last 2 h to disrupt cortical actin (Figure 4.6B‐D). Immunoblotting of cell lysates from cytochalasin‐treated macrophages and control cells for MMP14 and actin confirmed that total MMP14 levels remained unaffected by the treatment (Figure 4.6B). LPS‐activated macrophages treated in the presence or absence of cytochalasin were immunostained live and the surface levels of MMP14 were determined through fluorescence microscopy and flow cytometry. By microscopy, cytochalasin treatment did not appear to alter MMP14 surface levels (Figure 4.6C). This was confirmed by flow cytometry showing surface MMP14 expression on cytochalasin‐treated macrophages looked similar to those of control cells (Figure 4.6D). The number of MMP14 surface positive cells was similar for both groups (62%) (Figure 5.6E). Similarly, there were no significant differences in median fluorescence intensities of MMP14 between the cytochalasin treated and control cells (Figure 5.6F). This suggests that despite the localisation of some MMP14 to actin structures cell surface delivery of the protein is not greatly influenced by the presence or absence of cortical actin. 
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Figure 4.5. MMP14 cell surface levels are not dependent on microtubules. 
(A) RAW264.7 macrophages were stimulated with 100 ng/ml LPS for 12 h and treated with 
nocodazole (Noc) for the last 3 h to disrupt microtubules. Cell lysates were collected and 
analysed by immunoblotting for MMP14 and actin. (B) RAW264.7 macrophages stimulated 
with 100 ng/ml LPS for 9 h and treated with Nocodazole (Noc) for the last 3 h to disrupt 
microtubules were immunostained for surface MMP14 (unpermeabilised cells), and fixed. 
Scale bar is 20 μm. (C) Macrophages stimulated with 100 ng/ml LPS for 9 h and treated with 
nocodazole (Noc) for the last 3 h to disrupt microtubules were immunostained live 
(unpermeabilised cells) with anti-MMP14 antibody or with an isotype control antibody, fixed 
and analysed using a FACSAriaIII flow cytometer. The overlaid histograms show surface 
MMP14-immunostained cell populations in comparison to the control cells. (D) Bar graph 
shows the percentage of cells positive for surface MMP14, n=3; mean± SEM, n.s. P>0.05 
(unpaired, one-tailed Student’s t test). (E) Bar graph shows the relative MMP14 surface levels 
(MFI), n=3; mean± SEM, n.s. P>0.05 (unpaired, one-tailed Student’s t test). 
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Figure 4.6. Disruption of cortical actin does not affect MMP14 cell surface levels. 
(A) RAW264.7 macrophages were stimulated with 100 ng/ml LPS for 9 h, fixed and 
immunostained for MMP14 (red) and F-actin (green). Lower panels show pools of MMP14 that 
locate along ruffles, sheet-like protrusive actin structures at the cell surface. Scale bar is 
20 μm. (B) RAW264.7 macrophages were stimulated with 100 ng/ml LPS for 12 h and treated 
with cytochalasin (Cyto) for the last 2 h to disrupt cortical actin. Cell lysates were collected and 
analysed by immunoblotting for MMP14 and actin. (C) RAW264.7 macrophages stimulated 
with 100 ng/ml LPS for 9 h and treated with cytochalasin (Cyto) for the last 2 h to disrupt 
cortical actin were immunostained for surface MMP14 (unpermeabilised cells), and fixed. 
Scale bar is 20 μm. (D) Macrophages stimulated with 100 ng/ml LPS for 9 h and treated with 
cytochalasin (Cyto) for the last 2 h to disrupt cortical actin were immunostained live 
(unpermeabilised cells) with antibodies specific for MMP14 or with an isotype control antibody, 
fixed and analysed using a FACSAriaIII flow cytometer. The overlaid histograms show surface 
MMP14-immunostained cell populations in comparison to the control cells. (E) Bar graph 
shows the percentage of cells positive for surface MMP14, n=3; mean± SEM, n.s. P>0.05 
(unpaired, one-tailed Student’s t test). (F) Bar graph shows the relative MMP14 surface levels 
(MFI), n=3; mean± SEM, n.s. P>0.05 (unpaired, one-tailed Student’s t test). 
 
4.2.6 Newly synthesised MMP14 is trafficked via the Golgi complex MMP14 has an N‐terminal signal peptide targeting it for transient retention in the ER membrane during its biosynthesis [Egeblad and Werb, 2002]. Unless a protein possesses a retention signal in addition to the signal peptide localisation to the ER during biosynthesis can be very transient, which can make the detection of proteins that are not resident to the ER difficult [Alberts et al., 2002]. Accordingly, when simultaneously labelling MMP14 and the ER marker PDI in RAW264.7 macrophages stimulated with 100 ng/ml LPS for 6 h no overlap can be observed (Figure 4.7A). MMP14 is very quickly shuttled to the Golgi apparatus before being processed to the mature form and transported to the cell surface to be incorporated into the plasma membrane. In macrophages this route to the cell surface is unclear. To confirm MMP14 localisation to the Golgi complex in RAW264.7 macrophages, cells were stimulated with 100 ng/ml LPS for 6 h followed by immunostaining of MMP14 and the cis‐Golgi protein GM130 (Figure 4.7B). It can be seen from Figure 4.7B that a perinuclear pool of MMP14 co‐localises with GM130 on the Golgi complex as indicated by strong overlap of their fluorescence signals (Figure 4.7B). To test whether MMP14 trafficking via the Golgi complex is a prerequisite for its incorporation into the plasma membrane, RAW264.7 macrophages were stimulated with 100 ng/ml LPS for 12 h and treated with brefeldin A for the last 6 h, which leads to collapse of the Golgi complex. Immunoblotting of lysates shows that disrupting transport through the Golgi complex did not affect total MMP14 levels as compared to control cells (Figure 4.7C). Next, surface MMP14 was immunostained live in unpermeabilised macrophages to determine the effect of Golgi stack dispersal on delivery of MMP14 to the plasma membrane. Fluorescence imaging demonstrated that surface MMP14 was almost absent in macrophages treated with brefeldin A, while 
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control cells showed high levels of surface MMP14 (Figure 4.7D). This was confirmed by flow cytometry where histograms for MMP14 surface levels reflecting the dramatic left shift for populations that had been treated with the brefeldin A (Figure 4.7E). Only 8% of macrophages remain positive for surface MMP14 following brefeldin A treatment, which represents an almost 8‐fold decrease compared to the control with 62% of MMP14‐positive macrophages (**P≤0.01) (Figure4.7F). Relative to the control, median fluorescence intensities were also reduced by 88% after brefeldin A treatment (***P≤0.001) (Figure 4.7G). Taken together, this provides strong evidence that MMP14 trafficking through the Golgi complex is crucial for MMP14 cell surface delivery in macrophages.         
Figure 4.7. Newly synthesised MMP14 is trafficked via the Golgi complex. 
(A) RAW264.7 macrophages were stimulated with 100 ng/ml LPS for 6 h, fixed and 
immunostained for MMP14 (red) and the ER marker PDI (green). The smaller panels on the 
right show an enlarged region where perinuclear MMP14 is in proximity to PDI but does not 
overlap. Scale bar is 20 μm. (B) RAW264.7 macrophages were stimulated with 100 ng/ml LPS 
for 6 h, fixed and immunostained for MMP14 (red) and the cis-Golgi marker GM130 (green). 
The smaller panels on the right show an enlarged region where perinuclear MMP14 co-
localises with GM130. Scale bar is 20 μm. (C) RAW264.7 macrophages were stimulated with 
100 ng/ml LPS for 12 h and treated with brefeldin A (BFA) for the last 6 h to disrupt the Golgi 
complex. Cell lysates were collected and analysed by immunoblotting for MMP14 and actin. 
(D) RAW264.7 macrophages stimulated with 100 ng/ml LPS for 9 h and treated with brefeldin 
A (BFA) for the last 6 h to disrupt the Golgi complex were immunostained live 
(unpermeabilised cells) for surface MMP14, and fixed. Scale bar is 20 μm. (E) Macrophages 
stimulated with 100 ng/ml LPS for 9 hours and treated with brefeldin A (BFA) for the last 6 h 
were immunostained with an anti-MMP14 antibody or with an isotype control antibody, fixed 
and analysed using a FACSAriaIII flow cytometer. The overlaid histograms show surface 
MMP14-immunostained cell populations in comparison to the control macrophages. (F) Bar 
graph shows the percentage of cells positive for surface MMP14, n=3; mean± SEM, **P≤0.01 
(unpaired, one-tailed Student’s t test). (G) Bar graph shows the relative MMP14 surface levels 
(MFI), n=3; mean± SEM, ****P≤0.0001 (unpaired, one-tailed Student’s t test). 
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4.2.7 R-SNARE VAMP4 regulates delivery of MMP14 from the Golgi 
network en route to the cell surface Having shown that MMP14 is transported through the Golgi complex and that it is also located in late endosomes/lysosomes possibly en route to the cell surface it was next determined which SNARE proteins might regulate this transport. As SNAREs have precise subcellular localisations and mediate specific fusion events, identification of the trafficking machinery proteins involved in the incorporation of MMP14 into the plasma membrane would further pinpoint the intracellular trafficking pathways for this protein. VAMP4 is located in the Golgi complex in RAW264.7 macrophages [Lei et al., 2012] and is known to regulate fusion from and to the Golgi network in other cell types. As trafficking of newly made MMP14 via the Golgi was identified as prerequisite for its incorporation into the plasma membrane, VAMP4 knockdown was tested to determine whether it could regulate transport of MMP14. RAW264.7 macrophages were transfected with non‐targeted (scrambled) or VAMP4 siRNA on day 1, this was repeated on day 2 and then the cells were stimulated with LPS for 15 h. As determined in previous experiments, VAMP4 levels were reduced by 38% (**P≤0.01) without affecting any of the other tested R‐SNAREs (Figure 3.13). To test whether SNARE knockdown affected levels of total MMP14 cell lysates were immunoblotted for MMP14 (Figure 4.8B). Comparison of the intensity of MMP14 bands of samples following targeted knockdown of SNARE proteins to the scrambled control showed that MMP14 levels remained mostly unchanged. MMP14 surface levels following knockdown of VAMP4 were assessed through immunolabelling of unpermeabilised macrophages (Figure 4.8C). A reduction in MMP14 surface levels was seen by fluorescence microscopy when compared to a scrambled control. Quantification of flow cytometry data revealed a 40% reduction in cell numbers (**P≤0.01) and 38% reduction of overall MMP14 surface levels (n.s. P>0.05) for cells treated with VAMP4 siRNA compared to scrambled siRNA treated cells (Figure 4.8D). This suggests that VAMP4‐mediated trafficking of MMP14 from the Golgi complex is required for the delivery of MMP14 to the cell surface.   
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Figure 4.8. R-SNARE VAMP4 regulates delivery of MMP14 from the Golgi network en 
route to the cell surface. 
(A) Schematic of the subcellular distribution of SNARE proteins that were targeted using 
siRNA knockdown. (B) RAW264.7 macrophages were stimulated with 100 ng/ml LPS for 15 h 
following transfection with scrambled (scr), VAMP2, VAMP3, VAMP4, VAMP7 or VAMP8 
siRNA. Whole cell lysates were assayed for total MMP14 levels by immunoblotting, with actin 
serving as a loading control. (C) RAW264.7 macrophages grown on coverslips were 
immunostained for surface MMP14 (unpermeabilised cells) and fixed. Scale bar is 20 μm. (D) 
Live cells were immunostained for surface MMP14 or with an isotype control antibody 
(unpermeabilised cells), fixed and analysed using a FACSAriaIII flow cytometer. Bar graph 
shows the relative percentage of cells positive for surface MMP14 or fold change of MMP14 
surface levels (MFI) n=3; mean± SEM, **P≤0.01 (one-way ANOVA with Dunnett’s post-hoc 
test).   
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4.2.8 MMP14 is not trafficked via the recycling endosome After passing through the Golgi apparatus MMP14 is then transported to the surface anchored in the membrane of vesicles, which could occur either directly or via other organelles, such as the recycling endosomes or lysosomes. It has been suggested that trafficking of newly synthesised MMP14 to the cell surface could occur via the recycling endosome, as its transport to the plasma membrane in primary macrophages was shown to be mediated by Rab8a, which can act as a recycling endosome Rab [Wiesner et al., 2013]. However, no co‐localisation with Rab11, another recycling endosome Rab, was found [Wiesner et al., 2013]. It was therefore next determined whether MMP14 localises to recycling endosomes. RAW264.7 macrophages stimulated with 100 ng/ml LPS for 9 h were fixed, permeabilised and immunostained for MMP14 and the recycling endosome marker protein transferrin receptor (TfR). MMP14 was observed in the perinuclear region and in punctate structures in the cytoplasm (Figure 4.9A). TfR also appeared in punctuate structures, however no overlap was seen with MMP14 (Figure 4.9A). This suggests that newly made MMP14 is not trafficked via the recycling endosome. In fibrosarcoma cell lines MMP14 is trafficked via recycling endosomes and delivery to the plasma membrane is dependent on the recycling endosome R‐SNARE VAMP3 [Kean et al., 2009]. In cancer cells, MMP14 at the cell surface is continuously internalised and then either degraded [Takino et al., 2003] or recycled back to the cell surface [Remacle et al., 2003; Wang et al., 2004]. Thus, MMP14 that is delivered to the cell surface from a recycling endosome could be newly made or might also be endocytosed protein that is delivered back to the cell surface via a long‐loop recycling pathway [Frittoli et al., 2011]. In macrophages, VAMP3 mediates transport of newly synthesised proteins from the Golgi network to the recycling endosome and then from the recycling endosome to the plasma membrane [Murray et al., 2005a; Murray et al., 2005b]. It also mediates the transport of endocytosed material from the recycling endosome to the cell surface [Veale et al., 2010] and so VAMP3 has the potential to regulate both pathways. VAMP2 is an R‐SNARE that is located on early endosomes in macrophages [Veale et al., 2010] and has been found to regulate early endocytic events in neuronal and HeLa cells [Miller et al., 2011; Koo et al., 2011]. To test whether MMP14 could be trafficked through the recycling endosome en route to the cell surface or recycled through the early endosome and recycling endosome back to the cell surface VAMP2 or VAMP3 were targeted by siRNA knockdown. Following knockdown, VAMP2 levels were reduced by 38%, while VAMP3 levels were reduced by 70% (****P≤0.0001) 
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without affecting the levels of other tested R‐SNAREs (Figure 3.13). Total MMP14 levels remained unaffected in these cells compared to scrambled treated cells (Figure 4.8B). No changes in MMP14 surface levels were apparent by fluorescence microscopy when cells were treated with VAMP2 or VAMP3 siRNA compared to scrambled treated cells (Figure 4.9B). Quantification of macrophages positive for surface MMP14 showed minimal change in their populations, with a 7% reduction for VAMP2 siRNA treated cells and a 10% increase following knockdown of VAMP3 compared to scrambled treated cells, although these changes were not significant (n.s. P>0.05)(Figure 4.9C). Similarly, overall MMP14 surface levels were not significantly altered in these populations. These results together suggest that VAMP3 does not mediate the transport of newly synthesised MMP14 to the cell surface and the VAMP2 and VAMP3 data together suggest that unlike some cancer cells the majority of surface MMP14 is not recycled through an early endosomes and recycling endosomes in macrophages. 
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Figure 4.9. MMP14 is not trafficked via the recycling endosome. 
(A) RAW264.7 macrophages were stimulated with 100 ng/ml LPS for 9 h, fixed and 
immunostained for MMP14 (red) and the recycling endosome marker transferrin receptor (TfR) 
(green). Scale bar is 10 μm. (B) RAW264.7 macrophages were stimulated with 100 ng/ml LPS 
for 15 h following transfection with scrambled (scr), VAMP2 or VAMP3 siRNA. RAW264.7 
macrophages grown on coverslips were immunostained for surface MMP14 (unpermeabilised 
cells) and fixed. Scale bar is 20 μm. (C) Live cells were immunostained for surface MMP14 or 
with an isotype control antibody (unpermeabilised cells), fixed and analysed using a 
FACSAriaIII flow cytometer. Bar graph shows the relative percentage of cells positive for 
surface MMP14 or fold change of MMP14 surface levels (MFI), n=3; mean± SEM, n.s. P>0.05 
(one-way ANOVA with Dunnett’s post-hoc test). 
4.2.9 The R-SNAREs VAMP7 and VAMP8 regulate delivery of MMP14 from 
late endosomes/lysosomes en route to the cell surface In cancer cells, MMP14 is continuously internalised and either trafficked to late endosomes/lysosomes for degradation or recycled back to the cell surface. However, in macrophages MMP14 incorporated into the plasma membrane is mostly newly made protein (Figure 4.3). Delivery of newly made MMP14 to the cell surface could nonetheless occur via late endosomes/lysosomes. Hence, whether MMP14 localises to late endosome/lysosomes was next tested using antibodies specific for lysosome‐associated membrane protein 1 (LAMP1), a structural glycoprotein integrated into the limiting membranes of both late endosomes and lysosomes and a commonly used marker for these compartments [Chen et al., 1985; Eskelinen et al., 2003]. Thus, macrophages stimulated with LPS for 9 h were, fixed permeabilised and immunostained for MMP14 and LAMP1. A pool of MMP14 was found co‐localising with some LAMP1 compartments resulting in partial overlap of the two fluorescence signals (Figure 4.10A). This suggests that some MMP14 could be trafficked through a late endosomal/lysosomal compartment. Two R‐SNAREs, VAMP7 and VAMP8, are known to regulate late endosome/lysosome fusion [Pryor et al., 2004]. Both, VAMP7 and VAMP8, have also been implicated in trafficking events from lysosome‐related organelles to the cell surface in a range of immune cells [Braun et al., 2004; Dressel et al., 2010; Fader et al., 2009; Lippert 
et al., 2007; Logan et al., 2006; Mollinedo et al., 2003; Paumet et al., 2000]. Hence, VAMP7 and VAMP8 protein levels were reduced using siRNA to test for their involvement in MMP14 cell surface delivery via a late endosomal/lysosomal pathway (Figure 4.10B). Following knockdown, VAMP7 levels were reduced by 58% (****P≤0.0001), while VAMP8 levels were reduced by 71% (****P≤0.0001) without affecting any of the other tested R‐SNAREs (Figure 3.13). Total MMP14 levels remained unaffected (Figure 4.8B). Unpermeabilised macrophages were labelled live for surface MMP14 following siRNA knockdown and imaged by microscopy. MMP14 levels at the cell surface appear reduced 
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in both VAMP7 and VAMP8 siRNA treated cells when compared to the control scrambled siRNA treated cells (Figure 4.10B). From flow cytometry analysis it could be seen that treatment with VAMP7 siRNA reduced the number of macrophage that are positive for surface MMP14 by 31% (**P≤0.01) and VAMP8 siRNA treatment by 33% (**P≤0.01) compared to siRNA treated cells (Figure 4.10C). Overall MMP14 levels were reduced by 37% and 43% following VAMP7 or VAMP8 siRNA treatment, respectively. This suggests that MMP14 localising to late endosome/lysosome compartments is en route to the cell surface and its transport either through these compartments is mediated by VAMP7 and VAMP8.             
Figure 4.10. R-SNAREs VAMP7 and VAMP8 regulate delivery of MMP14 from late 
endosomes/lysosomes en route to the cell surface. 
(A) RAW264.7 macrophages were stimulated with 100 ng/ml LPS for 9 h, fixed and 
immunostained for MMP14 (red) and the late endosome/lysosome marker LAMP1 (green). 
Scale bar is 20 μm. (B) RAW264.7 macrophages were stimulated with 100 ng/ml LPS for 15 h 
following transfection with scrambled (scr), VAMP7 or VAMP8 siRNA. RAW264.7 
macrophages grown on coverslips were immunostained for surface MMP14 (unpermeabilised 
cells) and fixed. Scale bar is 20 μm. (C) Live cells were immunostained for surface MMP14 or 
with an isotype control antibody (unpermeabilised cells), fixed and analysed using a 
FACSAriaIII flow cytometer. Bar graph shows the relative percentage of cells positive for 
surface MMP14 or fold change of MMP14 surface levels (MFI) n=3; mean± SEM, *P<0.05 
(one-way ANOVA with Dunnett’s post-hoc test). 
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4.3 Discussion MMP14 expression is highly elevated in chronic wounds and as an activator of MMP9 it can contribute to excessive matrix degradation and tissue damage. Additionally, MMP14 also promotes the movement of macrophages into wounds allowing them to further perpetuate the inflammatory state of a non‐healing wound. Hence, preventing delivery of MMP14 to the cell surface, where the enzyme is incorporated into the plasma membrane and active, might not only lead to a reduction in proteolytic potential of MMP9 but might also reduce tissue infiltration by macrophages and therefore dampen inflammation. Thus, this chapter aimed to identify key organelles and machinery involved in the intracellular transport and cell surface delivery of MMP14 in macrophages.  The results showed that MMP14 expression is upregulated in macrophages and this newly synthesised MMP14 is incorporated into the plasma membrane upon LPS activation. The cell surface delivery of MMP14 appeared to be highly directional and along linear tracks from the cell body to the periphery but disruption of elements of the cytoskeleton did not affect levels of surface MMP14. MMP14 localises to the Golgi complex and is trafficked via this organelle prior to its incorporation into the plasma membrane. MMP14 was also found in late endosomes/lysosomes and targeted siRNA knockdown of the late endosome and lysosome R‐SNAREs VAMP7 and VAMP8 showed that MMP14 is trafficked through these organelles. In cancer cells a VAMP3 mediated recycling pathway has been found in some cells to regulate surface levels of MMP14 but knockdown of VAMP2 and VAMP3 had little effect on surface MMP14 levels. This suggests that MMP14 might be trafficked from the Golgi complex to late endosomes/lysosomes prior to its surface delivery and data from VAMP4 siRNA treated cells suggest VAMP4 could potentially regulate this step. Thus, the knockdown of specific SNARE proteins known to mediate different pathways allowed identification of specific machinery involved in the intracellular trafficking of MMP14 and its delivery to the cell surface.   
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4.3.1 MMP14 expression and cell surface delivery in RAW264.7 
macrophages  
MMP14 expression In contrast to cancer cells where MMP14 appears to be constitutively expressed and levels often correlate with invasiveness, MMP14 expression in macrophages is transient and induced upon exposure to external stimuli [Hald et al., 2012; Ming et al., 2012; Reel et al., 2011]. In chronic wounds, macrophage numbers, as well as MMP14 expression, appear to be highly elevated compared to normal skin leading to enhanced matrix turnover [Norgauer et al., 2002]. This underpins the importance of spatio‐temporal control of MMP14 activity to avoid unrestrained infiltration of macrophages into the wound and excessive tissue damage. MMP14 expression has been shown to be upregulated at the RNA level in human and mouse monocytes/macrophages following 2, 6, 18 h and 24 h LPS stimulation [Hald et al., 2012; Ming et al., 2012; Murray et al., 2013; Reel et al., 2011]. It has been shown that in RAW264.7 macrophages, upregulation of MMP14 mRNA is 10‐, 13‐ and 6‐fold following 2, 6 and 18 h of LPS stimulation, respectively, suggesting temporal upregulation of MMP14 [Hald et al., 2012]. At the protein level, MMP14 was shown to be upregulated in human macrophages after 24 h of IFN and LPS activation, with levels increasing about 3‐fold [Johnson et al., 2014]. Accordingly, herein unstimulated RAW264.7 macrophages showed low levels of MMP14. Protein levels then increased by 2.7‐fold after stimulation with LPS and peaked around 15 h post‐stimulus. Thus, activation of macrophages with LPS increased MMP14 synthesis. Interestingly, other factors found in wounds also upregulate MMP14 expression, for example monocytes differentiated on fibronectin have increased levels of  mRNA, peaking around 18 h, suggesting the wound environment could upregulate MMP14 [Reel et al., 2011]. An effect of the substratum on MMP14 levels has also been observed in breast adenocarcinoma cells where endocytosis events of MMP14 only occur in the absence of a matrix substratum and can be inhibited through plating of cells on collagen [Bravo‐Cordero et al., 2007; Lafleur et al., 2006]. In accordance with this, MMP14 surface levels were upregulated in RAW264.7 macrophages that were not LPS‐stimulated but plated onto fibronectin or gelatin, a hydrolysed form of collagen, to a similar extent as observed following stimulation with the endotoxin. After synthesis, at least two forms of MMP14 are present in the cell; MMP14 is initially synthesised as a zymogen (66 kDa) that requires cleavage of the pro‐peptide by furin in the TGN to form the mature active form (54 kDa) [Mazzone et al., 2004]. Although both forms of MMP14, cleaved and uncleaved, could potentially be expected to be 
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present in cell lysates only one band, representing the mature form, was detected in immunoblots of LPS‐stimulated RAW264.7 macrophages. The MMP14 antibody that was used for immunoblotting was raised against an immunogen sequence derived from a region within amino acids 150‐180 of the protein and should therefore be able to recognise both forms of MMP14. Localisation to the ER during biosynthesis can be very transient [Alberts et al., 2002] and the absence of the pro‐MMP14 band herein suggest that the transport of MMP14 through the ER and the Golgi apparatus is relatively fast leading to quick turnover of pro‐MMP14 to the mature form in the TGN. Accordingly, immunofluorescence images with MMP14 and the ER marker PDI showed no overlap in LPS‐stimulated RAW264.7 macrophages (Figure 4.7A). The fact that MMP14 exhibits multiple O‐glycosylation sites but in contrast to MMP9 no N‐glycosylation sites [Remacle 
et al., 2006] also suggests a short retention time within the ER which could lead to faster processing of pro‐MMP14 in the TGN.  In RAW264.7 macrophages that had been stimulated with LPS for 9 h, the majority of MMP14 was found to localise to the perinuclear Golgi complex (Figure 4.1B). After 18 h of LPS stimulation more MMP14 localised to punctate structures in the cell periphery and near the cell surface. This suggests that upon LPS stimulation newly made protein is delivered to the cell surface for incorporation into the plasma membrane. 
MMP14 cell surface delivery Transport of overexpressed MMP14 from perinuclear regions, most likely the Golgi complex, into cell periphery and protrusions for incorporation into the plasma membrane could be observed by live cell imaging (Figure 4.4.C). Small MMP14‐GFP‐positive vesicles appeared to follow straight paths in the cytosol towards the cell surface (Figure 4.4C). In some instances, what appeared to be two separate vesicles, moved along the same track in the same direction with similar velocity (Figure 4.4C). The average velocity of these moving vesicles was with 0.65±0.16 μm/s very similar to what has previously been reported for fluorescently‐tagged MMP14 transport in primary macrophages, which exhibited velocities of about 0.8 μm/s [Wiesner et al., 2010]. Together, this suggests that transport involves some kind of tracks. Occasionally, the small fast‐moving vesicles travelled via slightly larger and mostly stationary MMP14‐GFP‐positive vesicular endosomes, which did not change in fluorescence (Figure 4.4C, 16” frame). Similar trafficking behaviour has previously been observed for cell surface delivery of LAMP1‐positive vesicles in RAW264.7 macrophages where these kind of vesicular endosomes were identified as late endosomal/lysosomal compartments [Offenhauser, 2011]. 
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Immunolabelling of unpermeabilised cells allowed for specific detection of surface MMP14 and showed that in RAW264.7 macrophages the delivery of MMP14 to plasma membrane was induced upon LPS stimulation (Figure 4.2). Increased levels of MMP14 at the cell surface could be observed from 6 h post‐stimulation and continued to increase over an 18 h period. While total levels of MMP14 increased only by about three‐fold levels of surface MMP14 increased by over 10 times following LPS stimulation suggesting that the majority of newly made MMP14 is delivered to the cell surface. That the incorporation of MMP14 into the plasma membrane is coupled to the de novo synthesis of the protein was confirmed in RAW264.7 macrophages when protein synthesis was disrupted following cycloheximide treatment, which led to significantly reduced MMP14 surface presentation (Figure 4.3). This is in contrast to cancer cells, where a significant fraction of the MMP14 that is delivered to the cell surface occurs from endosome compartments that contain endocytosed rather than newly made protein, similar to endocytic recycling of integrins [Poincloux et al., 2009]. 
4.3.2 The cytoskeleton and MMP14 cell surface delivery Live imaging of MMP‐GFP showed the average velocity of the anterograde vesicles was 0.65±0.16 μm/s and that the long‐distance movement of these MMP14 vesicles was not random but showed high directionality (0.93±0.01) and appeared to follow straight paths in the cytosol towards the cell surface. Movement through the cytoplasm by diffusion alone, which is in the order of 0.1 μm/s, cannot account for the rate, directionality, and destinations of MMP‐GFP suggesting that transport involves some kind of tracks [Sarfaraz and Brown, 2016]. The cytoskeleton can assist in the anterograde transport of cargo‐containing vesicles to the cell surface [Anitei and Hoflack, 2012]. Anterograde transport of MMP14 vesicles in macrophages derived from human monocytes has been reported to occur along microtubules with velocities of 0.78 μm/s and involves the kinesins KIF5b, KIF3A and KIF3B [Wiesner et al., 2010]. Retrograde transport and internalisation of MMP14 was observed suggesting that MMP14 surface levels were at least partly influenced by dynein‐ and kinesin‐dependent recycling of MMP14 and not solely by newly made protein. However, the majority of the data obtained in this study relied on the transient overexpression of mCherry‐labelled MMP14 and assessment of MMP14‐mCherry surface levels was conducted 18 h post‐transfection, which means it might not represent early trafficking events of newly synthesised MMP14. Importantly, these studies were performed in unactivated macrophages. It is known that transport pathways in macrophages can be dramatically altered after activation [Murray and Stow, 2014]. 
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It was also reported that MMP14‐positive vesicles could spontaneously switch direction. This is indicative of the presence of both, antero‐ and retrograde motor proteins on the same vesicle. The bidirectional movement of late endosomes has been described as a ‘tug of war’ between dynein and kinesin motors [Granger et al., 2014]. The involvement of kinesins in the surface delivery of MMP14 was evaluated in macrophages with reduced kinesin levels, while microtubules remained intact [Granger et al., 2014]. This might have favoured the retrograde dynein‐mediated transport of MMP14 rather than just inhibiting anterograde transport. This study also showed that not all surface MMP14 is regulated by kinesins indicating that MMP14 cell surface delivery can also occur in the absence of kinesins or that anterograde transport is also influenced by other factors [Granger et al., 2014]. Nonetheless, a role for microtubules in the polarised delivery to invasive structures has been postulated [Linder, 2007] and transport of MMP14 vesicles along microtubules towards podosomes has been observed in macrophages [Wiesner et al., 2010]. Thus, investigating the role of the microtubule network on MMP14 surface levels, as well as the enzyme’s polarised delivery to invasive structures to allow matrix degradation and migration, could be informative. Disrupting microtubule networks with 
5 μM/ml nocodazole did not affect the levels of MMP14 at the cell surface in RAW264.7 macrophages (Figure 4.5B and C). A lack of an effect could be due to the fact that upon nocodazole‐induced microtubule disruption Golgi membrane components gradually redistribute from the MTOC to peripheral sites. Once these mini‐Golgi stacks are re‐established, efficient transport from dispersed Golgi sites to the cell surface is restored even though the microtubule network is still disturbed but is no longer directed to specific regions at the cell surface [Cole et al., 1996]. To add to this, microtubules only increase the probability for a cargo vesicle to encounter the target membrane, which means that the secretion in nocodazole‐treated samples is only slowed and not fully blocked [Wacker et al., 1997]. In a study investigating the dynamic movements of MMP14‐mCherry in breast cancer cells, these MMP14‐containing vesicles showed reduced mobility following nocodazole treatment but vesicles were not absolutely stationary and the effect on cell surface levels of the protein were not investigated [Marchesin et al., 2015]. As treatment with nocodazole was only for the last 3 h of 12 h LPS stimulation, there is a possibility that any effect could have been too small to be detected given the large amounts of MMP14 already being delivered to the cell surface during the absence of nocodazole. Differences in treatment times, as well as nocodazole concentration, and the activation of the macrophages with LPS might have added to the absence of an effect. However, this can only be speculated as dosage and timings for the 
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nocodazole treatment in the breast cancer cell study were not mentioned. It might, however, be valuable to test whether microtubules disruption does influence the distribution of MMP14 to invasive structures despite total surface levels of the protein being unaffected. In macrophages derived from human monocytes MMP14‐containing vesicles were also found to move along actin filaments at the cell periphery with velocities of 0.2‐0.5 μm/s [Wiesner et al., 2010]. In LPS‐stimulated RAW264.7 macrophages a pool of endogenous MMP14 was found to locate along ruffles, sheet‐like protrusive actin structures. However, disruption of cortical actin with cytochalasin did not affect MMP14 levels at the cell surface. Treatment of RAW264.7 macrophages with cytochalasin for 2 h had previously been shown to disrupt cortical actin and an effect on lysozyme secretion could be detected [Offenhauser, 2011]. Longer incubation times in the presence of cytochalasin are not recommended as it can induce apoptosis [Rubtsova et al., 1998]. But significant levels of surface MMP14 can only be observed from 9 h post‐stimulation. As a consequence, cells were treated with cytochalasin for the last 2 h of 9 h LPS stimulation and any effect could have been too small to be detected given the large amounts of MMP14 already being delivered to the cell surface before start of the treatment. The actin skeleton has also been reported to have both, supporting as well as hindering roles during the secretion process [Porat‐Shliom et al., 2013]. Actin filaments can assist in the guidance of exocytic vesicles to sites of fusion, but actin can also act as physical barrier for any cargo trying to access the plasma membrane [Porat‐Shliom et al., 2013]. So disruption of the cortical actin could allow for easier access of MMP14‐containing vesicles to the plasma membrane annulling any loss in vesicle guidance. It may also be the case that the actin filaments are necessary for proper localisation and function at the cell surface, rather than being a general prerequisite for the cell surface delivery. In fact, tethering of MMP14’s cytoplasmic tail to F‐actin, through the action of N‐WASP, was found to be necessary to stabilise MMP14 to invasive structures (invadosomes) and induce matrix degradation in breast cancer cells [Yu et al., 2012]. Macrophages do not have invadosomes, but instead have related structures termed podosomes, to which MMP14 also localises [Nusblat et al., 2011]. Thus, it could be interesting in future to test whether cytochalasin‐treated macrophages show reduced degradative capacity despite MMP14 surface levels remaining unchanged. The emerging picture for cancer cells is that the formation of invasive structures for subsequent matrix degradation relies on the local coordination of the cytoskeleton to assist delivery of MMP14 to these structures [Poincloux et al., 2009]. MMP14 is also implicated in 2D migration of macrophages and is delivered to podosomes at the front of migrating cells. But whether MMP14 is 
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specifically transported to podosomes or is also delivered to other places on the macrophage cell surface and then to the podosomes in macrophages has not been fully investigated yet [Verollet et al., 2011]. Trafficking of MMP14 to specific areas of the plasma membrane has also been suggested to rely on interactions with podosome‐associated matrix receptors, such as CD44 and integrins [Wiesner et al., 2010].   
4.3.3 Trafficking pathways for MMP14 in RAW264.7 macrophages 
Trafficking of newly made MMP14 via the Golgi complex MMP14 has an N‐terminal signal peptide targeting it for translation into the ER membrane during biosynthesis [Egeblad and Werb, 2002]. Following translation into the ER, MMP14 is shuttled through the Golgi apparatus. While localisation of MMP14 to the ER appeared to be only very transient, MMP14 was found to locate to perinuclear structures in a pattern typical for the Golgi complex in LPS‐stimulated RAW264.7 macrophages. A recent study using primary human macrophages revealed that MMP14 co‐localised with Golgi components, such as GM130, a cis‐Golgi marker, and TGN46, a trans‐Golgi protein [Wiesner et al., 2010]. Co‐localisation with GM130 in RAW264.7 macrophages established that newly made MMP14 also locates to the Golgi apparatus in these LPS activated cells. More interestingly, disruption of the Golgi complex with brefeldin A abolished incorporation of MMP14 into the plasma membrane, which confirms that trafficking via this organelle is essential for the cell surface delivery in activated macrophages. As trafficking of nascent MMP14, via the Golgi network, was identified as prerequisite for its incorporation into the plasma membrane SNARE machinery that could mediate this pathway in macrophages was investigated. As VAMP4 is located in the Golgi complex in RAW264.7 macrophages [Lei et al., 2012], and known to regulate fusion from the Golgi network in other cell types, it was considered a possible candidate for MMP14 trafficking. A significant reduction of MMP14 surface levels was observable following knockdown of VAMP4 suggesting that this SNARE is required for trafficking of MMP14 from the Golgi to the cell surface. VAMP4 could mediate either direct trafficking of MMP14 to the cell surface or via other organelles. In activated NK cells, VAMP4 localises to lytic granules, often referred to as ‘secretory lysosomes’ or ‘lysosome‐related organelles’ and is indispensable for LAMP1 cell surface delivery from these organelles [Krzewski et al., 2011]. VAMP4 (R‐SNARE), as well as Stx7 (Qa‐SNARE), Vti1b (Qb‐SNARE) and Stx8 (Qc‐SNARE), also localises to the lysosomal related lytic granules in 
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cytotoxic T lymphocytes [Pattu et al., 2012]. These SNAREs could theoretically function as a SNARE complex. VAMP4 might, thus, mediate trafficking of MMP14 from the Golgi network to late endosomal/lysosomal compartments in macrophages, from where the protein could then be incorporated into the plasma membrane. However, to confirm this hypothesis, the existence of a VAMP4/Stx7/Vti1b/Stx8 complex in macrophages and the involvement of the Q‐SNARE Stx7, Vti1b and Stx8 in MMP14 transport would have to be tested. 
Trafficking of newly made MMP14 via Recycling Endosome Evidence that MMP14 traffics through recycling endosomes has been shown for fibrosarcoma and breast carcinoma cell lines [Kean et al., 2015 Remacle et al., 2005]. However, this could potentially be a result of MMP14 recycling events that continuously occur in cancer cells. In primary human macrophages it has been proposed that newly made MMP14 could be trafficked via the recycling endosome as the GTPase Rab8a, which can mediate biosynthetic traffic through this compartment, was found to regulate MMP14 surface levels [Henry and Sheff, 2007; Wiesner et al., 2013]. Yet, the exact route is unclear and no co‐localisation with Rab11, a more established recycling endosome Rab, was found [Wiesner et al., 2013]. Herein it was found that in RAW264.7 macrophages, MMP14 did not co‐localise with TfR, another marker for recycling endosomes, suggesting newly made protein is not trafficked via this organelle. This confirms a study utilising an adenocarcinoma cell line where trafficking of newly made MMP14 was also found to depend on Rab8, but did not co‐localise with typical markers of the recycling endosomes, such as Rab11, transferrin and TfR suggesting it was not trafficked through this compartment [Bravo‐Cordero et al., 2007]. Interestingly, Rab8 has also been associated with ruffle formation and membrane recycling in fibrosarcoma cells [Hattula et al., 2006]. As pools of MMP14 were found to locate to ruffle structures in RAW264.7 macrophages trafficking of newly made protein to these structures could be a possibility. 
Recycling of MMP14 MMP14 is synthesised and delivered to the cell surface in macrophages upon LPS activation but surface MMP14 could also originate from previously endocytosed protein that is recycled back via a short‐loop (from the early endosome directly back to the cell surface) or long‐loop (from the early endosome to the recycling endosome and then to the surface) pathway. In cervical adenocarcinoma, fibrosarcoma and breast adenocarcinoma cell lines, the MMP14 delivered to the cell surface predominantly stems from pools of previously endocytosed protein that is recycled back to the cell surface 
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[Frittoli et al., 2014; Remacle et al., 2003; Remacle et al., 2005]. Rab 4 and Rab5 have been identified as regulators for fast short‐loop recycling of MMP14 from the early endosome to the plasma membrane, while Rab11 mediates the slower long‐loop delivery of recycled MMP14 via the recycling endosome to the cell surface [Frittoli et al., 2014; Remacle et al., 2003; Remacle et al., 2005]. The R‐SNARE VAMP3 has also been reported to regulate MMP14 surface delivery from the recycling endosome in fibrosarcoma cells [Kean et al., 2009]. In unactivated primary macrophages, Rab5a is responsible for endocytosis of MMP14, short‐loop recycling of MMP14 is mediated by Rab14, while Rab22a allows shuttling from the early endosome to the recycling endosome in a long‐loop recycling pathway [Wiesner et al., 2013]. However, SNARE proteins that could be involved in such a process and whether this was a major transport route in activated macrophages had not been tested. VAMP2 is located on early endosomes in RAW264.7 macrophages [Veale et al., 2010] and has been found to regulate endocytic events in neuronal and cervical adenocarcinoma cells [Miller et al., 2011; Koo et al., 2011]. VAMP3 is a recycling endosome SNARE and in macrophages mediates transport of both, newly synthesised proteins from the Golgi network to the recycling endosome and then from the recycling endosome to the plasma membrane [Murray et al., 2005a; Murray et al., 2005b] as well as endocytosed material from the recycling endosome to the cell surface [Veale et al., 2010]. To test whether VAMP2 or VAMP3 could be involved in MMP14 trafficking via an endocytosis/recycling pathway in RAW264.7 macrophages, levels of these SNAREs were reduced by siRNA knockdown. No significant effects were seen with MMP14 surface levels. From this it can be concluded that VAMP2 and VAMP3 may not mediate trafficking MMP14 and that the majority of the surface MMP14 is not transported through the recycling endosome as nascent MMP14 or recycled via the early endosome or early then recycling endosome. To further confirm this, MMP14 co‐localisation with markers for this pathway, e.g. EEA1, as well as involvement of other trafficking machinery for such events, should be tested in future experiments. Interestingly, it appears that in breast adenocarcinoma cells endocytosis of MMP14 only occur in the absence of a matrix substratum and it can be inhibited through plating of cells on collagen suggesting that endocytosis might only occurs under specific conditions [Bravo‐Cordero et al., 2007; Lafleur et al., 2006]. 
Trafficking via Late Endosome/Lysosome MMP14 locates to late endosome/lysosome compartment in melanoma, fibrosarcoma, breast and cervical adenocarcinoma cells [Clancy et al., 2015; Loskutov et 
al., 2014, Macpherson et al., 2014; Monteiro et al., 2013; Steffen et al., 2008; Williams and 
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Coppolino, 2011; Yu et al., 2012]. Whether MMP14 can also be found in late endosomes/lysosomes of macrophages was determine herein. MMP14 co‐localises with LAMP1, a late endosome/lysosome marker, in RAW264.7 macrophages. In fibrosarcoma, breast and cervical adenocarcinoma cells, MMP14 has been reported to be transported via the late endosome/lysosome en route to the cell surface [Loskutov et al., 2014; Macpherson et al., 2014; Marchesin et al., 2015; Monteiro et al., 2013; Steffen et al., 2008; Williams & Coppolino, 2011; Yu et al., 2012]. In these cells, MMP14 trafficking from such organelles to the cell surface was found to be mediated by GTPase Rab7 and Rab27, as well as the late endosomal/lysosomal R‐SNARE VAMP7 [Macpherson et al., 2014; Steffen 
et al., 2008; Williams and Coppolini, 2011]. Whether incorporation of MMP14 into the plasma membrane occurs from these organelles or MMP14 is targeted to these organelles for degradation was further investigated. In macrophages this route has been shown for secretion of the actin‐binding protein flightless‐1 or the glycoside hydrolase lysozyme from LAMP1‐positive late endosomes/lysosomes in RAW264.7 macrophages but has not been investigated for MMP14 surface delivery [Lei et al., 2012]. VAMP7 and VAMP8 can both regulate homotypic fusion of late endosomes, while VAMP7 also regulates late endosome to lysosome fusion [Pryor et al., 2004]. VAMP7 has further been shown to regulate fusion of late endosome/lysosome membrane with the cell surface during phagocytosis in RAW264.7 macrophages [Braun et al., 2004]. VAMP8 has been reported to mediate stimulated fusion of granules and secretory lysosomes with the plasma membrane in several other immune cells, such as cytotoxic T lymphocytes, basophils, mast cells, neutrophils and eosinophils [Dressel et al., 2010; Lippert et al., 2007; Logan et al., 2006; Mollinedo et al., 2003; Paumet et al., 2000. To test whether MMP14 was delivered to the cell surface via late endosomes/lysosomes RAW264.7 macrophages were treated with VAMP7 or VAMP8 siRNA. Cells with reduced levels of VAMP7 or VAMP8 showed significantly reduced levels of MMP14 at the cell surface suggesting that these SNAREs are indeed involved in the incorporation MMP14 into the plasma membrane from a late endosomal/lysosomal pathway after LPS activation. Thus, MMP14 is synthesised in the ER, transported to the Golgi complex and on to the late endosomes/lysosomes where it is delivered to cell surface (Figure 4.10). Transport from the Golgi complex requires VAMP4 mediated fusion and transport to or between the late endosomes/lysosomes to the cell surface requires VAMP7 and VAMP8 (Figure 4.10). In fibrosarcoma cells, the SNARE complex VAMP7/Stx4/SNAP23 has been proposed to mediate trafficking of MMP14 to invadopodia [Williams et al., 2014]. Whether these same SNAREs also regulate delivery to podosomes in macrophages is tested in the next chapter. 
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Figure 4.11. Schematic of MMP14 trafficking in macrophages. 
Newly made MMP14 is trafficked from the Golgi complex to late endosome/lysosomes prior to 
its surface delivery, which might be regulated by VAMP4. Incorporation of newly made MMP14 
into the plasma membrane through a late endosomal/lysosomal pathway and is mediated by 
R-SNAREs VAMP7/VAMP8. 
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Chapter 5: MMP14 and macrophage 
migration 
5.1 Introduction MMP14 promotes tumour growth and local invasion with its expression levels correlating with tumour progression and metastasis [Poincloux et al., 2009]. Similarly, MMP14 is believed to play a role in macrophage migration and infiltration of tissue [Verollet et al., 2011]. As high numbers of macrophages contribute to prolonged inflammation and wound chronicity it would be advantageous to elucidate mechanisms and influence of MMP14 incorporation into the plasma membrane for its activity and whether disruption of MMP14 cell surface delivery affects macrophage invasion.  Although the zymogen form of MMP14 is activated in the trans‐Golgi network prior to its incorporation into the plasma membrane it is clear that the active protease needs to be at the cell surface in order to access and degrade substrates, such as matrix material. Incorporation into the plasma membrane is achieved through a final fusion step mediated through SNARE complex formation at the cell surface. Evidence suggests that incorporation of MMP14 into the plasma membrane can specifically occur at ECM‐degrading adhesion structures called podosomes to fulfil its role in matrix degradation and cell migration [Azzouzi et al., 2016; Wiesner et al., 2010; Wiesner et al., 2013]. In other cell types surface Q‐SNAREs Stx4 and SNAP23 have been proposed to mediate trafficking of MMP14 to invadopodia [Williams et al., 2014]. In macrophages, Stx4/SNAP23 has been shown to regulate the polarised delivery of recycling endosome to the cell surface, such that membrane and cargo are focally delivered to where they are needed on the cell surface [Murray and Stow, 2014]. Whether this is the case for late endosome/lysosome delivery to podosomes/cell surface in macrophages had not been investigated. Importantly, whether disruption of this pathway can alter matrix degradation and macrophage migration and the effect on invasion has not been tested.  Therefore, this chapter begins with the identification of the surface SNARE machinery responsible for the final step to incorporate MMP14 into the plasma membrane in macrophages, as well as the characterisation of the localisation of cell surface‐delivered MMP14 upon matrix contact and studies the involvement of this particular MMP in matrix degradation. As intracellular trafficking pathways and SNARE machinery proteins that are responsible for incorporation of MMP14 into the plasma 
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membrane were identified and disruption of these pathways restricted cell surface delivery of MMP14, it was tested whether disruption of these pathways would affect matrix degradation and macrophage migration in different models of 2D and 3D migration. The results from this chapter could provide new targets to modulate macrophage migration to reduce inflammation and improve wound healing.   
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5.2 Results 
5.2.1 The Q-SNAREs Stx4 and SNAP23 regulate delivery of MMP14 to the 
cell surface and incorporation into the plasma membrane  In the previous chapter, three R‐SNAREs responsible for the intracellular trafficking of newly made MMP14 from the Golgi complex and late endosomes/lysosomes towards the cell surface have been identified. Ultimately, to allow cell surface delivery of MMP14, an R‐SNARE must form a complex with Q‐SNAREs to regulate fusion with the plasma membrane. To identify possible regulators of MMP14 incorporation into the plasma membrane, the four main Q‐SNAREs (Stx2, Stx3, Stx4 and SNAP23) found on the macrophage cell surface and most likely to mediate the final step of cell surface delivery [Veale et al., 2010] were targeted for knockdown with specific siRNA (Figure 5.1). As with the R‐SNAREs, RAW264.7 macrophages were transfected with siRNA to these SNARE proteins on day 1, this was repeated on day 2 and then cells were stimulated with LPS for 15 h. Knockdown was successful for all four tested surface SNARE proteins and did not alter the levels of other tested SNARE proteins. Knockdown efficiencies for Stx2, Stx3, Stx4 and SNAP23 were 74±6%, 50±8%, 55±19% and 20±6%, respectively (Figure 3.12). A reduction in these surface Q‐SNAREs did not affect the levels of total MMP14, as apparent from immunoblotting cell lysates for MMP14 following siRNA knockdown (Figure 5.1A). To determine the effect of loss of function of these SNAREs cells were immunolabelled for surface MMP14 and analysed by fluorescence microscopy (Figure 5.1B). Surface MMP14 levels did not significantly alter following knockdown of Stx2 or Stx3 (Figure 5.1B). However, in macrophages treated with Stx4 or SNAP23 siRNA MMP14 surface levels were strongly reduced (Figure 5.1B). By flow cytometry it can be seen that the relative number of macrophages positive for surface MMP14 did not significantly change following knockdown of Stx2 or Stx3 compared to cells treated with scrambled siRNA (P>0.05) (Figure 5.1C). In contrast, when Stx4 levels were reduced (55%), macrophage numbers positive for surface MMP14 decreased by 28% (Figure 5.1C). Reducing SNAP23 levels by only 20% led to a 33% decrease of the percentage of macrophages that remain positive for surface MMP14 compared to the scrambled control (Figure 5.1C). Overall, MMP14 surface levels were reduced by 27% and 43% following Stx4 or SNAP23 siRNA treatment, respectively. These results suggest that Stx4 and SNAP23 are the Q‐SNAREs responsible for surface delivery of MMP14. 
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Figure 5.1. The Q-SNAREs Stx4 and SNAP23 regulate delivery of MMP14 to the cell 
surface. 
(A) RAW264.7 macrophages were stimulated with 100 ng/ml LPS for 15 h following 
transfection with scrambled (scr), Stx2, Stx3, Stx4 or SNAP23 siRNA. Whole cell lysates were 
assayed for total MMP14 levels by immunoblotting, with actin serving as a loading control. (B) 
RAW264.7 macrophages grown on coverslips were stimulated with 100 ng/ml LPS for 15 h 
following transfection with scrambled (scr), Stx2, Stx3, Stx4 or SNAP23 siRNA, 
immunostained for surface MMP14 (unpermeabilised cells) and fixed. Scale bar is 20 μm. (C) 
Live cells stimulated with 100 ng/ml LPS for 15 h following transfection with scrambled (scr), 
Stx2, Stx3, Stx4 or SNAP23 siRNA were immunostained for surface MMP14 or with an isotype 
control antibody (unpermeabilised cells), fixed and analysed using a FACSAriaIII flow 
cytometer. Bar graph shows fold change of the percentage of cells positive for surface MMP14 
or fold change of MMP14 surface levels (MFI), n=3; mean±SEM, *P<0.05, **P≤0.01. 
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To confirm a role for Stx4 and SNAP23 in MMP14 cell surface delivery, macrophages stimulated with 100 ng/ml LPS for 9 h were simultaneously immunolabelled for Stx4 or SNAP23 and MMP14 to determine whether they co‐localise at the cell surface. A partial overlap of a pool of MMP14 near the cell surface with Stx4 (Figure 5.2A) and SNAP23 (Figure 5.2B) can be observed. This suggests that Qa‐SNARE Stx4 and Qbc‐SNARE SNAP23, perhaps as Q‐SNARE complex, mediate the final step of MMP14 cell surface delivery. 
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Figure 5.2. The Q-SNAREs Stx4 and SNAP23 co-localise with MMP14 on the plasma 
membrane. 
(A) RAW264.7 macrophages were stimulated with 100 ng/ml LPS for 9 h, fixed and 
immunostained for MMP14 (red) and the surface SNARE Stx4 (green) to show co-localisation. 
Enlarged regions (lower panels) show partial overlap of MMP14 and Stx4. Scale bar is 10 μm. 
(B) RAW264.7 macrophages were stimulated with 100 ng/ml LPS for 9 h, fixed and 
immunostained for MMP14 (red) and surface SNARE SNAP23 (green) to show co-localisation. 
Enlarged regions (lower panels) show partial overlap at the cell surface. Scale bar is 10 μm. 
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5.2.2 MMP14 localises to cell structures implicated in cell migration and 
matrix degradation in response to matrix contact Once delivered to the cell surface and incorporated into the plasma membrane, MMP14 has been reported to localise to actin‐rich structures thought to assist matrix degradation and migration [Poincloux et al., 2009; Verollet et al., 2011]. To determine where MMP14 is localised on the macrophage cells surface, RAW264.7 macrophages grown on gelatin‐coated coverslips for 18 h were immunostained for MMP14 and F‐actin (Figure 5.3). Cells migrating on flat two‐dimensional matrix surfaces, such as the one depicted in Figure 5.3, exhibit sheet‐like protrusions (lamellipodia) at the leading edge of the plasma membrane. Lamellipodia‐based migration is characterised by increased actin polymerisation and adhesion complex turn‐over, and rear detachment at the trailing edge of the cell. Thin actin rich protrusions, called filipodia, can also be found at the leading edge advancing the lamellipodium (Figure 5.3, Inset 2). Clustered behind the leading edge at the ventral cell surface are podosomes, dynamic actin‐rich adhesion structures that can be found in migratory cells of monocytic myeloid lineage [Murphy and Courtneidge, 2011]. Sometimes these podosomes can be found arranged to ring‐like structures that are termed rosettes (Figure 5.3, Inset 1). Podosomes are able to degrade the underlying matrix through the local secretion of proteases, such as MMP14 [Murphy and Courtneidge, 2011]. Indeed, MMP14 at the cell surface was found to localise to podosomes of RAW264.7 macrophages that had been grown on gelatin for 18 h (Figure 5.3, Inset 1). In these cells, surface MMP14 was also found at other actin‐rich structures, such as the leading edge, as well as trailing edge and on filopodia (Figure 5.3, Inset 2). Together, this supports the idea of the polarised delivery of MMP14 to actin rich podosomes implicated in macrophage migration in response to matrix contact for degradation. 
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Figure 5.3. MMP14 localises to cell structures implicated in cell migration in response 
to matrix contact. 
RAW264.7 macrophages grown on gelatin-coated coverslips for 18 h were immunostained 
live (unpermeabilised cells) for surface MMP14 (green), fixed and then stained for F-actin 
(red). Insets show regions where MMP14 localises to cell membrane structures that are 
implicated in cell migration. Inset 1 shows MMP14 at podosomes. Inset 2 shows MMP14 at 
filopodia. Scale bar is 10 μm. 
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In order to confirm that those regions facilitate degradation of the substratum an assay was developed. This entailed plating the cells on glass coverslips that had been coated with a thin layer of fluorescently‐labelled gelatin matrix. As degradation of this gelatin is accompanied by a loss of fluorescence, it allows for the detection of areas of degradation and whether this corresponds to surface MMP14 as well as testing the effect of inhibiting particular proteins or machinery. To investigate degradative behaviour of RAW264.7 macrophages, cells were seeded onto coverslips coated with fluorescently labelled gelatin, incubated for 18 h and immunostained for surface MMP14 (Figure 5.4). It was observed that all macrophages displayed proteolytic behaviour to varying degrees and degradation patterns, i.e. areas devoid of gelatin fluorescence, appeared punctate or blotchy and might be attributed the secretion of enzymes from podosomes in these areas. Interestingly, surface MMP14 also appeared in punctate patterns and intense MMP14 fluorescence signal (Figure 5.4A lower panel, arrow 1) localised to areas of strongly reduced gelatin fluorescence, while MMP14 was absent from areas where gelatin fluorescence remained high (Figure 5.4A lower panel, arrow 2) indicating that MMP14 is responsible for the degradation of the gelatin matrix (Figure 5.4A, lower panel). The intensity profile (Figure 5.4B) of the line scan (dashed line in lower panel of Figure 5.4A) demonstrates spatial separation of the intensity peaks (Figure 5.4B, arrows 1 and 2) for gelatin and MMP14 fluorescence signal. It is important to note that MMP14 was not detected at all areas of gelatin degradation. This could either suggest that surface MMP14 was downregulated following successful degradation of the substratum or degradation of these areas was MMP14‐independent.   
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Figure 5.4. MMP14 localises to cell structures implicated matrix degradation in 
response to matrix contact. 
(A) RAW264.7 macrophages were grown coverslips coated with fluorescent gelatin (green) 
for 18 h, immunostained live (unpermeabilised cells) for surface MMP14 (red) and then fixed. 
Enlarged inset (lower panel) shows region where MMP14 localises to areas of gelatin 
degradation. (B) The intensity profile of the line scan (dashed line in magnified inset, lower 
panel) demonstrates spatially separated intensity peaks (arrows 1 and 2) of gelatin (green) 
and MMP14 (red) fluorescence. Scale bar is 20 μm. 
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5.2.3 Gelatin degradation by MMP14 can be inhibited through targeting 
the key SNAREs implicated in MMP14 surface delivery Localisation of MMP14 to cell structures implicated in cell migration and matrix degradation suggested that proficient delivery of MMP14 to the cell surface is required for gelatin degradation by RAW264.7 macrophages. Thus, it was next tested whether targeted siRNA knockdown of those SNARE proteins that were identified to mediate MMP14 cell surface delivery would affect gelatin degradation. Firstly, the R‐SNARE implicated in transport of MMP14 from the Golgi complex, VAMP4, was tested for its ability to regulate gelatin degradation. Macrophages were transfected with siRNA to VAMP4, along with siRNA to the early endosome and recycling endosome SNAREs VAMP2 and VAMP3 that were shown not to regulate MMP14 surface delivery and with scrambled siRNA as a control. These cells were seeded onto fluorescently labelled gelatin and incubated for a further 18 h. Macrophages were fixed, stained for F‐actin and gelatin degradation was imaged by fluorescence microscopy (Figure 5.5A). With the control scrambled siRNA treated cells it can be seen that some areas below the cells have reduced or no fluorescence indicating that the gelatin has been degraded (Figure 5.5A). Similar patterns of reduced fluorescence were seen when the cells treated with VAMP2 or VAMP3 siRNA were plated on gelatin (Figure 5.5A). However, the area below cells treated with VAMP4 siRNA had much higher levels of fluorescence and it can be seen that there is some degradation but it was much less than the controls (Figure 5.5A). Areas of gelatin degradation were next quantified and normalised to the area of the cells (Figure 5.5B). Proficient gelatin degradation was observed in RAW264.7 macrophages that had been transfected with non‐targeted (scrambled) siRNA. Macrophages with reduced levels of VAMP2 and VAMP3, which did not have significant effects on MMP14 surface levels, showed little change in the degradation of gelatin (Figure 5.5A). The degradative capability was reduced by 2% and 11% for VAMP2 and VAMP3, respectively (Figure 5.5B, n.s. P>0.05). However, VAMP4 knockdown, which reduced MMP14 surface levels by 48% (Figure 4.8), diminished gelatin degradation by 54% (Figure 5.5B, 
****P≤0.0001). This confirms a role for VAMP4 in the surface delivery of MMP14 and degradation of its substrate gelatin. 
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Figure 5.5. Gelatin degradation by MMP14 can be inhibited through targeting the Golgi 
complex R-SNAREs VAMP4 or the late endosome/lysosome R-SNAREs VAMP7 or 
VAMP8. 
(A) RAW264.7 macrophages were grown on coverslips coated with fluorescent gelatin (upper 
panel) for 18 h following transfection with scrambled (scr), VAMP2, VAMP3, VAMP4, VAMP7 
or VAMP8 siRNA, fixed and stained for F-actin (lower panel). Scale bar is 50 μm. (B) 
Quantification of gelatin degradation by RAW264.7 macrophages following knockdown of 
VAMP2, VAMP3, VAMP4, VAMP7 or VAMP8. Areas of gelatin degradation were determined 
and normalised to the total surface area of the cells. Bar graphs show the degradation of 
gelatin by RAW264.7 macrophages following knockdown of VAMP2, VAMP3, VAMP4, 
VAMP7 or VAMP8 relative to cells that had been transfected with scrambled (scr) siRNA. The 
graph shows the analysis of 200 cells per siRNA treatment across two biological repeats; 
mean± SEM, ****P≤0.0001 (one-way ANOVA with Dunnett’s post-hoc test). 
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Next, the late endosome/lysosome R‐SNAREs, VAMP7 and VAMP8, identified in chapter 4 to regulate the transport of MMP14 to the cell surface from the late endosome/lysosome, were tested for a role in regulating gelatin degradation. Macrophages were transfected with siRNA to VAMP7 and VAMP8 and plated on fluorescently labelled gelatin. Figure 5.5B shows that the area below the cells has considerably less degradation (more fluorescence) than the control scrambled siRNA treated cells. This was quantified and gelatinolytic activity was seen to be decreased by 45% following VAMP7 knockdown (Figure 5.5B, ****P≤0.0001), when MMP14 surface levels were reduced by 37% (Figure 4.10). Similarly, when MMP14 surface levels were reduced by 43% due to VAMP8 knockdown there was a 51% drop of gelatin degradation (Figure 5.5B, ****P≤0.0001). Together these results suggest that targeting machinery proteins in the MMP14 intracellular pathway can lead to a reduction in surface MMP14, which in turn leads to a reduction in gelatin degradation. Next, it was determined whether knockdown of the surface Q‐SNAREs, Stx4 and SNAP23, that have been found mediate the final step of MMP14 surface delivery (Figure 5.1), also regulates the gelatinase activity of macrophages. Macrophages were transfected with siRNA to Stx4 and SNAP23, as well as siRNA to the surface SNAREs Stx2 and Stx3 that were found to have no significant effect on MMP14 surface delivery (Figure 5.1) as controls, along with scrambled siRNA. Next cells were seeded onto fluorescently labelled gelatin and incubated for a further 18 h. Macrophages were fixed, stained for F‐actin and gelatin degradation assessed by fluorescence microscopy (Figure 5.6A). Again, the areas below the cells treated with scrambled siRNA were reduced in fluorescence, suggesting degradation has occurred (Figure 5.6A). Cells treated with Stx2 or Stx3 siRNA showed similar levels of degradation to the control scrambled siRNA treated cells, but cells treated with Stx4 or SNAP23 siRNA showed reduced degradation, as indicated by the higher levels of fluorescence below the cells (Figure 5.6A). The areas of gelatin degradation were quantified and normalised to the area of the cells (Figure 5.6B). Gelatin degradation analysis of macrophages with reduced levels of Stx2 revealed that the degradative capability in these cells was reduced marginally (10%; Figure 5.6B, n.s. P>0.05). Macrophages with reduced levels of Stx3, which also does not hinder MMP14 surface delivery (Figure 5.1), showed no change in the degradation of gelatin (Figure 5.6B, n.s. P>0.05). Macrophages with reduced levels of Stx4 or SNAP23, which does significantly disrupt incorporation of MMP14 into the plasma membrane (Figure 5.1), had reduced gelatinolytic behaviour (Figure 5.6A). Knockdown of Stx4, which reduced MMP14 surface levels by 27%, diminished gelatin degradation by a striking 41% (Figure 5.6B, ***P≤0.001). SNAP23 knockdown, where MMP14 surface levels were found to be 
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reduced by 43% (Figure 5.1), led to gelatinolytic activity being reduced by 32% (Figure 5.6B, **P≤0.01). Thus, Stx4 and SNAP23 regulate the final stages of delivery of MMP14 to the cell surface and the degradation of gelatin. To confirm that MMPs are responsible for the gelatinase activity of RAW264.7 macrophages, cells were first seeded on fluorescently labelled gelatin and incubated for 18 h in the absence or presence of GM6001, a broad‐spectrum matrix metalloproteinase inhibitor (also known as galardin or ilomastat) (Figure 5.6C‐D). Specifically, GM6001 is known to inhibit MMP1, MMP2, MMP3, MMP7, MMP8, MMP9, MMP12, MMP13, MMP14, MMP15, MMP16, MMP20 and MMP26. Cells were imaged by fluorescence microscopy (Figure 5.6C) and it can be seen that upon inhibition of MMP activity macrophages showed reduced degradative capability when compared to control cells. Areas of degradation were quantified and normalised to cell area, which was determined from staining of the cell perimeter for F‐actin (Figure 5.6C, lower panel). In the presence of GM6001, degradation was reduced by 65% (*P<0.05) when compared to the control treated cells (Figure 5.6D), indicating that MMP activity is required for full degradative capacity.  To address the specific involvement of MMP14 in the degradation of the gelatin matrix by RAW264.7 macrophages, cells seeded on fluorescent gelatin were incubated for 18 h in the presence or absence of a commercially available functionally blocking MMP14 antibody that binds to the catalytic domain of the enzyme (Figure 5.6C‐D). This antibody was originally used to investigate MMP14‐dependent gelatinolytic activity in endothelial cells [Galvez et al., 2001]. Fluorescence images show that gelatin degradation by macrophages was almost absent in the presence of the MMP14 antibody (Figure 5.6C). Quantification of degraded areas revealed that the gelatinolytic capacity of anti‐MMP14‐treated macrophages was reduced by 97% (**P≤0.01) when compared to control cells that were treated with an isotype‐matched antibody (Figure 5.6D). This indicates that gelatin degradation by macrophages is dependent on functional MMP14. These results suggest that the reduced degradation seen when Stx4, SNAP23, VAMP4, VAMP7 or VAMP8 are knocked down is due to the reduced delivery of MMP14 to the cell surface. In summary, upon disruption of MMP14 cell surface delivery through targeting the SNAREs that mediate this process, namely VAMP4, VAMP7, VAMP8, Stx4 or SNAP23, MMP14‐dependant degradation of gelatin matrix can be reduced. 
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Figure 5.6. Gelatin degradation by MMP14 can be inhibited through targeting the Q-
SNARE complex Stx4/SNAP23. 
(A) RAW264.7 macrophages were grown coverslips coated with fluorescent gelatin (upper 
panel) for 18 h following transfection with scrambled (scr), Stx2, Stx3, Stx4 or SNAP23 siRNA, 
fixed and stained for F-actin (lower panel). Scale bar is 50 μm. (B) Quantification of gelatin 
degradation by RAW264.7 macrophages following knockdown of Stx2, Stx3, Stx4 or SNAP23. 
Areas of gelatin degradation were determined and normalised to the total surface area of the 
cells. Bar graphs show the degradation of RAW264.7 macrophages following knockdown of 
Stx2, Stx3, Stx4 or SNAP23 relative to cells that had been transfected with scrambled (scr) 
siRNA Analysis of 200 cells per siRNA treatment across two biological repeats; mean ± SEM, 
**P≤0.01, ***P≤0.001 (one-way ANOVA with Dunnett’s post-hoc test. (C) RAW264.7 
macrophages were grown on coverslips coated with fluorescent gelatin (upper panel) for 18 h 
in the presence or absence of GM6001 or anti-MMP14 antibody, fixed and stained for F-actin 
(lower panel). Scale bar is 50 μm. (D) Quantification of gelatin degradation by RAW264.7 
macrophages in the presence and absence of GM6001 or anti-MMP14 antibody. Areas of 
gelatin degradation were determined and normalised to the total surface area of the cells. Bar 
graphs show the degradation of RAW264.7 macrophages in the presence of anti-MMP14 
antibody relative to control cells grown in the presence of an isotype control antibody. n=3; 
mean ± SEM, *P<0.05, **P≤0.01 (unpaired, two-tailed Student’s t test). 
5.2.4 3D migration of macrophages through different matrices During migration into a wound macrophages will have to perform 3D migration through tissue. The fact that matrix degradation is MMP14 dependant and can be disrupted by targeting SNARE machinery involved in the cell surface delivery of MMP14 suggests that this could also be true for macrophage migration through 3D matrices. To be able to test the effect of disrupting intracellular MMP14 trafficking on mesenchymal migration of macrophages, it was first necessary to develop an assay that allows the analysis of macrophage migration through a matrix along a chemotactic gradient. For this, RAW264.7 macrophages were seeded onto the bottom side of a Transwell® membrane where the upper well contains a thick layer of Matrigel™ or collagen I matrix with media containing the chemoattractant fMLP placed on the matrix. Cells were allowed to migrate for 3 days through Matrigel™ or collagen I matrix. After the 3 days, macrophages in the Transwell® were fixed, stained for F‐actin and visualised by confocal microscopy to assess macrophage migration (Figure 5.7). At the bottom of the gel matrix, macrophages were found passing through the randomly distributed pores of the membrane (Figure 5.7A). Within the gel, invading cells were found in grape‐like clusters across the gel (Figure 5.7B). These macrophages that have successfully invaded the gel exhibited actin‐rich protrusions that resembled filopodia and lamellipodia (Figure 5.7C and 5.7D) and actin‐rich podosomes near the leading edge (Figure 5.7D). MMP14 was found to be enriched in these 3D podosomes (Figure 5.8E). As macrophages successfully migrated into 3D matrices, both Matrigel™ and collagen I, and exhibit a mesenchymal phenotype with MMP14 localising to cell structures implicated in migration, the assay was considered adequate for studying the effects of manipulating MMP14 trafficking pathways on macrophage migration in to 3D matrices. 
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Figure 5.7. 3D migration of macrophages through Matrigel™ and collagen I matrices. 
(A) An inverted invasion assay performed to assess 3D migration of RAW264.7 macrophages. 
Macrophages were allowed to invade into a collagen I plug for 72 h along a gradient of fMLP. 
Cells were stained with TRITC-phalloidin (red) and macrophages passing through pores of the 
membrane (grey) were imaged by bright field and confocal microscopy. Scale bar is 100 μm. 
(B) Invading cells within a Matrigel™ plug were stained with TRITC-phalloidin and visualised 
by confocal microscopy. Serial optical sections of the gel plugs were captured at 3 μm intervals 
and a typical example of groups of invaded cells shown as a Maximum Intensity Projection; 
scale bar is 100 μm. (C-D) An inverted invasion assay was performed to assess the 
morphology of RAW264.7 macrophages migrating through collagen I. Macrophages were 
allowed to invade into a collagen plug for 72 h along a gradient of fMLP. Invading cells (within 
the gel plug) were stained with TRITC-phalloidin and morphology visualised by confocal 
microscopy. Scale bar is 25 μm. (E) An inverted invasion assay was performed to assess 
MMP14 localisation in RAW264.7 macrophages during 3D migration. Macrophages were 
allowed to invade into a collagen plug for 72 h along a gradient of fMLP. Invading cells (within 
the gel plug) were stained with MMP14 (green) and TRITC-phalloidin (red) and the morphology 
visualised by confocal microscopy. Scale bar is 10 μm. 
 
5.2.5 SNAREs regulate macrophage invasion of Matrigel™ In order for macrophages to migrate into a wound site, monocytes recruited from the blood stream are first required to emigrate from the blood vessel into the surrounding tissue in a process called diapedesis. Monocyte migration through the vessel walls involves transmigration through the endothelium, as well as degradation of the associated basement membrane. Transendothelial migration of monocytes is MMP14‐dependent [Matias‐Roman et al., 2005; Gonzalo et al., 2010; Sithu et al., 2007]. However, there is conflicting data about whether degradation of the basement membrane by monocytes/macrophages is MMP‐dependant [Agrawal et al., 2008; Murray et al., 2013] or MMP‐independent [Van Goethem et al., 2010]. Matrigel™ is a gel‐like mixture of ECM proteins, mainly laminin, collagen IV, heparin sulphate proteoglycans and entactin, secreted by a mouse sarcoma cell line that has been widely used to mimic the basement membrane. It is therefore a good model to study the effect of targeting MMP14 cell surface delivery on the ability of macrophages to cross the basement membrane. Hence, it was tested whether reducing the levels of SNARE machinery identified as being involved in the intracellular trafficking and surface delivery of MMP14 would affect macrophage migration through Matrigel™. As knockdown of R‐SNAREs VAMP4, VAMP7 and Q‐SNAREs Stx4 and SNAP23 had dramatic effects on both, MMP14 cell surface delivery and degradative function, the effect of reducing the levels of these SNAREs was investigated. RAW264.7 macrophages were transfected with non‐targeted (scrambled), VAMP4, VAMP7, Stx4 or SNAP23 siRNA on day 1, this was repeated on day 2 and then cells were seeded onto the bottom side of a Transwell® membrane and 
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allowed to migrate for 3 days through a thick layer of undiluted Matrigel™ along a chemotactic gradient of fMLP. After the 3 days, cells were fixed, stained for F‐Actin and visualised by confocal microscopy (Figure 5.8). Images taken before the Transwell® membrane show that cell numbers between different siRNA treatment groups (scrambled, VAMP4, VAMP7, Stx4 or SNAP23) remained similar (Figure 5.8A, first panels). Macrophages treated with scrambled siRNA were found to invade into the gel in grape‐like clusters (Figure 5.8A) as described in section 5.2.4. These clusters of varying sizes were found all across the gel and invaded on average about 140 µm into the gel. Invasion of the overall macrophage population was quantified by adding up the area covered by invading cells for each section as an indicator of cell numbers across a certain distance. When disrupting MMP14 trafficking from the Golgi complex through siRNA targeted knockdown of R‐SNARE VAMP4, macrophages were found to invade the gel only to about 100 µm as apparent from comparing sequences of optical sections from invaded cells (Figure 5.8A). The size of the macrophage clusters within the gel were also much smaller as less cells passed through the Transwell® membrane (Figure 5.8A). Overall, invasion of macrophages that had been treated with VAMP4 siRNA was reduced by 99% in comparison to the control (Figure 5.8B). Macrophages treated with siRNA targeting the late endosomal/lysosomal R‐SNARE VAMP7 invaded only about as far as 60 µm into the gel and overall much less cells were found to have invasive potential. When quantified invasion was found to be reduced by 95% following treatment with VAMP7 siRNA (Figure 5.8B). When disrupting incorporation of MMP14 into the plasma membrane through targeting of surface Q‐SNAREs Stx4 or SNAP23 macrophages did not invade as far (85 and 65 µm, respectively) into the Matrigel™ as control cells (Figure 5.8A). For the whole population, invasion was diminished by over 90% or 94% following treatment with Stx4 or SNAP23 siRNA, respectively (Figure 5.8B). This suggests that targeting these SNAREs, which are involved in the cell surface delivery of MMP14, impedes 3D migration of RAW264.7 macrophages through Matrigel™. To confirm that the observed effect of diminished macrophage invasion following SNARE knockdown is a result of reduced MMP14 activity at the cell surface, 3D migration of macrophages through Matrigel™ in the absence or presence of MMP inhibitor GM6001 or anti‐MMP14 antibody was assessed. Comparing sequences of optical sections from invaded cells it becomes clear that GM6001‐ or MMP14‐antibody‐treated macrophages did not invade as far into the Matrigel™ as untreated cells (Figure 5.8C). While the depth of the clusters of invaded cells was highly variable, on average 
control macrophages were found to migrate 145 μm into the Matrigel™ within the three days while GM6001‐ or MMP14‐antibody‐treated cells invaded less than 65 μm within 
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the 3 days. Overall invasion was reduced by 77% (**P≤0.01) or 78 % (**P≤0.01) following treatment with GM6001‐ or MMP14‐antibody, respectively (Figure 5.8D). This means generally less macrophages invaded the gel upon inhibition of MMPs or MMP14 and those cells that did invade into the Matrigel™ plug were unable to travel as far. Taken together, the data suggests that MMP14 is necessary for efficient infiltration of 3D Matrigel™. Importantly, knockdown of key SNARE proteins identified to regulate MMP14 transport to the cell surface lead to a loss in the ability to efficiently migrate through Matrigel. 
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Figure 5.8. 3D migration through Matrigel™ can be inhibited through targeting SNAREs that are involved in the cell surface delivery of MMP14. 
(A) An inverted invasion assay was performed to compare 3D migration of RAW264.7 macrophages through Matrigel™ following their transfection with 
scrambled (scr), VAMP4, VAMP7, Stx4 or SNAP23 siRNA. Macrophages were allowed to invade into a Matrigel™ plug for 72 h along a gradient of fMLP. 
Invading (within the plug) and non-invading cells (on the membrane) were stained with TRITC-Phalloidin and visualised by confocal microscopy. Serial optical 
sections of the Matrigel™ plug were captured at 30 μm intervals. Typical examples are presented as a sequence in which the individual optical sections are 
placed alongside one another with increasing depth from left to right, as indicated. (B) Bar graph represents invasion of macrophages following transfection with 
scrambled (scr), VAMP4 or SNAP23 siRNA quantified by adding up the area covered by invading cells (as an indicator of cell numbers) for each section and is 
expressed relative to the control; VAMP4 and SNAP23 n=2, VAMP7 and Stx4 n=1. (C) An inverted invasion assay was performed to compare 3D migration 
through Matrigel™ of RAW264.7 macrophages in the absence or presence of MMP inhibitor GM6001 or anti-MMP14 antibody. Macrophages were allowed to 
invade into a Matrigel™ plug for 72 h along a gradient of fMLP. Invading (within the plug) and non-invading cells (on the membrane) were stained with TRITC-
Phalloidin and visualised by confocal microscopy. Serial optical sections of the Matrigel™ plug were captured at 15 μm intervals and typical examples are 
presented as a sequence in which the individual optical sections are placed alongside one another with increasing depth from left to right, as indicated. (D) Bar 
graph represents invasion of macrophages in the absence or presence of MMP inhibitor GM6001 or anti-MMP14 antibody quantified by adding up the area 
covered by invading cells for each section and is expressed relative to the control; n=3, mean± SEM, **P≤0.01 (one-way ANOVA with Dunnett’s post-hoc test. 
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5.2.6 3D migration through collagen I can be inhibited through targeting 
SNAREs that are involved in the cell surface delivery of MMP14 After having emigrated from blood vessels, macrophages have to migrate through a 3D network of interstitial type I collagen on their way to the wound site. In order to move through dense matrix material macrophages create a path by proteolytically degrading the matrix. In macrophages, the proteolytic processing during this mesenchymal mode of migration has been shown to occur at cell protrusions where 3D podosomes form [Van Goethem et al., 2010; Van Goethem et al., 2011]. To study the role of SNARE‐mediated trafficking of MMP14 in migration of macrophages through collagen, RAW264.7 cells were transfected with non‐targeted (scrambled), VAMP4, VAMP7, Stx4 or SNAP23 siRNA on day 1, this was repeated on day 2 and then cells were seeded onto the bottom side of a Transwell® membrane and allowed to migrate for 3 days through a thick layer of gelled collagen I along a chemotactic gradient of fMLP. After the 3 days, cells were fixed, stained for F‐Actin and visualised by confocal microscopy (Figure 5.9).  Images taken before the Transwell® membrane show that cell numbers between different siRNA treatment groups (scrambled, VAMP4, VAMP7, Stx4 or SNAP23) remained similar (Figure 5.9A, first panels). As before, macrophages treated with scrambled siRNA were found to invade into the collagen gel in grape‐like clusters (Figure 5.9A). These clusters of varying sizes were found all across the gel and invaded on average about 94 µm into the gel. Invasion of the overall macrophage population was quantified by adding up the area covered by invading cells for each section as an indicator of cell numbers across a certain distance. First, the effect of reducing levels of R‐SNARE VAMP4 was investigated as this had a dramatic effect on MMP14 cell surface delivery as well as degradative function. When disrupting MMP14 trafficking from the Golgi complex through siRNA targeted knockdown of R‐SNARE VAMP4, macrophages were found to invade the gel only to about 60 µm as determined from comparing sequences of optical sections from invaded cells (Figure 5.8A). The size of the macrophage clusters within the gel were also much smaller as less cells passed through the Transwell® membrane (Figure 5.8A). Overall, invasion of macrophages that had been treated with VAMP4 siRNA was reduced by 72% (P<0.05) in comparison to the control (Figure 5.8B). Similarly, macrophages treated with siRNA targeting the late endosomal/lysosomal R‐SNARE VAMP7 invaded only about as far as 74 µm into the gel and overall much less cells were found to have invasive potential. When quantified invasion was found to be reduced by 59% (n.s.) following treatment with VAMP7 siRNA 
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(Figure 5.8B). The effect of reducing levels of the Q‐SNAREs Stx4 and SNAP23 was also investigated, as these SNAREs were found to be responsible for incorporation of MMP14 into the plasma membrane, and, as such, regulate the degradative function of macrophages. It was observed that depth of invasion into collagen I of invading macrophages was reduced to 60 and 58 µm following transfection with Stx4 or SNAP23 siRNA, respectively, compared to the scrambled control (Figure 5.9A). Invasiveness of macrophages overall was diminished by 57% following treatment with Stx4 siRNA (n.s. P>0.05) while it was impacted by 78% upon SNAP23 knockdown (**P≤0.01; Figure 5.9B).  Using the same inverted migration assay, RAW264.7 cells were allowed to migrate through a thick layer of gelled collagen I in the absence or presence of either MMP inhibitor GM6001 or MMP14 antibody to confirm that the observed effect on macrophage chemotactic migration is due to altered MMP14 levels. Treatment with inhibitor or antibody did not negatively affect cell viability as cell numbers of non‐invading cells, i.e. cells that did not cross the membrane, between control and treated groups were similar (Figure 5.9C, first panel). Comparing sequences of optical sections of the gels it becomes clear that GM6001‐ or MMP14‐antibody‐treated macrophages only invade about half as far into the collagen I plug compared to untreated cells (Figure 5.9C). Relative invasion of the macrophage population was quantified by adding up the area covered by invading cells for each section and revealed that invasion was reduced by 87% (**P≤0.01) or 91% (**P≤0.01) following treatment with GM6001‐ or MMP14‐antibody, respectively (Figure 5.8E). This data suggests that MMP14 is necessary for efficient migration through 3D collagen I. In summary, some macrophages continued to migrate into the collagen I matrix following SNARE knockdown. However, significantly less macrophages had invasive properties when pathways responsible for trafficking of MMP14 to the plasma membrane were disrupted. Therefore, targeting SNAREs that are involved in the cell surface delivery of MMP14, namely VAMP4, VAMP7, Stx4 and SNAP23, hampers MMP14‐dependent 3D migration of RAW264.7 macrophages through collagen I. 
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Figure 5.9. 3D macrophage migration through collagen can be inhibited through targeting SNAREs that are involved in cell surface delivery of MMP14. 
(A) An inverted invasion assay was performed to compare 3D migration of RAW264.7 macrophages through collagen I following transfection with scrambled 
(scr), VAMP4, VAMP7, Stx4 or SNAP23 siRNA. Macrophages were allowed to invade into a collagen I plug for 72 h along a gradient of fMLP. Invading (within 
the plug) and non-invading cells (bottom of the membrane) were stained with TRITC-Phalloidin and visualised by confocal microscopy. Serial optical sections 
of the collagen I plug were captured at 30 μm intervals and typical examples are presented as a sequence in which the individual optical sections are placed 
alongside one another with increasing depth from left to right, as indicated. (B) Bar graph represents invasion of macrophages following transfection with 
scrambled (scr), VAMP4, VAMP7, Stx4 or SNAP23 siRNA quantified by adding up the area covered by invading cells for each section and is expressed relative 
to the control; n=3 for VAMP4 and VAMP7, n=4 for Stx4 and SNAP23, mean± SEM, *P<0.05, **P≤0.01 (one-way ANOVA with Dunnett’s post-hoc test). (C) An 
inverted invasion assay was performed to compare 3D migration through collagen I of RAW264.7 macrophages in the absence or presence of MMP inhibitor 
GM6001 or anti-MMP14 antibody. Macrophages were allowed to invade into a collagen I plug for 72 h along a gradient of fMLP. Invading (within the plug) and 
non-invading cells (before the membrane) were stained with TRITC-Phalloidin and visualised by confocal microscopy. Serial optical sections of the collagen I 
plug were captured at 15 μm intervals and typical examples are presented as a sequence in which the individual optical sections are placed alongside one 
another with increasing depth from left to right, as indicated. (D) Bar graph represents invasion of macrophages in the absence or presence of MMP inhibitor 
GM6001 or anti-MMP14 antibody quantified by adding up the area covered by invading cells for each section and is expressed relative to the control; n=3, 
mean± SEM, **P≤0.01 (one-way ANOVA with Dunnett’s post-hoc test). 
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5.3 Discussion Macrophage infiltration of wound tissue during the inflammatory phase is part of normal wound healing. However, increased numbers of macrophages leading to excessive inflammation are associated with poor wound healing outcomes. The influx of macrophages into the tissue is believed to be dependent on the activity of MMP14. In this chapter, SNARE machinery responsible for the incorporation of MMP14 into the plasma membrane was identified. Furthermore, it was determined whether the SNARE proteins that were identified to regulate the transport of MMP14 to the cell surface also regulate degradation and invasion. Initially, two Q‐SNAREs, namely Stx4 and SNAP23, were identified to mediate the incorporation of MMP14 into the plasma membrane of macrophages. It was observed that the incorporation of MMP14 at the cell surface does not occur at random but that MMP14 localises to filopodia and podosomes, F‐actin‐rich cell membrane structures implicated in cell migration, in response to matrix contact. Once MMP14 is specifically delivered to these regions it facilitates matrix degradation and macrophage movement. Delivery of MMP14 to areas of matrix degradation was found to be reliant on the action of specific SNARE proteins. MMP14‐dependant degradation of gelatin could be repressed through targeting SNARE proteins that were previously identified as mediators of MMP14 cell surface delivery, namely VAMP4, VAMP7, VAMP8, Stx4 and SNAP23. 3D migration of macrophages through different ECM materials, thick layers of Matrigel™ or gelled collagen I, was studied using an inverted invasion assay. Infiltration of these gel plugs by macrophages occurred in grape‐like cell clusters. Individual cells that successfully invaded the gel matrix exhibited actin‐rich protrusions that resembled filopodia and 3D podosomes. The numbers of macrophages that were able to migrate into gels of Matrigel™ or collagen I as well as the distance covered by invading cells was dependent on MMP14 activity at the cell surface. As a consequence, disrupting SNARE machinery that is required for the incorporation of MMP14 into the plasma membrane significantly reduced the ability of macrophages to effectively invade into both, Matrigel™ and collagen I gels. Thus, targeting these SNAREs might allow attenuation of macrophage tissue infiltration and inflammation. 
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5.3.1 Trafficking to the cell surface Ultimately, to allow cell surface delivery of MMP14 an R‐SNARE must form a complex with Q‐SNAREs to regulate fusion with the plasma membrane. In various cell types, the Q‐SNAREs Stx4 and SNAP23 mediate this final fusion event to deliver MMP14 to the cell surface [Kean et al., 2009; Miyata et al., 2004; Williams et al., 2014]. Knockdown of the four main surface Q‐SNAREs (Stx2, Stx3, Stx4 and SNAP23) found on the macrophage cell surface confirmed that Stx4 and SNAP23 mediate MMP14 cell surface delivery in macrophages (Figure 5.1). Co‐localisation of MMP14 with Stx4 and SNAP23 at the cell perimeter in RAW264.7 cells provided final clues that these SNAREs regulate MMP14 incorporation into the plasma membrane in macrophages. Protein cargo can be delivered from the Golgi complex to the cell surface directly and R‐SNARE VAMP4 is known to interact with the Qa‐SNARE Stx4 in neuroendocrine pheochromocytoma (PC12) cells [Thomas et al., 1999], two‐hybrid systems [Rolland et 
al., 2014; Rual et al., 2005] and affinity capture mass spectrometry of human embryonic kidney cells [Huttlin et al., 2015]. Furthermore, VAMP4 has been found to interact with Qbc‐SNARE SNAP23. This opens up the possibility of a VAMP4/Stx4/SNAP23 complex and therefore transport of MMP14 from the Golgi complex to the cell surface directly. However, VAMP4 has also been shown to regulate delivery from lysosome‐related organelles to the cell surface in activated NK cells [Krzewski et al., 2011]. As newly made MMP14 has also been found in late endosomes/lysosomes, it could be more likely that VAMP4 is regulating the transport of MMP14 from the Golgi complex to late endosomes/lysosomes. Subsequently, incorporation of newly made MMP14 into the plasma membrane from a late endosomal/lysosomal pathway could be regulated by a possible complex of VAMP7 (R‐SNARE), Stx4 (Qa‐SNARE) and SNAP23 (Qbc‐SNARE) (Figure 5.10). A VAMP7/Stx4/SNAP23 complex has previously been found to allow MMP14 cell surface delivery, as well as targeting it to invasive structures and is required for cell invasion of MDA‐MB‐231 cells [Williams et al., 2014].   
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Figure 5.10. Schematic of MMP14 trafficking to podosomes in macrophages. 
In response to external stimuli, MMP14 is synthesised and then transported through a 
biosynthetic pathway via the Golgi complex as well as late endosomes and lysosomes to the 
plasma membrane. Cell-matrix contact, facilitated through integrin-mediated adhesion 
(orange), initiates the assembly of podosomes, which are specialised actin-rich membrane 
protrusions of invading cells that facilitate matrix degradation. The microtubule (green) and 
actin (red) cytoskeleton and associated scaffolding proteins are believed to be involved in the 
polarised delivery of MMP14 to podosome sites but were not further investigated in this study. 
The R-SNARE protein VAMP7 (pink) was found to regulate delivery of MMP14 (olive) to 
podosomes, indicating that the SNARE machinery regulates the fusion of MMP14-containing 
vesicles with the plasma membrane. The plasma-membrane Q-SNAREs Stx4 and SNAP23 
(aqua) were also identified to mediate MMP14-dependant matrix degradation and migration.   
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5.3.2 Localisation of MMP14 to structures for migration and degradation Following cell‐matrix contact MMP14 was found to localise to F‐actin rich membrane structures that resembled podosomes and filopodia, structures that are implicated in matrix degradation and cell migration (Figure 5.10). Specific localisation of MMP14 to lamellipodia and filopodia has previously been shown in human peripheral blood mononuclear cells following attachment to fibronectin [Matias‐Roman et al., 2005]. The polarised delivery of MMP14 to the leading edge was also previously shown for monocytes migrating over activated endothelial cells through co‐localisation staining with leading edge marker profilin [Matias‐Roman et al., 2005]. Furthermore, MMP14 localisation to podosomes has previously been reported for primary macrophages, as well as RAW264.7 cells, and is crucial for matrix degradation at podosomes [Nusblat et 
al., 2011; Wiesner et al., 2010]. Previously, degradation of fibronectin, collagen I and gelatin has been shown to correlate with the presence of overexpressed MMP14 at the cell surface of primary macrophages [Wiesner et al., 2010]. The study herein showed endogenous MMP14 localised to areas of gelatin degradation, indicating that MMP14 may be responsible for the degradation of the gelatin matrix. The pattern of gelatin degradation suggested podosome formation in these areas (Figure 5.10). However, to be fully confident, staining for podosome‐specific markersan such as cortactin, talin, TKS5, vinculin or N‐WASP would have to be conducted. The recruitment of MMP14‐containing vesicles towards podosome sites occurs via podosome‐contacting microtubules and motorproteins KIF5B (kinesin‐1 subunit) and KIF3A/KIF3B (kinesin‐2 subunits) in primary macrophages [Wiesner et al., 2010]. In breast adenocarcinoma cells it has been show that the GTP‐binding protein ARF6 at the plasma membrane interacts through the scaffold effector proteins JIP3/JIP4 with kinesin‐1 to control the positioning and tubulation of MMP14‐positive endosomes. Activation of the actin cytoskeleton regulator Arp2/3 complex, which is dependent on actin‐regulator WASH, further coordinates the delivery of MMP14 to invadopodia [Marchesin et al., 2015; Monteiro et al., 2013]. Furthermore, WASH interacts with the exocyst complex to tether MMP14‐positive late endosomes to the target membrane in the same cells [Monteiro et al., 2013]. Finally, delivery of MMP14 to podosomes was found to be dependent on N‐WASP, inducer of actin polymerisation, in RAW264.7 macrophages [Nusblat et al., 2011]. N‐WASP‐mediated tethering of MMP14’s cytoplasmic tail to F‐actin was found to be necessary to stabilise MMP14 to invasive structures and induce matrix degradation in breast cancer cells [Yu et al., 2012]. 
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Others have found different SNARE trafficking machinery proteins that also regulate MMP14 transport and membrane docking, such as the late endosomal/lysosomal SNARE protein VAMP7 and plasma membrane SNAREs Stx4 and SNAP23, which were found to mediate the delivery of MMP14 to invadopodia in breast adenocarcinoma cells [Steffen et al., 2008; Williams et al., 2014]. However, the role of these or other SNAREs in the delivery of MMP14 to podosomes and the effect of blocking their function on matrix degradation by macrophages has not been investigated. 
5.3.3 Matrix degradation by macrophages can be inhibited through 
targeting SNAREs that are involved in the cell surface delivery of 
MMP14 As MMP14 is responsible for gelatin degradation by RAW264.7 macrophages, it was next tested whether disruption of MMP14 trafficking through targeted siRNA knockdown of those SNARE proteins that were identified to mediate incorporation of MMP14 into the plasma membrane would affect gelatin degradation. And indeed, upon disruption of MMP14 cell surface delivery through targeting VAMP4, VAMP7, VAMP8, Stx4 or SNAP23, MMP14‐dependant degradation of gelatin matrix was significantly reduced. MMP14 was found to co‐localise with Stx4 and SNAP23 at the plasma membrane of macrophages in this study herein. MMP14 has also previously been shown to co‐localise with VAMP7, Stx4 and SNAP23 at focal sites of matrix degradation and targeting these SNAREs was found to impede delivery of MMP14 to podosomes and MMP14‐mediated gelatin degradation by breast adenocarcinoma cancer [Steffen et al., 2008; Williams et al., 2014] endorsing the results seen for RAW264.7 macrophages (Figure 5.10). In fibrosarcoma cells, disrupting trafficking facilitated by VAMP3 also negatively affected gelatin proteolysis [Kean et al., 2009]. However, proteolytic activity was only reduced by about 60% and could therefore be attributed to recycled pools of MMP14 rather than newly made protein. In RAW264.7 macrophages, reducing VAMP3 levels did not significantly affect gelatinolytic activity. This is not surprising as MMP14 surface levels were not found to be decreased in RAW264.7 macrophages with reduced VAMP3. A role for VAMP4 and VAMP8 in the regulation of MMP14‐dependent matrix degradation has not previously been reported. In macrophages, studies that investigate the effect of disrupting trafficking machinery on matrix degradation have so far been limited to Rab proteins only [Wiesner et al., 2013]. Thus, the here identified SNAREs proteins represent novel targets to modify the degradative capacity of macrophages. It was next tested whether targeting the SNAREs would also influence macrophage migration. 
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5.3.4 3D migration of macrophages can be inhibited through targeting 
SNAREs that are involved in the cell surface delivery of MMP14 
In vivo monocytes are recruited through adhesion to the activated endothelium of the blood vessel, rolling then crawling over it, before subsequent diapedesis and emigration through the basement membrane to then migrate towards the wound [Verollet et al., 2011]. Transendothelial migration of murine bone marrow‐derived macrophages and human peripheral blood monocytes has been shown to be MMP14‐dependent based on knockout, knockdown or functional blocking of MMP14 [Gonzalo et 
al., 2010; Matias‐Roman et al., 2005; Sithu et al., 2007]. In an ex vivo model using mesothelial and epithelial basement membrane, it was shown that the activity of MMP14 and other transmembrane MMPs are responsible for basement membrane breaching by human breast adenocarcinoma cells [Hotary et al., 2006]. It was therefore interesting to characterise the role of SNARE machinery proteins in the migration of RAW264.7 macrophages through a basement membrane‐like gel and whether basement membrane degradation could be manipulated by targeting SNAREs that are involved in MMP14 trafficking. For this, macrophage migration through Matrigel™ was assessed. In dense matrices such as Matrigel™ and gelled collagen I macrophages use the mesenchymal migration mode, which is characterised by the requirement of proteases to create their path. Through the use of proteases macrophages create tunnels when migrating through an extracellular matrix [Van Goethem et al., 2011]. This might explain why macrophages were often found as cell clusters within the gel: Once a path has already been established within the gel, other macrophages might follow as a result of a principle of least effort. RAW264.7 macrophages were found to migrate on average 145 
μm into the Matrigel™ within the three days, which corresponds to an average velocity of about 30 nm per minute. As the basement membrane is only about 100 nm in thickness [Kalluri, 2003], breaching of the basement membrane could be expected to occur in only a few minutes. Considering that Matrigel™ is less crosslinked and more vulnerable to degradation compared to native basement membrane [Poincloux et al., 2009], this time frame is in agreement with in vivo imaging studies showing that the majority of leukocytes extravasation takes between 10 and 20 min [Hyun et al., 2012]. When reducing the levels of SNARE proteins that are involved in the cell surface delivery of MMP14, namely VAMP4, VAMP7, Stx4 and SNAP23, MMP14‐dependent 3D migration of RAW264.7 macrophages through Matrigel™ was dramatically impaired. The observed effect was similar to treatment of RAW264.7 macrophages with GM6001 or function blocking MMP14‐antibody. This suggests a direct involvement of MMP14 in the 
  172  Chapter 5: MMP14 and macrophage migration 
proteolytic degradation process rather than it being only required for the activation of secreted MMPs, as previously been reported for basement membrane breaching of breast adenocarcinoma cells [Hotary et al., 2006]. It also shows the influence of disrupting the SNARE machinery is specific to disturbed MMP14 trafficking. A negative effect on invasion through Matrigel™ following the inhibition of VAMP7, Stx4 and SNAP23 has previously been shown for breast adenocarcinoma and fibrosarcoma cells [Steffen et al., 2008; Williams and Coppolino, 2011; Williams et al., 2014]. VAMP4 has not yet been reported to regulate migration through Matrigel™ in any cell type. Studies examining the effect of disrupting MMP14‐related trafficking machinery on macrophage penetration of Matrigel™ have not been described either. It is important to note that following SNARE‐targeted siRNA treatment some macrophages were still able to penetrate a basement membrane‐resembling gel. This could be owed to the fact that siRNA knockdown was not complete and some macrophages were known to still be positive for MMP14 at the cell surface even when overall levels were reduced. However, macrophage movement appeared to be much slower. Thus, it could be hypothesised that the extravasation process in vivo would possibly be delayed. Overall there were also a smaller number of macrophages that retained their invasive properties upon inhibition of MMP14 meaning that potentially less macrophages would be able to infiltrate the tissue in vivo. Taken together, this demonstrates that MMP14 is necessary for efficient migration through a basement membrane‐resembling matrix and targeting of SNARE machinery that was identified here to be involved in the cell surface delivery of MMP14 could potentially reduce macrophage extravasation from the bloodstream into the surrounding tissue. Following the successful emigration from the blood vessel by diapedesis, macrophages will then have to migrate through the interstitial tissue, which is a complex 3D environment made from different extracellular matrix components, primarily type I collagen, and can vary in architecture and rigidity. Depending on the architecture of the matrix, macrophages can either use the amoeboid mode, which does not use proteases, to migrate through materials with large pores such as pepsin‐extracted fibrillar collagen I or the use the mesenchymal mode, which is dependent on protease activity, to migrate through dense matrices, such as gelled collagen I [Cougoule et al., 2010; Van Goethem et 
al., 2010]. When using the mesenchymal mode, macrophages form 3D podosomes at the tip of cell [Van Goethem et al., 2010; Van Goethem et al., 2011]. Accordingly, RAW264.7 macrophages that successfully invaded into gels of collagen I also exhibited actin‐rich protrusions that resembled filopodia and 3D podosomes as would be found in cells using 
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the mesenchymal mode of migration. It is known that proteolytic degradation of the matrix takes place at these protrusions and the secretion of MMPs and other proteases is believed to occur at podosomes [Van Goethem et al., 2011; Wiesner et al., 2013; Wiesner et al., 2014]. Whether the actin‐rich structures are indeed podosomes would have to be confirmed through the staining with known podosome markers, such as vinculin or paxillin. It was possible to confirm the localisation of MMP14 to these 3D podosomes in this model. In human peripheral blood monocytes embedded in collagen I MMP14 was shown to be enriched at F‐actin‐rich cell protrusions resembling 3D podosomes, which locally degraded the collagen matrix [Wiesner et al., 2013]. It was therefore interesting to characterise the role of SNARE machinery proteins in the migration of RAW264.7 macrophages through 3D collagen I and whether it could be manipulated by targeting SNAREs that are involved in MMP14 trafficking. Indeed, targeting SNARE machinery involved in the cell surface delivery of MMP14, namely VAMP4, VAMP7, Stx4 and SNAP23, hampered MMP14‐dependent 3D migration of RAW264.7 macrophages in an inverted 3D invasion assay using a gel of native collagen I, as significantly less RAW264.7 macrophages had invasive properties. Similarly, reduced invasion of RAW264.7 macrophages in the presence of function blocking MMP14 antibody supports the idea that this particular MMP is essential for the invasion of macrophages into collagen I‐rich matrices but, more importantly, shows that MMP14‐mediated migration can be specifically targeted by disrupting the mentioned trafficking machinery. Although the role of SNARE machinery in 3D migration of macrophages has not previously been elucidated, primary macrophage invasion into 3D collagen gels has been shown to be inhibited when Rab trafficking machinery responsible for the cell surface delivery of MMP14 was disrupted [Wiesner et al., 2013]. Rab GTPases initiate vesicle docking and facilitate SNARE complex formation, while formation of the SNARE complex mediates membrane fusion. Together, Rabs and SNAREs regulate selective delivery of vesicle cargo to the proper organelle or target membrane. The reported findings on the effects of disrupting MMP14 trafficking are not surprising considering that intact collagen fibres, due to their triple‐helical structure, can only be cleaved by a limited number of proteases, which include some of the MMPs, cathepsins and a few serine proteinases [Song et al., 2006]. In terms of the MMPs, fibrillar collagen cleavage can only be initiated by MMP1, MMP8, MMP13 and MMP14, while fragments of the cleaved fibrillar collagen may subsequently be further degraded by MMP2 and MMP9 [McKleroy et al., 2013]. In a study with human monocyte‐derived classically activated macrophages, MMP14 was expressed at much higher levels than 
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MMP1 and MMP8, while MMP13 was not expressed at all [Huang et al., 2012]. Furthermore, MMP14 proteolytically activates MMP‐8 and MMP‐13 [Barbolina and Stack, 2008]. Together this would support an important role for the proper trafficking of MMP14 in the migration of macrophages through collagen matrices.  It has been suggested that macrophages could use different sets of proteases subject to the composition of the 3D matrix they encounter [Wiesner et al., 2014]. Thus, differences in the architecture and connectivity of the matrix used in individual studies could have a strong influence on the degree of protease‐dependency of mesenchymal macrophage migration. collagen I can be of gel‐like or fibrillar architecture, which differs in fibre density and fibre thickness, dependent on factors such as monomer concentration, temperature or pH during the polymerisation process [Wiesner et al., 2014]. Therefore, the polymerisation process strongly influences the effective pore size of the resulting matrix. But it is not only the polymerisation conditions that have an effect on the rigidity of the matrix but also the origin, tissue source and collagen isolation procedure used [Wiesner et al., 2014]. The degree of intermolecular connectivity of pepsin‐extracted collagens compared to collagens isolated without the use of enzymes differs considerably. Although pepsin‐treated collagen appears to have a similar architecture to enzyme‐free collagen (i.e. pore size and density of fibrils), it possesses less intermolecular cross‐links and is therefore less rigid. This might be an explanation for why mesenchymal migration of macrophages through pepsin‐treated collagen is MMP‐independent [Van Goethem et al., 2010] while MMP activity was required for migration in enzyme‐free collagen, as observed herein and in previous studies [Wiesner 
et al., 2014]. The extracellular matrix that comprises the connective tissue in vivo is expected to be even more heterogeneous and will encompass both, dense and loose areas [Wiesner et al., 2014]. Nonetheless, the data presented here suggests that targeting of SNARE machinery identified to be involved in the cell surface delivery of MMP14 could potentially reduce macrophage tissue infiltration.  
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Chapter 6: General discussion 
 The overall aim of this thesis was to identify the intracellular trafficking pathways and trafficking machinery proteins responsible for the cell surface delivery of important MMPs and investigate the effect of disrupting these pathways on macrophage migration. Part of the biosynthetic route of MMP9 trafficking in macrophages was identified. It would appear that there is crosstalk with endocytic pathways in terms of regulating extracellular levels of MMP9 and SNAREs that might regulate these pathways were identified. Intracellular trafficking pathways for the cell surface delivery of MMP14 were also investigated and trafficking of newly made MMP14 via the Golgi complex could be confirmed in macrophages. The R‐SNARE VAMP4 was identified to mediate the post‐Golgi trafficking of MMP14. This study shows for the first time that newly made MMP14 is trafficked via late endosomes/lysosomes en route to the cell surface and that the R‐SNAREs VAMP7 and VAMP8 mediate this pathway in macrophages. Incorporation of MMP14 into the plasma membrane was found to be regulated by the Q‐SNAREs Stx4 and SNAP23. The SNARE‐mediated delivery of MMP14 to cell surface areas of matrix degradation could successfully be disrupted. The disruption also attenuated macrophage migration in vitro. These findings might lead to development of new therapeutics to reduce macrophage tissue infiltration and inflammation. 
The role of MMP9 and MMP14 secreted from macrophages during wound healing In response to wounding, immune cells are recruited to the site of injury following haemostasis. This inflammatory phase of the wound healing process is important for wound cleansing, pathogen defence and promotion of subsequent healing processes. Macrophages play an influential role on the level of inflammation within the tissue, and as such their recruitment from the blood stream towards the wound has to be highly efficient, but also tightly regulated. For the efficient degradation of the blood vessel basement membrane and the interstitial tissue macrophages are equipped with potent matrix‐degrading enzymes, such as MMP9 and MMP14. These are specifically delivered to cell membrane structures implicated in matrix degradation, invasion and migration in response to external stimuli, such as matrix components or pathogens. To avoid excessive tissue damage and inflammation, expression and secretion of these enzymes is temporally and spatially regulated. Accordingly, MMP9 and MMP14 levels were very low in unactivated macrophages and their cell surface delivery absent. But expression and secretion of newly made protein was found highly upregulated from 3 h 
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to 18 h post‐stimulation with the bacterial cell wall component LPS. MMP14 cell surface delivery was also found upregulated upon cell‐matrix contact. Activation of macrophages with bacterial and matrix components simulates macrophages encountering pathogen‐ and damage‐associated molecular patterns within the tissue following wounding. Similar time‐ and stimulus‐dependant regulation has also previously been shown for other MMPs, such as MMP10, MMP12 and MMP13 at the mRNA level in macrophages [Hald et al., 2012; Murray et al., 2013]. The observed time‐dependent upregulation of proteases, such as MMP9 and MMP14, is in alignment with the concept that macrophage tissue infiltration as well as proteolytic activity is transient and regulated in order to avoid excessive tissue damage. In acute wounds, macrophages can be found to invade the wound site from about one day following injury and numbers peak around day 2 post‐wounding [Sindrilaru et al., 2011]. In a normal healing wound, macrophage numbers will then start to decline over the next few days. However, chronically inflamed tissue will continue to be infiltrated by macrophages that secrete more MMPs contributing to the continuous cycle of inflammation, as seen in chronic wounds. When dysregulated, elevated levels of certain MMPs do not only lead to uncontrolled matrix degradation in these wounds, but also causes the depletion of important growth factors and activation of pro‐inflammatory cytokines. For example, MMP9 can cleave the precursors of cytokines TNFα and IL‐1β and therefore increase pro‐inflammatory signalling [Gearing et al., 1994; Schonbeck et 
al., 1998]. Through cleavage of TGFβ precursor, MMP9 also increases the bioavailability 
of TGFβ, which is believed to play a role in hypertrophic scarring [Yu and Stamenkovic, 2000]. MMP14 can also activate TNFα and therefore has pro‐inflammatory potential [D’Ortho et al., 1997]. Furthermore, MMP14 has an indirect effect on cell migration through shedding of the cell surface glycoprotein CD44 [Kajita et al., 2001]. Unrestrained MMP expression and activity does not only play a role in inflammation in chronic wounds, it also contributes to tumour growth, invasion and metastasis through proteolytic degradation of the ECM, alteration of cell–cell and cell–ECM interactions, migration and angiogenesis [Gialeli et al., 2010]. Particularly MMP14 has been considered a key player in these processes as levels correlate with the invasiveness and metastasis of the cancer. Hence, a lot of studies have investigated the trafficking of MMP14 in cancer cell lines and its role in cell migration. In these cell lines, MMP14 appears to be constitutively expressed and surface pools of the enzyme are endocytosed and recycled in the absence of cell‐matrix contact. This is in strong contrast to the observations made for MMP14 expression in macrophages. 
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Whether the trafficking routes for MMP14 in macrophages are different to those identified in cancer cell lines is largely unknown. There is currently only one other study that has begun to investigate the trafficking pathways of MMP14 in primary macrophages and as such these pathways in macrophages remained still poorly understood and required further investigation in order to manipulate macrophage infiltration and tissue inflammation. 
Intracellular trafficking and secretion of MMP9 and MMP14 in macrophages To be functional MMPs need to be delivered to the cell surface where they can access their substrates. The newly made enzymes are trafficked via the Golgi compartment en route to the cell surface. Apart from the Golgi complex, newly made MMP9 and MMP14 were also found in structures in the periphery of the cell, which were identified as late endosomal/lysosomal compartments. These organelles are well known for their involvement in protein degradation but can also have secretory functions. Whether trafficking via these organelles to the cell surface is a requisite for MMP9 and MMP14 secretion could be further tested by blocking this pathway through a HRP inactivation assay [Laulagnier et al., 2011]. Targeting the SNARE proteins Stx2, SNAP23, VAMP2, VAMP3, VAMP4, VAMP7 and VAMP8 led to an increased release of MMP9 levels in the extracellular environment rather than reducing its secretion. This suggests that, in addition to a biosynthetic pathway, endocytic mechanisms are involved in regulating MMP9 levels. Co‐localisation with organelle markers, such as the transferrin receptor (TfR), a recycling endosome marker, or early endosome antigen 1 (EEA1), an early endosome marker, could give further evidence for MMP9 endocytic trafficking. Trafficking of newly made MMP9 could also be imaged live by transfecting the cells to express MMP9 fused to a photoactivatable/photoconvertible tag in conjunction with live‐staining organelle markers. This would allow focussing on MMP9‐positive vesicles leaving the Golgi complex and would provide evidence to whether these vesicles traffic through late endosomal/lysosomal compartments before being delivered to the cell surface. Comparing co‐localisation of MMP9 and late endosome/lysosome markers following treatment with cycloheximide to disrupt protein synthesis might also give further insight into whether newly made MMP9 is trafficked via the late endosome/lysosome as one would expect less MMP9 fluorescence in these compartments if this was the case. More understanding of the endocytic pathways of MMP9 could also be achieved by performing a cell surface biotinylation assay [Schmidt et al., 1997]. This assay would involve 
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precipitation of surface molecules that are endocytosed following biotin‐labelling and samples could be probed for the presence of MMP9. Detection of MMP9 would confirm endocytic pathways in macrophages. Binding of MMP9 to LRP‐1 is a known clearance mechanism for previously secreted MMP9 via endocytic pathways [Hahn‐Dantona et al., 2001]. Thus, MMP9‐LRP‐1‐coimmunoprecipitation experiments as well as immunofluorescence co‐localisation studies of these two proteins should be considered to further investigate LRP‐1‐mediated endocytosis of MMP9 in macrophages. A LRP‐1‐mediated clearing mechanism of MMP9 might explain why knockdown of the SNAREs VAMP3, VAMP4, VAMP7, VAMP8, Stx2 and SNAP23 increased the level of extracellular MMP9 as these SNAREs might regulate LRP‐1 trafficking. Nonetheless, other SNARE machinery could also be tested to possibly identify SNARE proteins more specific for the biosynthetic pathway for newly made MMP9 without affecting LRP‐1 trafficking. If newly made MMP9 was found in the recycling endosome of macrophages, the Q‐SNAREs Stx7 (Qa), Vti1b (Qb) and Stx6 (Qc) could be 
tested as a STX7/Vti1b/Stx6 complex has been implicated in trafficking of TNFα and IL‐6 from the Golgi complex to the recycling endosome prior to their secretion from macrophages [Manderson et al., 2007; Murray et al., 2005]. If MMP9 is trafficked from the Golgi complex to the early endosome the Q‐SNAREs Stx16 (Qa), Vti1a (Qb) and Stx6 (Qc) could be tested for their role in MMP9 trafficking as they are known to mediate this pathway [Scheller, 2013]. Trafficking of MMP9 from late endosomes to lysosomes could potentially be mediated by Stx7 (Qa), Vti1b (Qb) and Stx8 (Qc) and could therefore also be tested [Scheller, 2013]. Involvement of the SNAREs Stx13 (Qa) and SNAP25 or SNAP29 (Qbc) in MMP9 secretion could also be examined as these SNAREs mediate fusion events at the plasma membrane [Hong and Lev, 2014]. If MMP9 secretion cannot be targeted directly other options to specifically block MMP9 activity could be pursued, for example on the level of MMP9 activation. An MMP14/MMP2/TIMP complex at the cell surface has been suggested to activate MMP9 from its zymogen form [Itoh et al., 2001; Itoh and Seiki, 2004; Toth, 2003]. Thus, targeting this complex might allow influencing MMP9 activity on that level. If any of the components of this complex became unavailable, then activation of MMP9 is expected to be disturbed and ECM damage might be reduced. Trafficking pathways necessary for the cell surface delivery of MMP14 have been identified here and were successfully disrupted by targeting responsible SNARE machinery leading to significantly reduced MMP14 surface levels. Whether this would affect zymogen activation of MMP9 remains to be elucidated. Interestingly, MMP14 has also been identified to cleave LRP‐1 [Rozanov 
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et al., 2003]. Therefore, targeting MMP14 could not only have an inhibiting effect on MMP9 activation but might also improve MMP9 clearance as more LRP‐1 becomes available. Trafficking of MMP14 from the trans‐Golgi network was found to be regulated by the R‐SNARE VAMP4. To allow membrane fusion, an R‐SNARE must form a complex with two (Qa and Qbc) or three Q‐SNAREs (Qa, Qb and Qc). Since VAMP4 could mediate either trafficking of MMP14 to the cell surface directly or via other organelles, partnering Q‐SNAREs would have to be identified but are unknown in macrophages. One option is that VAMP4 partners with Stx4/SNAP23 to allow direct trafficking of MMP14 from the Golgi network to the plasma membrane There are, however, some indications that VAMP4 could mediate trafficking of MMP14 from the Golgi complex to the late endosome/lysosome, as VAMP4 localises to lysosome‐related organelles in activated NK cells and cytotoxic lymphocytes [Krzewski et al., 2011; Pattu et al., 2012]. Stx7 (Qa‐SNARE), Vti1b (Qb‐SNARE) and Stx8 (Qc‐SNARE) could possibly form a SNARE complex with VAMP4 (R‐SNARE), as they all localise to the lysosomal related lytic granules in cytotoxic T lymphocytes [Pattu et al., 2012]. To confirm this hypothesis, the existence of a VAMP4/Stx7/Vti1b/Stx8 complex in macrophages could be tested through immunoprecipitation experiments while the involvement of the Q‐SNARE Stx7, Vti1b and Stx8 in MMP14 transport could be tested through siRNA targeted knockdown of these SNAREs. Trafficking of MMP14 from late endosomal/lysosomal structures was found to be mediated by R‐SNAREs VAMP7 and VAMP8 and the Q‐SNAREs Stx4 and SNAP23 were found to mediate the final step of incorporation of MMP14 into the plasma membrane. Immunoprecipitation experiments could establish if VAMP7 (R‐SNARE) is forming a complex with Stx4 (Qa‐SNARE) and SNAP23 (Qbc‐SNARE) or whether VAMP4 could also interact with Stx4/SNAP23 and allow direct trafficking of MMP14 from the Golgi network to the plasma membrane. A VAMP7/Stx4/SNAP23 SNARE complex has been proposed to mediate trafficking of MMP14 from the lysosome to the plasma membrane in breast adenocarcinoma cells [Williams et al., 2014]. Long‐range transport of vesicles from the trans‐Golgi network towards the cell periphery can be assisted by elements of the cytoskeleton, such as microtubules and associated motor proteins, and has previously been reported for MMP9 and MMP14. Surprisingly, disruption of the cytoskeleton did not affect levels of secreted MMP9 or MMP14 in this study. This could be owed to the fact that any changes could have been too small to detect as treatment with cytoskeleton‐disrupting agents did not occur for the whole period that cells were stimulated with LPS due to the cytotoxic effects of these 
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drugs. It has also been reported that cytoskeleton disruption has more influence on the rate of long‐range transport rather than fully abolishing cell surface delivery of cargo. Live imaging of fluorescently labelled MMP9 or MMP14 in the presence of cytoskeleton‐disrupting agents could allow determining if there is a difference in the transport speed of vesicles in comparison to control cells. As the cytoskeleton is also important for the polarised delivery of the protein cargo it would be interesting to investigate whether the specific localisation of MMP14 at the cell surface of polarised macrophages remains equally unaffected or whether delivery of MMP14 to specialised structures important for cell migration, such as podosomes, and degradative function is disturbed upon cytoskeleton disruption. Previous studies have shown that many cytoskeleton‐associated molecules, such as JIP3/4, WASH and N‐WASP, are involved in the proper trafficking of MMP14 to podosomes and indispensable for MMP14 localisation to podosomes and matrix degradation. As such, these proteins have been suggested as potential targets in aggressive cancers. However, agents that could disrupt the action of these machinery proteins would not be specific enough for an application on non‐healing wounds and negatively affect the cellular behaviour of various other cell types in the wound environment. The polarised cell surface delivery of MMP14 to membrane structures important for migration and invasion is therefore a highly efficient but also regulated process and allows to limit matrix degradation to necessary areas of the cell such as the leading edge. As a transmembrane protein MMP14 activity is also restricted to the pericellular space. MMP9 on the other hand is secreted as a soluble enzyme. To concentrate the activity of soluble MMPs, such as MMP9, to the pericellular space they can bind back to the cell surface at plasma membrane structures implicated in cell migration. MMP9 is known to 
bind to CD44, as well as integrins β1 and β5 [Deryugina and Quigley, 2011]. Interestingly, these molecules are also found at podosomes allowing a highly efficient migration process. Co‐localisation studies would confirm if these interactions are also present in macrophages. Whether disruption of the interaction between MMP9 and its surface receptors has an impact on the efficiency of macrophage invasion could also be investigated. 
Disrupting MMP14 trafficking to attenuate matrix degradation and cell migration Upon successful delivery of MMP14 to podosomes, MMP14 is responsible for matrix degradation and macrophage migration. Thus, when targeting SNARE machinery proteins that were identified to mediate MMP14 cell surface delivery, namely VAMP4. 
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VAMP7, VAMP8, Stx4 and SNAP23, macrophage degradative capacity and migration in 
vitro were significantly impaired. This effect appeared to be specific for those SNAREs that are involved in MMP14 trafficking, as for example treatment with VAMP3 siRNA, which has previously been shown to affect integrin recycling and persistent migration on fibronectin in macrophages [Veale et al., 2011], did not significantly reduce degradation of gelatin. Similarly, treatment with VAMP2, Stx2 or Stx3 siRNA did also not change matrix degradation. The effect of disrupting trafficking machinery responsible for MMP14‐mediated matrix degradation and protease‐dependent cell migration could lead to development of therapeutics that attenuate macrophage tissue infiltration and inflammation. However, it would be important to confirm these effects on protease‐dependent migration in vivo as the definition of amoeboid and mesenchymal migration modes by macrophages have been identified in vitro [Verrolet et al., 2011]. The cell morphology of can be an indication whether macrophages are using the amoeboid or mesenchymal migration mode and as such be a predictor of the involvement of proteases. Studies using techniques that allow 
intravital imaging have shown that migrating macrophages exhibit mesenchymal characteristics with a polarised cell shape and cytoplasmic protrusions, rather than the rounded cell morphology that is characteristic for the amoeboid mode of migration and observed with neutrophils and T lymphocytes [Egen et al., 2008; Leimgruber et al., 2009]. Another indicator for mesenchymal migration is that upon deletion or mutation of mesenchymal migration effectors macrophages show altered migration in vivo. Macrophages from patients expressing truncated forms of actin polymerisation regulator WASP, which consequently lack podosomes, show defective cell migration and impaired immunostimulatory activation [Linder et al., 1999]. Thus, it seems to be very likely that macrophages do use the mesenchymal migration mode in vivo. But more work will be required to confirm this as well as endorse the role of MMP14 in macrophage migration in vivo. In cancer, MMP14 expression is correlated with invasiveness illustrating the significance of MMP14 for tissue infiltration in these cells. Interestingly, conditional knockout of MMP14 in the monocyte/macrophage lineage leads to a reduction in the number of macrophages in inflamed tissue when compared with wildtype mice in a contact dermatitis model. However, no differences were found for wound closure, granulation tissue formation, and angiogenesis between wildtype and knockout groups [Klose et al., 2013]. Potentially, it could be more relevant to investigate the role of disrupting MMP14‐mediated macrophage migration in a mouse model with impaired wound healing. Widely used models of impaired healing involve 
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mice with type 2 diabetes as a result of leptin (ob/ob) ‐ or leptin receptor (db/db) knockout [Baetens et al., 1978; Boquist et al., 1974]. 
Targeting SNAREs with Clostridial neurotoxins The family of clostridial neurotoxins (CNTs) is comprised of one tetanus neurotoxin (TeNT) and seven (A to G) distinct botulinum neurotoxins (BoN). They specifically bind to molecules on the cell surface of neuronal cells, which allows endocytosis of the toxin followed by membrane translocation of the catalytic domain and finally proteolytic cleavage. To fulfil this multistep process, the two‐chain toxin is encompasses three domains. Binding of the C‐terminal domain of the heavy chain (HC) to gangliosides and synaptic vesicle protein SV2, which are found particularly enriched at the presynaptic membrane, allows receptor‐mediated endocytosis of the toxin. As the pH decreases the toxin undergoes structural rearrangement so that the N‐terminal domain of the heavy chain (HN) initiates membrane translocation of the light chain which is the domain of the toxin that contains the protease activity. Depending on the substrate specificity of the individual toxin they can proteolytically cleave the SNAREs VAMP2, VAMP3, Stx1, or SNAP25 leading to a defect in the release of the neurotransmitter acetylcholine causing the diseases tetanus and botulism. Synthesised, unmodified BoNT‐A and B are used as therapeutics in the clinic to treat diseases such as upper motor neuron syndrome, focal hyperhidrosis, blepharospasm, strabismus, chronic migraine and bruxism but have also been utilised for cosmetic treatments. Although these toxins are known to specifically bind to motor neurons and Stx1 is only expressed in neuronal cells, it could be shown that unmodified BoNT‐A can inhibit insulin secretion from beta cells [Boyd et al., 1995]. This served as a proof of concept that CNTs could be modified to target non‐neuronal secretory processes. Through engineered replacement of the motor neuron‐specific cell binding domain (HC) it was possible to inhibit secretion in epithelial cell line [Foster et al., 2006]. Furthermore, it has been suggested that the L chain of CNTs can also be catalytically modified to specifically target other SNARE family protein members [Pickett and Perrow, 2011]. For example, BoNT‐E was successfully modified (BoNT‐E K224D) to cleave 
SNAP23 in addition to SNAP25 and when added to TNFα‐stimulated HeLA cells reduced IL‐8 secretion, which is usually mediated by SNAP23 [Chen et al., 2009]. It has furthermore been suggested that engineering of these BoNT to target the R‐SNARE VAMP7 will also be possible [Binz et al., 2010]. 
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This opens up the opportunity to use modified CNTs to explicitly disrupt MMP14 trafficking in macrophages.  Being able to selectively inhibit macrophage‐derived MMP14 activity is important as not only macrophages but also fibroblasts, endothelial cells as well as keratinocytes express MMP14. Therefore, non‐specific inhibition of MMP14 could be expected to impede not only macrophage but also fibroblast, endothelial and keratinocyte migration and as such negatively affect important healing processes like re‐epithelialisation and angiogenesis. The binding domain (HC) of the toxin could be modified to interact with macrophage‐specific surface molecules, for example CD68 (low density lipoprotein/Macrosialin, pan marker for macrophages). However, as macrophages of the anti‐inflammatory M2 type are considered to promote healing, markers that are known to be highly expressed on pro‐inflammatory M1 macrophages within the wound tissue, such as Ly6C (mouse marker) or CD192/CCR2 (human and mouse marker), could be targeted. In combination with re‐engineering of the catalytic domain (L chain) to specifically target the SNAREs VAMP7 or SNAP23, this might allow disruption of inflammatory macrophage‐specific MMP14 trafficking and attenuation of macrophage invasion. Therefore, the findings from this work together with future drug development might lead to the advancement of chronic wound treatments. 
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